European network for Health Technology Assessment Joint Action (EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis by Woodford Guegan, Eleanor & Cook, Andrew
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 18 ISSUE 37 JUNE 2014
ISSN 1366-5278
DOI 10.3310/hta18370
European network for Health Technology Assessment 
Joint Action (EUnetHTA JA): a process evaluation 
performed by questionnaires and documentary analysis
Eleanor Woodford Guegan and Andrew Cook
European network for Health Technology
Assessment Joint Action (EUnetHTA JA):
a process evaluation performed by
questionnaires and documentary analysisEleanor Woodford Guegan* and Andrew CookNational Institute for Health Research (NIHR) Evaluation Studies and Trials
Co-ordinating Centre, University of Southampton, Southampton, UK
*Corresponding author
Declared competing interests of authors: Both authors work for the National Institute for Health
Research (NIHR) Evaluation, Trials and Studies Co-ordinating Centre. EUnetHTA project is supported by a
grant from the European Commission. Both authors were members of the EUnetHTA Executive Committee
from April 2008 until December 2012, which includes the period when this evaluation was undertaken.
This committee had overall responsibility for the delivery of the EUnetHTA JA, of which the work described
in this monograph is a part.Published June 2014
DOI: 10.3310/hta18370This report should be referenced as follows:
Woodford Guegan E, Cook A. European network for Health Technology Assessment Joint Action
(EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis.
Health Technol Assess 2014;18(37).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TARISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Five-year impact factor: 5.804
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is
assessed for inclusion in the Database of Abstracts of Reviews of Effects.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: www.hta.ac.uk/
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 05/52/03. The contractual start date
was in January 2010. The draft report began editorial review in May 2013 and was accepted for publication in October 2013. The project was
jointly funded by the HTA programme and the European Commission. The authors have been wholly responsible for all data collection,
analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’
report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for
damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reﬂect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reﬂect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Woodford Guegan et al. under the terms of a
commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor Jane Norman Professor of Maternal and Fetal Health, University of Edinburgh, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, University College London, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.ukNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37AbstractEuropean network for Health Technology Assessment Joint
Action (EUnetHTA JA): a process evaluation performed by
questionnaires and documentary analysisEleanor Woodford Guegan* and Andrew Cook
National Institute for Health Research (NIHR) Evaluation Studies and Trials Co-ordinating Centre,
University of Southampton, Southampton, UK
*Corresponding author
Background: The European network for Health Technology Assessment Joint Action (EUnetHTA JA)
project’s overarching objective was to ‘establish an effective and sustainable HTA [Health technology
assessment] collaboration in Europe that brings added value at the regional, national and European level’.
Speciﬁc objectives were to develop a strategy and business model for sustainable European collaboration
on HTA, develop HTA tools and methods and promote good practice in HTA methods and processes.
We describe activities performed on behalf of the National Institute for Health Research HTA programme;
evaluating the project processes and developing a data set for a registry of planned clinical studies of
relevance to public funders.
Methods: Annual self-completion online questionnaires were sent to project participants and external
stakeholders to identify their views about the project processes. Documentary review was undertaken at
the project end on the ﬁnal technical reports from the work packages to examine whether or not their
deliverables had been achieved. The project’s impact was assessed by whether or not the deliverables were
produced, the objectives met and additional ‘added value’ generated. The project’s effectiveness was
evaluated by its processes, communication, administration, workings of individual work packages and
involvement of external stakeholders. A two-stage Delphi exercise was undertaken to identify the data
elements that should be included in a registry of planned clinical studies of relevance to public funders.
The data set was validated by an efﬁcacy testing exercise.
Results and discussion: High response rates were achieved for the questionnaires sent to project
participants and this was attributed to the evidence-based strategy implemented. Response rates to
questionnaires sent to external stakeholders were disappointingly lower. Most of the high-level objectives
were achieved, although applying the developed tools in practice will be implemented in the European
network for Health Technology Assessment Joint Action 2 (EUnetHTA JA2). Most work packages produced
their planned deliverables. Networking emerged as one of the main beneﬁts of the project and
face-to-face meetings were important. However, the overarching objective did not appear to have been
met because there will be a follow-up EUnetHTA JA2 project (reliant on project funding) before the
establishment of any permanent network. Twelve organisations from three continents participated in
the Delphi exercise to develop the data set. It was demonstrated that a registry for matching pragmatic
clinical studies under consideration by funders could be built on a very small data set. This would include
10 unique items, of which ﬁve are required to describe a study and the rest are metadata. In the test
sample the data set with an appropriate matching rule was able to deliver a sensitivity of between 50%
and 100% and a speciﬁcity of between 43% and 86% for matching different elements.v
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Woodford Guegan et al. under the terms of a commissioning contract issued by the Secretary of
State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ABSTRACT
viConclusions: A number of recommendations have been made for the next EUnetHTA JA2 project and its
evaluation. This included that the evaluation of the EUnetHTA JA2 project should extend beyond the end
of the project to allow assessment of its impact; that the quality, usability and cost-effectiveness of
tools in ‘real-world HTA practice’ should be assessed and tangible beneﬁts of international networking
should be evaluated. It is worth proceeding to develop a database registry aimed at identifying trials
in development based on the data set developed.
Funding: The study was funded by the National Institute for Health Research Health Technology
Assessment programme (50%) and the European Union Commission (50%).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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HTA Core Model® A methodological framework for shared production and sharing of HTA information.
It consists of three components: (1) an ontology containing a set of generic questions that define the
contents of a HTA; (2) a methodological guidance that assists in answering questions; and (3) a common
reporting structure that enables standardised reporting of HTAs. Information is created and presented as
assessment elements. Some elements are prioritised over others to support European collaboration through
defining them as ‘core elements’.
Stakeholders Those who have an interest in the project or its deliverables. For the EUnetHTA JA project the
external stakeholders were in four categories: industry, patients/consumers, providers and payers.xvii
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The National Institute for Health Research Health Technology Assessment programme produces researchabout health interventions for those who make health-care decisions. The European network for Health
Technology Assessment Joint Action project aimed to help collaboration in HTA around Europe. We
performed two activities in the project.
We evaluated the project to see whether or not it successfully completed its aims and examined the
internal workings of the project. We did this by sending questionnaires each year to people working on
the project and those with a relevant interest in it. We also reviewed reports that the individual work
activities submitted at the end of the project. The project’s main objective did not appear to have been
met because there needs to be a follow-up project. Most of the deliverables were produced according to
the project plans. One of the main beneﬁts of the project was networking – bringing together European
colleagues to discuss HTA.
Those who fund research about health interventions from public money have a duty to ensure this money
is used wisely. It is important to know if similar trials are being planned in different countries. This prevents
duplication and ensures that trials are designed so their results can be compared. We asked people from
different countries which items of data would be useful to know about. We then tested to check that we
had identiﬁed all the relevant data. It is planned that a database will be developed to store these data
about planned trials funded by public money.xxi
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The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme
[represented by the NIHR Evaluation, Trials and Studies Co-ordinating Centre, (NETSCC)] was invited to
join the European network for Health Technology Assessment Joint Action (EUnetHTA JA) project
2010–12. Participation in this project was part-funded by the European Union (EU) Commission and the
NIHR HTA programme.
The authors took on formal roles in three work packages under two broad activities.Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
Health technology assessment produces high-quality research about health interventions for those who
make decisions about health care. There have been various initiatives aiming to increase communication
and collaboration in HTA across Europe. The EUnetHTA JA project was established in 2010, with the
overarching objective being to ‘establish an effective and sustainable HTA collaboration in Europe that
brings added value at the regional, national and European level.’ At its formation the EUnetHTA JA
comprised 35 government-appointed organisations from 24 EU member states, Switzerland, Norway and
Croatia. The project was co-ordinated by a secretariat and structured into eight work packages. Evaluation
is an important facet of project management, and evaluation of the EUnetHTA JA was a prerequisite of
the European Union. As recommended in conducting evaluations of European projects, the evaluation plan
was a key component and integrated within the EUnetHTA JA project from the beginning. A work
package was included in the project to consider this and the authors were invited to lead it. This was their
primary role within the EUnetHTA JA. Project evaluation allows monitoring of the processes of the project
and achievements against speciﬁed criteria for success. This enables assessment of the effectiveness and
achievements of the project and the formation of ‘lessons learned’ recommendations to inform future
projects. It also ensures accountability against project plans.Informing clinical decision-makers about clinical research studies
under development: development of a data set to inform a registry
There is progressive growth and interest in pragmatic trials (and other study designs) which deliver clinical
effectiveness and cost-effectiveness information to directly inform policy, commissioning and clinical
decision-makers. For established, funded clinical trials the scenario is simple. All such studies should be
entered into one of a number of international clinical trials registries, such as ClinicalTrials at the National
Institutes of Health and Current Controlled Trials. Pragmatic studies reﬂect the actual clinical environment
and create robust evidence. However, there is no widely used registry that tracks such trials in
development. Therefore, funders run the risk of duplicating or developing trials in parallel, which may have
been avoided or improved if they had been aware of planned parallel activity. There is, therefore, a need
for a system to facilitate the identiﬁcation of pending similar pragmatic studies by international trial
funders. This would enable optimisation of scarce public resources, both ﬁnancial and in terms of patients
and researchers. It was, therefore, considered that a registry of ‘trials which funders are considering’
could have potential for ﬁlling this gap. It is important that such a registry contains the appropriate data
ﬁelds and the authors led an activity to compile such a data set. Building an electronic registry based on
the developed data set was beyond the scope of the project, but will be performed by a EUnetHTA JA
sister organisation.xxiii
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SCIENTIFIC SUMMARY
xxivObjectives
1. The main objective of the internal evaluation was to evaluate the EUnetHTA JA project with respect
to its effectiveness and impact. This considered whether or not the project met its overarching and
speciﬁc objectives.
2. The secondary objective was to establish the data elements required to inform a registry of clinical
studies planned by organisations which provide public funding for pragmatic research.MethodsEvaluation of the processes of the European network for Health Technology
Assessment Joint Action project
A prospective internal evaluation of the EUnetHTA JA was performed. This evaluation was a systematic
data collection designed to develop generalisable knowledge to contribute to quality improvement of the
EUnetHTA JA project and to inform future projects. The impact of the project was assessed by an outcome
evaluation to identify the success of delivering the stated project deliverables. The effectiveness of the
project was evaluated by the processes employed during the project. The annual policy-setting meetings
were also evaluated by participants. Key success criteria were developed for the project and used to
evaluate its performance.
Annual self-completion online questionnaires were sent to project participants and external stakeholders.
These were designed according to best practice, including performing a pre-send-out pilot phase and
issuing targeted reminders. Special consideration was given to the fact that English was not the native
language of most respondents, and the questionnaires contained both ‘open’ and ‘closed’ questions.
A strategy to optimise response rate was employed. Documentary review was undertaken on the ﬁnal
technical reports submitted from the individual work packages at the end of the project.Informing clinical decision-makers about clinical research studies
under development: development of a data set to inform a registry
The methods for developing a data set to inform a registry for planned clinical studies were in two phases:
development of a data set on which to base a registry and assessment of the likely accuracy of that data
set. The data set was developed by the consensus-building method of a two-stage Delphi process. This
involved developing an initial iteration of the data set. Questionnaires were then distributed to participants
and the data set revised in order to achieve a consensus about what data elements should be included.
Respondents were asked which clinical areas should be used to test the data set. Suggestions were
trastuzumab (Herceptin®, Genentech) for breast cancer, transcatheter aortic valve implantation compared
with other surgery for aortic stenosis, vertebroplasty and kyphoplasty compared with conservative therapy
(e.g. physiotherapy, occupational therapy) for compression fractures in osteoporosis and bevacizumab
(Avastin®, Genentech) for macular degeneration compared with bevacizumab for other indications.
Therefore, these indication and intervention combinations were used for efﬁcacy testing of the data set.
The Delphi participant organisations were asked to complete the data set for studies they were aware of
which may be similar to the index studies listed above.ResultsEvaluation of the processes of the European network for Health Technology
Assessment Joint Action project
An excellent response rate was received to the annual evaluation questionnaires sent to project
participants: 88% (2010), 86% (2011) and 88% (2012). This is a very high response rate to self-completion
questionnaires and indicates the effectiveness of the structured response incentive strategy used. Lower
response rates of between 60% and 83% were obtained for the questionnaires distributed to externalNIHR Journals Library www.journalslibrary.nihr.ac.uk
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stakeholder organisation does not consider EUnetHTA JA of sufﬁcient importance to engage with), but it
would be preferred to have this opinion explicitly stated. It was interesting to observe that the number of
project participants changed during the project. The largest overall increase in members was seen from
2010 to 2011. Approximately one-quarter of participants left the project after the initial year and one-third
of the 2011 population were new.
The overarching objective of the EUnetHTA JA was to establish an ‘effective and sustainable HTA
collaboration in Europe that brings added value at the regional, national and European level’. This would
be met if the EUnetHTA JA succeeded in establishing an ongoing European HTA collaboration that was
independent of project funding. However, an additional EUnetHTA Joint Action 2 project (EUnetHTA JA2),
part-funded by the European Union, was developed as a link between the EUnetHTA JA and such a
network. Therefore, it was considered that this overarching objective had not been achieved.
EUnetHTA JA had three speciﬁc objectives:
1. Development of a general strategy and a business model for sustainable European collaboration on
HTA. This was a deliverable of work package 1 and it was reported in their ﬁnal technical report that
this had been delivered by the project end. Unfortunately it was beyond the evaluation scope to
consider the quality of this deliverable.
2. Development of HTA tools and methods. All tools and methods were developed by the end of the
project apart from methodological guidance for relative effectiveness assessment of pharmaceuticals,
which was predicted to be delivered the month following the project end. It was interesting to
note that further work was planned in EUnetHTA JA2 to further develop the HTA Core Model®
(EUnetHTA, Helsinki).
3. Application and ﬁeld-testing of developed tools and methods. The EUnetHTA JA project appeared to be
successful in developing the tools, but not in testing them in actual practice. This facet will be further
pursued in the follow-up EUnetHTA JA2 project.
The impact of the project was evaluated by assessing the project deliverables, which are the results or
products of the project. Production of deliverables, according to the work plan, are indicators of project
management success and allowed assessment of the performance of the project with respect to time
(although considerations of quality and cost were beyond the scope of the present evaluation). In this
respect, documentary analysis of the ﬁnal technical reports revealed that the majority of the deliverables
had been produced by the end of the project (December 2012). Deliverables that were tools or methods to
help production of HTAs were an online tool for HTA information, a HTA Core Model on screening, a
web-based toolkit about evidence generation on new technologies and a quarterly communication
protocol for information exchange on ongoing or planned assessments of the same technology. Pilots of
HTAs prepared by collaboration were a relative effectiveness assessment of pharmaceuticals and a set
of two core HTAs. The tool of methodological guidance for the assessment of relative effectiveness of
pharmaceuticals was planned to be delivered after the end of the project. The potential use in practice
of these tools, and training requirements prior to use, were also evaluated. It was difﬁcult for participants
to predict whether or not they were likely to use these tools in their future HTA practice. The HTA Core
Model and the planned and ongoing projects database were the tools that were predicted to be the most
useful for producing HTAs.
All project-speciﬁc deliverables were produced on time. These were an information management system,
a communication and dissemination plan, a stakeholder policy, a business model for sustainability and
reports for the EUnetHTA JA.
The processes of the project appeared to run fairly smoothly. However, more time could have been
factored in for the start-up of the project. Better budgeting and project management techniques should be
used in EUnetHTA JA2 to ensure that sufﬁcient resources are allocated to organisations and speciﬁc tasks.xxv
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SCIENTIFIC SUMMARY
xxviIt was interesting that there was a large turnover of project participants during the project; one-third
of the population in 2011 was new to the project in that year. Therefore, it was of concern that almost
two-ﬁfths of organisations had no succession plan within their organisation. This has important
implications for the continuity of the project and necessitates that induction materials are prepared.
The overall support offered by the secretariat appeared adequate, although some concern was expressed
about the reliance on the project lead. Communication in the common language appeared to be adequate
and the important role of the project intranet and face-to-face meetings was highlighted. The involvement
of stakeholders seemed to have improved since the EUnetHTA 2006–8 project, but it was noted that this
should further evolve in the follow-up EUnetHTA JA2 project.
Recommendations were made from the EUnetHTA 2006–8 project to be followed in the EUnetHTA JA.
These were met with respect to securing funding and maintaining a dedicated co-ordinating secretariat,
continuing the tool development process, involving people in the work, encouraging collaboration,
arranging face-to-face meetings and communicating in English. However, some concerns were noted
about the commitment of some members and this will be addressed in EUnetHTA JA2 by grading
organisations for their activity. The tools had not been evaluated in routine practice in the EUnetHTA JA.
This will be pursued in EUnetHTA JA2.Informing clinical decision-makers about clinical research studies
under development: development of a data set to inform a registry
Twelve of the 13 invited organisations participated in the ﬁrst Delphi round to develop the data set for
pragmatic studies under consideration. This gave a response rate of 92%. Responses were collected in the
topic areas of language, coding systems, PICO (population, intervention, comparison and outcome),
contact, study title and research question, unit of registration, source of research idea, outcomes and other
types of information. Following the responses received the data set was developed into another iteration.
A second-round Delphi questionnaire was designed and sent to the same 12 organisations that had
responded to the ﬁrst-round Delphi questionnaire. Ten organisations participated, giving a response rate of
83%. More speciﬁc responses were collected in the topic areas of language, coding system, unique
identiﬁer, outcomes, unit of registration and other information, building on the responses from the ﬁrst
round. Research studies were submitted by participants in the four topic areas for the validation exercise.
In the test sample, the data set with an appropriate matching rule was able to deliver a sensitivity of
between 50% and 100%, and a speciﬁcity of between 43% and 86% for matching different elements.Conclusions
A number of recommendations have been made for the next EUnetHTA JA2 project and its evaluation.
This included that the evaluation of the EUnetHTA JA2 project should extend beyond the end of the
project to allow assessment of its impact; that the quality, usability and cost-effectiveness of tools in
‘real-world HTA practice’ should be assessed and tangible beneﬁts of international networking should be
evaluated. The involvement of stakeholders should evolve from the EUnetHTA JA. Face-to-face meetings
are beneﬁcial and this training method should be used for the HTA methodological tools. Support with
project management and budgeting should be offered by the secretariat and consideration given to having
a deputy project leader.Funding
The study was funded by the National Institute for Health Research Health Technology Assessment
programme (50%) and the European Union Commission (50%).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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[represented by the NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)] was invited to join
the European network for Health Technology Assessment Joint Action (EUnetHTA JA) project 2010–12.
Participation in this project was part-funded by the European Union (EU) Commission and the NIHR
HTA programme.
The authors from NETSCC took on formal roles in three work packages under two broad activities.Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
It is important that such a project is appropriately evaluated and lessons learnt for future initiatives. A work
package was included in the project to consider this and NETSCC was invited to lead it. This was our
primary role within the EUnetHTA JA project.
The Directorate-General of the European Commission for Health and Consumers (DG SANCO) requires a
process evaluation (rather than an outcome valuation) for all its funded projects. We undertook this role,
but extended it slightly by offering some evaluation work to other work packages.Informing clinical decision-makers about clinical research studies
under development: development of a data set to inform a registry
Broadly speaking there are two methods for performing HTA: prospective clinical studies and retrospective
systematic reviews. The majority of EU member organisations of the EUnetHTA JA perform only systematic
reviews. In addition to these, the UK NIHR HTA programme has a strong history of conducting prospective
clinical studies. The Netherlands also commissions such clinical studies and Norway, France, Italy and
Portugal have mechanisms to request them. Having a database registry of planned prospective clinical
studies would prevent duplication of effort and enable alignment of trial designs to produce more
outcome data. It would also be of beneﬁt to those EUnetHTA JA project participants who only perform
systematic reviews – they would know when primary research was due to ﬁnish and could align the start
of their systematic reviews accordingly. It is important that such a registry contains the appropriate data
ﬁelds and the UK NIHR HTA programme led an activity to compile such a data set. This workstream was
within the work package concerned with the production of additional evidence for new technologies
[work package 7 (WP7)].
Both activities were performed by the NETSCC using the principles of project management and are
described in detail in the following chapters.Evaluation of the European network for Health Technology
Assessment Joint Action project
Health technology assessment in the United Kingdom
Health technology assessment has been described as ‘the provision for health-care decision-makers of
high-quality research information on the cost, clinical effectiveness and broader impact of health
technologies. Health technologies are . . . all interventions offered to patients’.1 The ﬁndings of applied
research studies are vital in supporting an effective and efﬁcient health system.21
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INTRODUCTION
2Early attempts to improve health-care decisions in the UK’s NHS were aided by the publication of
Effectiveness and Efficiency: Random Reflections on Health Services by Cochrane in the early 1970s.3
This inﬂuential book identiﬁed the lack of good-quality data to guide health decisions and highlighted
the randomised controlled trial (RCT) as the most reliable assessment method. The UK’s NIHR Health
Technology Assessment programme (formerly the NHS Health Technology Assessment programme)
was established in the UK in 1993 with the purpose of producing such information for NHS clinicians.1
It commissions both evidence syntheses and RCTs.Previous European Union initiatives in health technology assessment
The EU Commission recognised HTA as a key tool in making health-care decisions.4 It supported
HTA-related studies in the 1980s and this continued throughout the 1990s and 2000s:
l EUR-ASSESS 1994–7: This represented the ﬁrst of a number of initiatives which aimed to form a
European network for HTA. It investigated harmonisation of HTA methodology, priority-setting
processes, strategies for disseminating results and issues on how to link the results of HTA
to coverage.5
l HTA Europe 1997–8: The main activity of HTA Europe was to describe the HTA processes and health
systems of all members of the European Union. These reports were published in the International
Journal of Technology Assessment in Health Care.6
l ECHTA/ECAHI (the European Collaboration for Assessment of Health Interventions and
Technology) 2000–2: This informal network provided the beneﬁts of working together, sharing
information, providing education and training and sharing methodologies.7European network for Health Technology Assessment 2006–8
In 2005 the EU called for proposals for projects to establish a European network for HTA. A group led by
the Danish Board of Health was invited to bid for this work, with the goal of developing a set of tools to
facilitate co-operation. Following this the EUnetHTA 2006–8 project was formed based on a contract
funded by an EU grant. This project aimed to ‘create an effective and sustainable network for HTA across
Europe that could develop and implement practical tools to provide reliable, timely, transparent and
transferable information to contribute to HTAs in member states’.8Project structure
The project was divided into eight work packages co-ordinated by a secretariat:
l co-ordination
l communications
l evaluation
l common core HTA
l adapting existing HTAs from one country into other settings
l transferability of HTA to health policy
l monitoring development for emerging new technologies and prioritisation of HTA
l system to support HTA in member states with limited institutionalisation of HTA.
Thirty-four associated partners (contributing to the budget and receiving a share of the grant) and
30 collaborating partners (participating at their own expense) contributed to the project. A 3-year work
plan was devised and followed.8 Governance was through a steering committee (consisting of all
associated partners) and an executive committee (consisting of all work package lead partners).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The main project deliverables were practical tools for conducting HTA. The two tools of potentially
immediate use to most HTA agencies were:
1. The core model: This is intended to serve as a platform to aid co-operation in developing a new HTA
report.9 It describes a number of domains (e.g. clinical, economic, etc.). The underlying idea is that
different HTA organisations can prepare each domain then enter their ﬁndings into a central library.
Each individual national organisation can then prepare its own local report for its own health economy
by drawing mainly on material contained within the central library (with minor modiﬁcations to ﬁt
local idiosyncrasies).
2. The adaptation toolkit: This toolkit helps HTA practitioners convert a report between different
health-care settings by working through a number of domains.10,11Evaluation of the European network for Health Technology Assessment
2006–8 project
Internal evaluation of the EUnetHTA project was an essential requirement of the EU and was the subject of
work package 3. This had three objectives:
1. to provide an audit function during the project with regular feedback to the European Commission and
the project organisation
2. to evaluate changes over time during the project period to show development towards the
establishment of an effective and sustainable network
3. to summarise lessons learned to support the effectiveness and sustainability of the network in its next
phase, from 2009 and onward.
The prospective evaluation consisted of three approaches: annual surveys of project participants,
twice-yearly interviews with work package leads and documentary analysis of work packages.12 It
concluded that the project had been successful in developing tools that describe a standard for conducting
and reporting HTAs and this should facilitate greater international collaboration. Support was evident for a
future network.12
The evaluation report included nine recommendations for a future sustainable network:
1. Secure funding, and maintain a dedicated co-ordinating secretariat.
2. Improve efﬁciency through an organisational structure made up of work packages managed by a core
of dedicated partners, with less committed partners taking part as a wider review group.
3. Continue developing and evaluating the tools as necessary.
4. Involve people in the work to ensure commitment, a high level of knowledge and a broad basis for
decision-making processes.
5. Encourage collaboration and communication among all parties to ensure coherence within groups
and EUnetHTA.
6. Continue developing the communication platform and functionality of the clearinghouse to make
EUnetHTA a central reference point for HTA in Europe.
7. Arrange face-to-face meetings, particularly at the start of group or committee work to strengthen social
coherence and reach a common understanding of the work.
8. Evaluate the tools used in real setting and the technical communication platform.
9. English should continue to be the main language.Evaluation of the European network for Health Technology
Assessment collaboration
After the completion of the project at the end of 2008, a number of the partners decided to maintain the
network and relationships which had been established over the previous 3 years. This collaboration was
established by 25 founding partner organisations from 13 EU member states, Norway and Switzerland.3
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4The main output from this year was an application for funding to DG SANCO’s call for a joint action in the
ﬁeld of public health, which became the ﬁrst EUnetHTA JA.European network for Health Technology Assessment Joint Action:
description of the project
The EUnetHTA JA was a further project funded by DG SANCO, with an overall aim of producing a
self-sustaining ongoing European collaboration in HTA. It aimed to ‘ensure the completion and
development of HTA in the EU, including work on relative effectiveness of drugs’. Collaboration between
the EU Commission and member state-appointed HTA agencies resulted in the establishment of a 3-year
joint action project (2010–12), which EUnetHTA was asked to perform. At its investure it was foreseen that
sustainability following the project would be ensured through an EU directive.8
The EUnetHTA JA project was based on a contract of a funding grant with the EU Commission DG SANCO
(2009 23 02 – EUnetHTA Joint Action) which speciﬁed what it must achieve. The technical annex of the
grant agreement described the action as ‘exchanging knowledge and best practice’ with the subaction,
‘Building on the expertise already developed in the ﬁeld of health technology assessment, ensure the
continuation and development of HTA in the EU, including work on relative effectiveness (RE) of drugs’.
It is important to make explicit the context of EUnetHTA within local political procedures. The strategic
position of the EUnetHTA JA is that ‘its outputs will be used to inform, but not mandate the content of
national/regional/institutional HTA reports’.13Aims and objectives of the European network for Health Technology
Assessment Joint Action project
The project had three aims:13
1. to facilitate the efﬁcient use of resources available for HTA
2. to create a sustainable system of HTA knowledge sharing
3. to promote good practice in HTA methods and processes.
The overarching objective of the EUnetHTA JA was to ‘establish an effective and sustainable HTA
collaboration in Europe that brings added value at the regional, national and European level’.
This was separated into three speciﬁc objectives:13
1. Development of a general strategy and a business model for sustainable European
collaboration on HTA. Speciﬁcally, this involves constructing a business model for collaboration
addressing the sustainability of the HTA collaboration within the EU.
2. Development of HTA tools and methods. Speciﬁcally, developing principles, methodological
guidance and functional online tools and policies.
3. Application and ﬁeld-testing of developed tools and methods. Speciﬁcally, testing and
implementation of tools and methods.Project participant health technology assessment agencies
At its commencement in autumn of 2012 the EUnetHTA JA comprised 38 government-appointed
organisations from 26 EU member states, Norway and Croatia. Organisations who were members of the
EUnetHTA JA were either associate partners (which received 50% funding from the EU grant and 50%
from national resources) or collaborating partners (who participated in the project at their own expense).
The main partner was the Danish Health and Medicines Authority, which also led the secretariat.European network for Health Technology Assessment Joint Action:
project structure
The work of the EUnetHTA JA was divided into eight work packages: three cross-cutting and ﬁve
stand-alone (Table 1).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 1 The structure of the EUnetHTA JA
Work
package Title Aim
1 Co-ordination To facilitate the achievement of the EUnetHTA JA general objective of putting into
practice an effective and sustainable HTA collaboration in Europe that brings added
value at the European, national and regional level
2 Communication To facilitate coherent, effective and sustainable external communication of the
EUnetHTA JA, where its aims, objectives, work in progress, results and ﬁnal
products are known to all partners, identiﬁed stakeholders and target groups in
the EU and at a national regional level
3 Evaluation To identify to what extent the individual work packages enable the EUnetHTA JA
to meet its objective
4 Core model Further development and testing of the core model developed in the
project 2006–8
5 Relative effectiveness
assessment of
pharmaceuticals
To apply the concepts developed in the core model to provide methods to test the
relative effectiveness of pharmaceuticals
6 Information platform Developing the tools and internal communication platform to support the other
work packages
7 New technologies To support collaboration on new technologies and to contribute to reducing
duplication of work by:
l exchanging information on and developing tools to facilitate evidence
generation (strand A)
l exchanging information on current assessments of new health technologies
(strand B)
8 Business plan Construction of a detailed business model for collaboration addressing the
sustainability of the HTA collaboration within the EU
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37All work packages had a lead partner agency that was responsible for submitting the 3-year work plan for
the work package, delivering its deliverables and reporting via the annual technical reports. WP2, WP4,
WP5 and WP7 also had a co-lead partner agency.
The governance structure is outlined in Figure 1.
Executive committee
The executive committee was composed of the lead partners of the eight work packages, the chairperson
of the plenary assembly (a non-voting member) and three elected members (from the EUnetHTA JA
member agencies). This committee was the main executive body involved in strategic leadership of the
project. Regular face-to-face meetings were held and e-meetings were held every 2 months.Plenary assembly
The plenary assembly was the main governance and policy-setting body of the EUnetHTA JA. It was
composed of the head of each partner organisation (or their representative). The chairperson was elected
by plenary assembly members and ensured liaison between the executive committee and the plenary
assembly. This annual meeting was of crucial importance because it represented the only meeting of all
project organisations and its function was to agree policy.The stakeholder forum
In formation of the EUnetHTA JA the EU Commission emphasised the importance of giving a greater focus
to stakeholders than had been given during the EUnetHTA 2006–8 project. The stakeholder forum was5
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FIGURE 1 The governance structure of the EUnetHTA JA. (Reproduced from www.eunethta.eu with permission from
EUnetHTA secretariat).
INTRODUCTION
6established in 2010 to facilitate information exchange with the stakeholders and was part of the
governance structure for the EUnetHTA JA.
European umbrella organisations, with four types of expertise, were invited to apply to join the stakeholder
forum: industry, patients/consumers, providers and payers. Despite several attempts it was not possible
to recruit experts to the health media category. Some eligible organisation that were approved for
participation in the EUnetHTA JA stakeholder forum were not selected for the ﬁnal list of the EUnetHTA JA
stakeholder forum members because of the limitation of the number of seats per stakeholder group. These
organisations received all the information that was circulated to members of the stakeholder forum. They
were able to provide written comments on such documents through representative organisations on the
forum or via the secretariat. Expertise was represented as follows.Industryl The European Co-ordination Committee of the Radiological Electromedical and Healthcare
IT Industry (COCIR).
l The European Federation of Pharmaceutical Industries and Associations (EFPIA).
l The European Generic Medicines Association (EGA).
l Eucomed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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a place:
l Association of the European Self-Medication Industry (AESGP)
l European Diagnostic Manufacturers Association (EDMA)
l EuropaBio
l The European Association of Pharmaceutical Full-line Wholesalers (GIRP).Patients/consumersl The European Consumers’ Organisation (BEUC).
l The European Cancer Patient Coalition (ECPC).
l The European Patients’ Forum (EPF).
l The European Rare Diseases Organisation (EURORDIS).
An additional organisation applied to join the EUnetHTA JA stakeholder forum, but was unsuccessful in
gaining a place:
l The European Federation of Neurological Associations (EFNA).Providersl The Standing Committee of European Doctors (CPME).
l European Hospital and Healthcare Federation (HOPE).Payersl Association Internationale de la Mutualité (AIM).
l European Social Insurance Platform (ESIP).European network for Health Technology Assessment Joint Action:
project deliverables
There were eleven project deliverables, which are shown in Table 2.TABLE 2 The project deliverables of the EUnetHTA JA13
Number Title Description
Work
package
responsible
Month of
delivery
1 An online tool and service for
producing, publishing, storing and
retrieving HTA information
It facilitates the use of the
paper-based HTA Core Model
developed previously, allowing to
produce, publish, store and retrieve
core HTAs and other HTA
information not included in core
HTAs. It supports production of local
reports using core HTAs
WP4 December
2012
HTA Core Model on screening A new application of the HTA
Core Model
WP4 March
2011
2 A set of two core HTAs Two completely new core HTAs on
topics that are pertinent to several
HTA agencies and that can be
utilised when producing local HTA
reports on the same topics
WP4 December
2012
continued
7
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ABLE 2 The project deliverables of the EUnetHTA JA13 (continued )
Number Title Description
Work
package
responsible
Month of
delivery
3 A methodological guidance that
will be appropriate for the
assessment of relative effectiveness
of pharmaceuticals
A common methodology for REA of
pharmaceuticals consisting of a
tutorial that describes the
fundamental principles of REA
and a toolbox that can be used in
daily practice for REA in
standardised fashion
WP5 December
2012
4 Operational web-based toolkit
including database-containing
information on evidence
generation on new technologies
Database including information on:
l questions that deserve AEG
l technologies with (conditional
approval) requirements for AEG
l planned, ongoing or completed
collection of data, e.g.
(pragmatic) clinical trials
WP7 September
2012
5 Quarterly communication protocol
for information ﬂow on ongoing/
planned national assessments of
same technologies
Protocols containing information on
ongoing/planned national
assessments of identical and
therefore alerted topics, to facilitate
the analysis of hindrances and
chances of collaboration on
speciﬁc topics
WP7 December
2012
6 IMS and the related
documentation, processes
and policies
The IMS provides a single point of
access ensuring compatibility to
resources that help to conduct HTA,
with emphasis on automation of the
content update processes
WP6 September
2012
7 Communication and
dissemination plan
Building on the communication
strategy developed during EUnetHTA
2006–8 project, an elaborated
communication and dissemination
plan will be written and
implemented as part of the
EUnetHTA JA
WP2 June 2011
8 Stakeholder policy Development of a stakeholder
involvement policy
WP1/WP8 October
2010
9 Collaboratively developed business
model for sustainability
Development of a collaborative
business model for sustainability
WP8 December
2011
10 A relative effectiveness assessment
of a (group of) pharmaceutical(s)
As a part of methodological
guidance development and in line
with the core-HTA development
WP5 March
2012
11 Final report from the EUnetHTA JA Final report including
evaluation results
WP3 December
2012
AEG, additional evidence generation; IMS, information management system; REA, relative effectiveness assessment;
WP, work package.
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Tools were developed during the EUnetHTA JA to help the production of HTA reports and collaboration
in HTA:
l EUnetHTA Planned and Ongoing Projects Database (POP; Ludwig Boltzmann Institute,
Vienna, Austria): This database was developed during the new technologies work package (WP7). It
aims to reduce duplication in HTA production and to facilitate collaboration between HTA agencies.
During 2010 it was available as an Microsoft Excel datasheet (Microsoft Corporation, Redmond, WA,
USA) and was converted into a database in 2011. Access to the POP database was restricted to those
EUnetHTA Partners who contributed data.
l HTA Core Model: This online tool aims to help with the production, storage and utilisation of
structured HTA information. It was developed during the EUnetHTA 2006–8 project and work
continued in EUnetHTA JA in the HTA Core Model work package (WP4).
l EVIdence DatabasE on New Technologies (EVIDENT): The EVIDENT was developed from the
EUnetHTA Interafe to Facilitate Furthering of Evidence Level (EIFFEL) database which was developed
during the EUnetHTA 2006–8 project. It allows the sharing of information about promising new health
technologies, remaining evidence gaps, recommendations or requests for further information and
additional data being collected.Informing clinical decision-makers about clinical research
studies under development: development of a data set to
inform a registry
The number of clinical trials is increasing yearly and many are undertaken for regulatory purposes. These
are explanatory in nature, thereby identifying whether or not an intervention can produce the desired
effect under ideal conditions.14 Such trials tend to be small in scale or involve investigational interventions
which are not in wide clinical use. By their nature they take place within small communities of
investigators. They are often funded by manufacturers or research charities – organisations with no wider
responsibility beyond their shareholders or donors.15
However, there is progressive growth and interest in pragmatic trials (and other prospective study designs)
which are designed to deliver clinical effectiveness and cost-effectiveness information to directly inform
policy, commissioning and clinical decision-makers. Pragmatic studies reﬂect the actual environment in
which clinical practice occurs and create robust evidence to inform these decision-makers,16,17 including
organisations such as the National Institute for Health and Care Excellence (NICE) in the UK. These studies
are often large and expensive – as they often involve active comparators and ‘soft’ concepts such as ‘usual
care’ and ‘best current treatment’.18 They are often commissioned through publicly funded research
management organisations, such as the NIHR in the UK and, hence, these funders must consider taxpayer
value for money in their decision-making processes. This is money which if not spent on medical research
would, in all likelihood, have been spent on direct clinical care. It behoves such funders to be aware of the
activities of their counterparts in other international funding agencies so as not to commission work when
the answers would be available elsewhere.
For established, funded clinical trials the scenario is simple. All such studies should be entered into one of
a number of international clinical trials registries, such as ClinicalTrials at the National Institute of Health
and Current Controlled Trials. Among other beneﬁts, this enables:
l triallists to see what work is under way in their ﬁeld
l clinicians to identify trials in which they might like to take part or enrol their patients
l reviewers and policy-makers to assess publication bias, by using registered trials as a denominator.9
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INTRODUCTION
10Some funders make this a condition of funding and many journals will only publish studies which have
been prospectively registered.19,20 A funder, therefore, only has to check a limited number of registries for
overlapping studies to become aware of what is already under way in a ﬁeld and decide if it is sufﬁciently
similar to what is planned.
The scenario is much more complex for pragmatic trials when earlier in their gestation. A trial is effectively
invisible outside the organisation which may fund it when it is anywhere in its life from a funder having an
idea or receiving an application through to a short period of time after a funding decision. Importantly, this
runs the risk of multiple funders accidentally spending their limited resource on similar studies – which,
perversely, may not be similar enough to allow subsequent meta-analysis of outcomes. Existing registries
go part way to addressing this need by allowing funders to identify trials that are under way. However,
there remains a gap because there is no widely used registry that tracks trials in development. Therefore,
funders run the risk of developing trials in parallel, which may have been avoided or ameliorated if they
had been aware of parallel activity.
An example of limited alignment of outcome measures is illustrated by the SOLD (Synergism or Long
Duration), PERSEPHONE (Phase III Randomized Study of Neoadjuvant or Adjuvant Trastuzumab (Herceptin®)
in Women With HER2-Positive Early Breast Cancer) and PHARE (Protocol of Herceptin Adjuvant With
Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving
Adjuvant Herceptin) trials, which were all funded around 2006.21,22 These studies all compared the use of
various durations of trastuzumab (Herceptin®, Genentech), using patient relevant outcomes and were, in
essence, pragmatic in design. The commissioned trials are comparatively ‘stand alone’. None of their
primary outcomes were directly comparable – they used different measures, and those with similar
measures assessed them at different end points. It is likely that had the agencies been aware of these
trials in parallel development, they could have included appropriate outcome measures to facilitate
meta-analysis or other comparison between them.
An example of what should be possible is the interaction between the CATT (Comparison of Age-Related
Macular Degeneration Treatments Trials) and IVAN [A randomised controlled trial (RCT) of alternative
treatments to Inhibit VEGF in patients with Age-related choroidal Neovascularisation (IVAN)] trials.23–25
These trials investigated the use of ranibizumab and bevacizumab (Avastin®, Genentech) in the
management of wet age-related macular degeneration (AMD). Brieﬂy, both agents are manufactured by
the same drug company. Ranibizumab is licensed for the management of wet AMD and bevacizumab is
not. Ranibizumab is approximately two orders of magnitude more expensive. There were good biological
reasons to believe that both drugs would have similar clinical effectiveness in the management of wet
AMD. Discussion between the trial teams during the design and set up of these trials led to an agreed set
of primary and secondary outcome measures and a subsequent demonstration that neither drug is
superior to the other. Given the hostility of the pharmaceutical industry towards these trials (and the
implication of their ﬁndings for industry proﬁt margins), the similar results demonstrated against the same
outcome measures will give commissioners added conﬁdence should they decide to commission a service
based on the cheaper (and, hence, more cost-effective) agent.
There is, therefore, a need for a system to facilitate the identiﬁcation of pending similar pragmatic studies
by international trial funders. This would enable optimisation of scarce public resources – both ﬁnancial,
and in terms of patients and researchers. Desbiens suggested that a ‘Registry of Hypothesis’ should be
developed and shared by the medical community.26 It seems to us that such a registry is too far divorced
from the reality of actual funding of a trial – there are many ideas but not all are worth committing
resources to. In addition, to a funder, what is important is not who had an idea, but who else might be
funding a relevant trial.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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ﬁlling this gap, and led to several opportunities:
l Funders could commit to one multinational study, rather than multiple smaller studies.
l Funders could ensure that at least some outcome data in multiple studies would be directly
comparable – thus facilitating meta-analysis.
l On a global basis, this would facilitate an optimum distribution of trial funding, e.g. knowledge of
what each funder had planned could facilitate interfunder discussion to obtain maximum value from
the resources each had to contribute.
l With an indicative map of possible trials, systematic reviewers may be able to better plan when to
conduct updates of existing reviews.
l Similarly, policy-makers may be able to plan when to consider updates of their guidance.
Such a registry could (indeed, should) include the hypothesis to be tested, therefore addressing Desbiens’
call for hypotheses to clearly be developed a priori.26
We considered who such a registry should be aimed at and, speciﬁcally, who should register potential
studies and who should have read access. The two options are funders and researchers. The incentives and
disincentives are different for the two groups.
Funders are motivated to avoid unconscious duplication of funding and maximise the value of the overall
research resource they control. They are, therefore, more likely to register studies they are considering with
a registry and keep that information up to date.
A researcher might feel this, but is also driven to obtain funding for their own ideas and, hence, avoid the
risk of having their research ideas copied by others. We considered that an individual researcher is less
likely to submit their ideas to a public registry.
Therefore, we consider that a registry for pragmatic trials in development is more likely to work if the main
adopting groups are trial funders.
Should a registry go ahead, consideration should be given to its performance characteristics, but also
whether or not it contributes to the originally identiﬁed issues of reducing unconscious duplications and
promoting discussion and potentially collaboration between funders.11
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Technology Assessment Joint Action projectEvaluation approach
Internal evaluation process
Evaluation is an important facet of project management and evaluation of the EUnetHTA JA was a
requirement of the EU. There are two types of evaluation: internal evaluation (performed by staff directly
involved in the project work) and external evaluation (performed by an expert who is not involved in the
project). The EU Commission had speciﬁed that the former approach should be used, as it had been used
in the previous EUnetHTA 2006–8 project. As recommended in conducting evaluations of European
projects, the evaluation plan was a key component and integrated within the EUnetHTA JA project from
the beginning.27
These activities were the subject of a speciﬁc work package [WP3 (Evaluation)], led by the NETSCC
represented by Dr Eleanor Guegan and Dr Andrew Cook.Strategic evaluation outcome
Rationale
Evaluation has been deﬁned as, the ‘systematic assessment of the operation and/or the outcomes of a
program or policy, compared with a set of explicit or implicit standards, as a means of contributing to the
improvement of the program or policy’.28 Such critical reﬂection can be performed retrospectively (after
the programme has ended) or prospectively (designed at the start of the programme). A prospective
methodology is the gold standard for evaluation research and was used to evaluate the EUnetHTA JA.
Project evaluation allows monitoring of the processes of the project and achievements against speciﬁed
criteria for success. This enables assessment of the effectiveness and achievements of the project and the
formation of ‘lessons learned’ recommendations to inform future projects. It also ensures accountability
against project plans.29 There are three main types of evaluation for projects:29
1. Formative evaluation: This ongoing evaluation starts early in the project and assesses the nature of
the project, the needs that the project addresses and monitors the progress of the project. It identiﬁes
gaps in the content and operational aspects.
2. Process evaluation: This monitors the project to ensure it is being completed as designed and to the
time schedule.
3. Summative evaluation: This is an overall assessment of the project’s achievements and the
effectiveness of its processes. It is completed at the end of the project and provides evidence to support
the performance of future projects.
The ﬁrst stage in the evaluation process was creating a project evaluation plan. The main purpose of the
evaluation was to identify to what extent the individual work packages enabled the EUnetHTA JA to meet
its objectives. This included project participants’ and external stakeholders’ perception of the project
processes and deliverables. Documentary review enabled identiﬁcation about whether or not the
deliverables had been produced by the work streams according to the work plan.13
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METHODS
14This evaluation was a systematic data collection designed to develop generalisable knowledge and to
contribute to quality improvement of the EUnetHTA JA project:
i. The impact of the project was assessed by an outcome evaluation (identifying the success of delivering
the stated project deliverables). However, it should be noted that, although it was possible to measure
whether or not the outputs had been delivered in accordance with the work plan, assessment of their
quality and cost–utility was beyond the scope of the evaluation agreed by the EU Commission.
ii. The effectiveness of the project was evaluated by its processes (identifying the effectiveness of the
processes employed during the project).Evaluation questions
There were two primary evaluation questions:
1. Will the EUnetHTA JA achieve its overarching objective, and ultimately did it?NIHRThe overall objective was deﬁned in the technical annex for the EUnetHTA JA as, ‘The overarching
objective of the JA, including work on relative effectiveness of pharmaceuticals, is to put into practice
an effective and sustainable HTA collaboration in Europe that brings added value at the European,
national and regional level.’
This was assessed by whether or not an effective and sustainable HTA collaboration, not reliant on
project funding, had been set up at the end of the EUnetHTA JA project.2. Will the EUnetHTA JA achieve its speciﬁc objectives, and ultimately did it?
Three subobjectives were deﬁned in the technical annex of the grant agreement for the EUnetHTA
JA13 as:
– Development of a general strategy and a business model for sustainable European collaboration on
HTA.
– Development of HTA tools and methods.
– Application and ﬁeld-testing of developed tools and methods.¢ Documentary analysis was used to determine whether or not the work packages had produced
their deliverables by the end of the EUnetHTA JA project.
¢ A prospective evaluation strategy mapped out and evaluated how the activities and deliverables
of the individual work packages supported the EUnetHTA JA objectives. The individual work
packages within the EUnetHTA JA can themselves be seen as individual projects (with their own
objectives, milestones and deliverables) contributing to the overall programme of work of the
EUnetHTA JA. This means it was necessary to aggregate evaluation outcomes from the
individual projects.Questions were included in the questionnaires sent to participants to examine:
l demographic information about the nature of participants, their organisations and the HTA
information they produce
l the setting-up process for the project
l progress of the project in the interim year
l administrative support and communication from the co-ordinating secretariat
l the role of information technology in supporting the project
l involvement of external stakeholders
l the workings of the eight internal work packages
l the planned follow-up project – European network for Health Technology Assessment Joint action 2
(EUnetHTA JA2).Journals Library www.journalslibrary.nihr.ac.uk
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l the mechanisms of the stakeholder forum
l the EUnetHTA JA project
l the workings of the eight internal work packages
l the planned follow-up project – EUnetHTA JA2.
Various terms were used in the evaluation and these are summarised in Box 1.
Evaluation methodologyPossible evaluation methods
Several research instruments could have been used to perform the evaluation, such as interviews, focus
groups, observations, case studies, questionnaires and document review, which are described below:
l Interviews: This research methodology enables the probing of a topic with one interviewee to
explore meanings and uncover new areas not anticipated at the outset of the research.30 These can
adhere strictly to a formalised interview schedule (structured) or allow divergence from a schedule to
pursue an idea in more detail (semistructured).30 They have the advantage of probing a subject in detail
to obtain rich qualitative data, but are expensive and can be difﬁcult to arrange. It would have been
useful to have used this methodology in the evaluation to probe the questionnaire data in greater
depth, but unfortunately this was beyond the resource agreed by the EU.
l Focus groups: This is a form of group interview that generates data from the interaction of the group
participants.31 This has particular advantages in exploring the way people think and perceive things,
with ﬁndings being generated as a result of group discussions. Like individual interviews, they allow
the probing of qualitative data. However, they are expensive and it can be difﬁcult to arrange all
participants together in one location at a speciﬁed time to conduct the focus group.31 It would have
been useful to have employed this methodology in the evaluation, for instance with a group of
stakeholders, but unfortunately this was beyond the resource agreed by the EU.BOX 1 Terminology used in the evaluation
Overarching objective: This was the main objective of the EUnetHTA JA and was assessed by whether or
not an effective and sustainable HTA collaboration, not reliant on project funding, had been set up at the
end of the EUnetHTA JA project.
Speciﬁc objectives: These were the secondary project objectives of the EUnetHTA JA and were assessed by
documentary analysis of whether or not the speciﬁed deliverables had been produced.
Deliverables: These were the 11 speciﬁc deliverables (see Table 2) that the project committed to produce.
Whether or not these had been delivered according to plan was assessed by documentary analysis of ﬁnal
technical reports submitted by work packages at the project end.
Performance indicators: These are criteria developed for evaluation of the overall success of the project.
Project impact: This was measured by evaluating whether or not the project’s overarching objective and
speciﬁc objectives had been met and the deliverables produced. These were the speciﬁc performance
indicators to enable judgement about the project’s impact.
Project effectiveness: This was measured by evaluating how well the project’s processes had worked. The
speciﬁc performance indicators for this were assessment of communication within the project, administration
by the co-ordinating secretariat, involvement of external stakeholders and management of the eight
constituent work packages. Whether or not lessons had been learnt and progress made from the preceding
EUnetHTA 2006–8 project was also evaluated.
15
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METHODS
16l Observations: This methodology involves the researcher systematically watching people and events to
discover behaviours and interactions in a setting, then describing and analysing what has been
observed.32 This allows identiﬁcation of any discrepancies between what people say they do and what
they actually do. This method was not considered appropriate for the current evaluation.
l Case studies: This research methodology is used when broad questions need to be addressed in
complex circumstances and it typically involves mixed methods of quantitative and qualitative
methods.33 The selection of sites is of key importance to this methodology. This method was not
considered appropriate for the current evaluation.
l Self-completion questionnaires: These confer several advantages for collection of data from project
participants and external stakeholders: standardisation of question wording eliminates the possibility of
interviewer bias, respondents are allowed to complete the questionnaire at their own convenience and
a greater degree of conﬁdentiality is provided than in interviews.34 However, they also pose several
disadvantages; they are difﬁcult to design, are impersonal and inﬂexible and are dependent on having
a valid sampling frame of the correct details of recipients.27 They are often the only viable survey
format when trying to obtain information from a large cohort of respondents that are within a
geographically dispersed population.35
l Documentary review: This allows review of a project using documents routinely produced without
artiﬁcially interfering with the project. This enables retrieval of contextual and historical information
about a project. However, by deﬁnition this means that the data collection is limited and inﬂexible, and
incomplete data might be encountered.
It was necessary to select which evaluation methods would be most appropriate and feasible within the
economic, geographic and time restraints of the project. The methods chosen were self-completion
questionnaires (owing to the international location and large number of evaluation participants) and
documentary review. It would have been ideal to have also used key informant interviews to obtain richer,
qualitative data about what was going well in the project, what could be improved and suggestions for
improvement, etc. However, unfortunately, this was not possible owing to time and cost restraints
(according to the scope of the evaluation agreed by the EU), and this is a major limitation of the
methodology. This meant that it was unfortunately not possible to follow up non-respondents to questions
with qualitative enquiry to interpret their views. This has meant that the reasons for non-response have
been speculated but it was impossible to substantiate this.Self-completion questionnaires
The evaluation participants were in two survey populations:
l project participants – members of EUnetHTA JA partner organisations
l external stakeholders.
This allowed triangulation of information between the project participants and external stakeholders for
common topics. Participants at the annual policy-setting plenary assembly meeting were asked to evaluate
the meeting.
l Annual electronic surveys were sent to project participants and external stakeholders. In some cases
the same questions were repeated in questionnaires of different years to allow some assessment of
longitudinal data. However, evaluation of such longitudinal elements was severely limited because the
large turnover of staff meant it was difﬁcult to assess whether an element had changed over time or
this change was due to the responses of different respondents.
l Paper questionnaires were disseminated at each of the annual plenary assembly meetings which asked
respondents to evaluate the meeting.
The process for each questionnaire followed the same schedule (Figure 2).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The ﬁrst stage in the design of a questionnaire is the preparation of a ‘questionnaire speciﬁcation’ – a
comprehensive list of every variable that must be measured.36 In the current research these were the
important aspects, or ‘dimensions of performance’, of the EUnetHTA JA project that needed to be
measured.27 In any evaluation it is impossible to assess all component parts of a project and, therefore, a
conscious selection process was performed to consider what needed to be evaluated. Questions were then
grouped into a series of ‘question modules’ each concerned with a particular variable, as recommended
for survey design.36 Attention was paid to the order of the individual questions within the question
modules to ensure a logical sequence throughout the questionnaire.Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
A mapping exercise was undertaken to identify which aspects of the project should be assessed at the
different time points. One of the objectives of the evaluation was to ‘generate maximum support for
the work packages whilst actively seeking evaluation and monitoring solutions that minimise the burden’.
This objective was met by decreasing the burden of answering extra questionnaires issued by different
work packages. This was achieved by combining questions from other work packages into the
questionnaires. The evaluation had been speciﬁcally contracted to include questions from the information
management work package (WP6). As a courtesy it also included questions from the training strand of the
WP8 work package in all three questionnaires and from the dissemination work package (WP2) in 2010.
Extensive collaboration was undertaken with the leaders of these other EUnetHTA JA work packages to
incorporate their questions. In addition, a questionnaire design workshop was held with participants
of the WP6.
Evaluation was performed at three checkpoints within the project, i.e. baseline, interim and towards
the end:
l The formative evaluation started at the baseline of the project (month 6, June 2010). This incorporated
the key processes of measuring and monitoring to enable identiﬁcation of emerging issues, and
feedback to the executive committee by evaluation reports. These reports were an appendix to the
annual reporting mechanism. The baseline questionnaire captured expectations for the project,
experiences during the set-up and identiﬁed early concerns about the project.
l The interim evaluation (mid-term evaluation) of progress against the project plan was performed in
month 18 of the project (June 2011). This identiﬁed progress against the plan and identiﬁed problems
requiring corrective action, which were fed back to the executive committee.
l The ﬁnal annual questionnaire survey was performed in month 30 (June 2012). This was a
towards-the-end evaluation to identify whether or not the objectives of the EUnetHTA JA had been
met and ﬂagged-up problems effectively resolved. A limitation of the evaluation was that the EU had
requested this be completed before the end of the project.17
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18Evaluation of the plenary assembly meetings
Following the process described above, a standard paper evaluation form was designed to measure
participants’ attitudes about attributes of this policy-setting meeting. This was designed to consider:
l whether or not the meeting met its objectives
l satisfaction with the conference venue and facilities
l what the best thing about the meeting was
l what the worst thing about the meeting was
l how the next year’s meeting could be improved.
Analysis of the ‘open’ questions from the 2010 survey allowed identiﬁcation of themes. Therefore, the
2011 and 2012 surveys also included a grid of meeting attributes and Likert answer options to address
these themes:
l receiving meeting documents in advance
l leadership of the meeting
l relevance of items discussed
l meeting and networking with colleagues
l venue and meeting facilities
l social event.
At the request of the secretariat, additional questions were included in the 2011 and 2012 surveys.
These addressed:
l when meeting documents were received
l when meeting documents were read
l input into developing the meeting agenda.Question design
Broadly speaking, there are two types of questions that can be used in questionnaires: ‘closed’ questions
and ‘open’ questions. Both types of questions were used in the questionnaires.
Closed questions have possible answers predeﬁned by the survey designer and are analysed by frequency
measures. They are several different formats: multiple choice, only one choice, Likert scale and matrix.
They have the advantage of being easier to analyse than open questions.37 Multiple-choice questions
allowed various choices to be chosen as applicable or may only allow one answer. Likert questions
requested respondents to indicate their response according to a predeﬁned scale. However using closed
questions means that respondents do not have the ability to provide their own response and, therefore,
the richness of potential responses can be limited.38 There is also the possibility that the answer options are
biased and it is important to test this during the piloting phase. A limitation of closed questions is that
respondents do not have the ability to explain their answers.39 This aspect was considered in the design of
the questionnaires in the evaluation. To counterbalance this potential problem, most closed questions also
included a free-text box to allow respondents to explain their answer, if they wished. This type of question
is classiﬁed as an ‘expansion’ open question. Such questions act as safety nets, explaining the results of
closed questions and identifying new issues not covered by closed questions.24
Open or free response questions allow respondents to provide their own answers and allow respondents
to express their thoughts in their own language.36 These enable respondents to explain their responses and
provide qualitative data. Although these types of questions provide rich data they require more effort to
analyse and this was factored into the analysis period.39 The Cochrane systematic review about methods
to increase response to postal and electronic questionnaires identiﬁed that the odds of response were
reduced by more than half when open questions are used.40 It was important to be aware of this and to
design the questionnaire to contain both open and closed questions. The majority of questions combinedNIHR Journals Library www.journalslibrary.nihr.ac.uk
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their response.
The questions included in the participant questionnaires are summarised below in Table 3.
The questions included in the external stakeholder questionnaires are summarised in Table 4.
Attention was paid to the design and wording of the individual questions, according to
recognised guidance:36,41
l avoid long questions
l avoid double-barrelled questions
l avoid double negatives
l ensure inclusion of ‘Don’t Know’ and ‘Not Applicable’ answer options where applicable
l use simple words, avoid jargon, and avoid abbreviations
l avoid ambiguous words
l make questions speciﬁc
l ensure all reasonable response alternatives are included.TABLE 3 Questions included in questionnaires for the project participants
Question topic
Question
type
Baseline
questionnaire
(2010)
Interim
questionnaire
(2011)
Final
questionnaire
(2012)
Tracker
question
Demographics
Professional expertise Closed ✓ ✓ ✓ ✓
Gender Closed ✓ ✗ ✗ ✗
Age Closed ✓ ✓ ✓ ✓
Length in HTA Open ✓ ✗ ✓ ✓
Membership of international
HTA organisations
Closed ✓ ✗ ✗ ✗
HTA practitioner Closed ✗ ✓ ✓ ✓
Lead person Closed ✗ ✓ ✓ ✓
Organisational expertise Closed ✗ ✗ ✓ ✗
Organisational and HTA information
Difﬁculties applying Combined ✓ ✗ ✗ ✗
Sufﬁcient funding Combined ✓ ✓ ✓ ✓
Sufﬁcient staff Combined ✓ ✓ ✓ ✓
Succession planning Combined ✓ ✗ ✗ ✗
HTA information Closed ✓ ✗ ✓ ✓
Setting-up process
Achievement of objectives Combined ✓ ✗ ✗ ✗
Set-up with EU Combined ✓ ✗ ✗ ✗
Organisation into work packages Combined ✓ ✗ ✗ ✗
Understand the aims of
work packages
Closed ✓ ✗ ✗ ✗
continued
19
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TABLE 3 Questions included in questionnaires for the project participants (continued )
Question topic
Question
type
Baseline
questionnaire
(2010)
Interim
questionnaire
(2011)
Final
questionnaire
(2012)
Tracker
question
Foundation as a sustainable
collaboration
Combined ✓ ✗ ✗ ✗
Progress
Achievement of objectives Combined ✗ ✓ ✓ ✓
Foundation of a sustainable
European collaboration
Combined ✗ ✓ ✓ ✓
Value added Combined ✗ ✓ ✗ ✗
Concerns about work packages Combined ✗ ✓ ✓ ✓
Evaluation
Achievements Combined ✗ ✗ ✓ ✗
Personal gain Combined ✗ ✗ ✓ ✗
External promotion Open ✗ ✗ ✓ ✗
Administration and communication
Secretariat leadership Combined ✓ ✓ ✓ ✓
Secretariat administration Combined ✓ ✓ ✓ ✓
Secretariat other activities Combined ✓ ✗ ✗ ✗
Understood information needed Combined ✓ ✗ ✗ ✗
Secretariat e-mails Combined ✓ ✗ ✗ ✗
Project intranet Combined ✓ ✗ ✓ ✓
E-meetings Combined ✓ ✗ ✗ ✗
Communication issues Combined ✓ ✓ ✓ ✓
Communication methods Combined ✗ ✓ ✓ ✓
Project conference Combined ✗ ✗ ✓ ✗
Renewal of project identiﬁcation Combined ✗ ✗ ✓ ✗
Improvement of communication Open ✗ ✓ ✗ ✗
Project challenges Open ✓ ✓ ✓ ✓
Project beneﬁts Open ✓ ✓ ✓ ✓
Negative effects of participation Combined ✗ ✓ ✓ ✓
Positive effects of participation Combined ✗ ✓ ✓ ✓
Information technology
Operating system Closed ✓ ✗ ✗ ✗
Browser Closed ✓ ✗ ✗ ✗
Software packages Closed ✓ ✗ ✗ ✗
Communication systems Closed ✓ ✗ ✓ ✓
Social media Closed ✓ ✗ ✓ ✓
Smart phone/tablet Closed ✗ ✗ ✓ ✗
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TABLE 3 Questions included in questionnaires for the project participants (continued )
Question topic
Question
type
Baseline
questionnaire
(2010)
Interim
questionnaire
(2011)
Final
questionnaire
(2012)
Tracker
question
Tools
Use/awareness Closed ✓ ✓ ✓ ✓
Priority for training Closed ✓ ✓ ✓ ✓
Preferred training method Closed ✓ ✗ ✓ ✓
Anticipated mobile use Closed ✗ ✗ ✓ ✗
Barriers to tools Closed ✓ ✓ ✓ ✓
Improvements to tools Open ✓ ✓ ✓ ✓
Stopped using tools Open ✗ ✗ ✓ ✗
Stakeholders
Concerns Open ✗ ✓ ✓ ✓
Beneﬁts Open ✗ ✓ ✗ ✗
EUnetHTA JA2
Concerns Combined ✗ ✓ ✓ ✓
Process Combined ✗ ✓ ✗ ✗
Impact of planning Combined ✗ ✓ ✗ ✗
Improvement Open ✗ ✓ ✗ ✗
Use as a follow-up Combined ✗ ✗ ✓ ✗
Main learning point Open ✗ ✗ ✓ ✗
Involvement of stakeholders Open ✗ ✗ ✓ ✗
Improvement of communication Open ✗ ✗ ✓ ✗
Work packages
WP1 Combined ✓ ✓ ✓ ✓
WP2 Combined ✓ ✓ ✓ ✓
WP3 Combined ✓ ✓ ✓ ✓
WP4 Combined ✓ ✓ ✓ ✓
WP5 Combined ✓ ✓ ✓ ✓
WP6 Combined ✓ ✓ ✓ ✓
WP7 Combined ✓ ✓ ✓ ✓
WP8 Combined ✓ ✓ ✓ ✓
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TABLE 4 Questions included in the questionnaires for the external stakeholders
Question topic
Question
type
Baseline
questionnaire
(2010)
Interim
questionnaire
(2011)
Final
questionnaire
(2012)
Tracker
question
Stakeholder forum
Purpose of stakeholder forum Open ✓ ✓ ✗ ✓
Fulﬁlment of purpose Combined ✗ ✓ ✓ ✓
Awareness of stakeholder forum Open ✓ ✗ ✗ ✗
Why applied for membership Open ✓ ✗ ✗ ✗
Membership role as expected Combined ✗ ✓ ✗ ✗
Role as a member of the forum Open ✓ ✗ ✗ ✗
Role represents a good use of
organisation’s time
Combined ✗ ✓ ✓ ✓
Beneﬁts of membership Open ✓ ✗ ✓ ✓
Challenges of membership Open ✗ ✗ ✓ ✗
Effectiveness of the stakeholder
advisory groups
Open ✗ ✓ ✓ ✓
Contributions to the project Open ✗ ✓ ✓ ✓
Offer by membership Open ✓ ✗ ✗ ✗
Setting up of the forum Combined ✓ ✗ ✗ ✗
Comments about relevant
documents
Open ✓ ✗ ✗ ✗
Comments about the meetings Open ✓ ✓ ✓ ✓
Consideration of stakeholders’
views
Combined ✓ ✓ ✓ ✓
Feedback to stakeholders Open ✓ ✓ ✓ ✓
Correct organisations included Combined ✗ ✗ ✓ ✗
Concerns about involvement of
stakeholders
Combined ✗ ✗ ✓ ✗
EUnetHTA JA project
Achieving objectives Combined ✓ ✓ ✓ ✓
Organisational structure Combined ✓ ✗ ✗ ✗
A foundation for a European
collaboration
Combined ✓ ✓ ✗ ✓
Functions of a European
collaboration
Open ✓ ✓ ✓ ✓
Added value of a European
collaboration
Combined ✗ ✗ ✓ ✗
Achievement of a European
collaboration
Open ✗ ✓ ✗ ✗
Interactions of a European
collaboration with stakeholders
Open ✗ ✓ ✗ ✗
Attendance at plenary assembly
meeting
Combined ✗ ✓ ✗ ✗
External project promotion Combined ✗ ✗ ✓ ✗
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TABLE 4 Questions included in the questionnaires for the external stakeholders (continued )
Question topic
Question
type
Baseline
questionnaire
(2010)
Interim
questionnaire
(2011)
Final
questionnaire
(2012)
Tracker
question
Use of tools for HTA producers Combined ✗ ✗ ✓ ✗
Would appreciate training in tools Combined ✗ ✗ ✓ ✗
Holding a regular conference Combined ✗ ✗ ✓ ✗
EUnetHTA JA2
Consultation about planning Combined ✗ ✓ ✗ ✗
Concerns about EUnetHTA JA2 Combined ✗ ✓ ✓ ✓
Usefulness as a project follow-up Combined ✗ ✗ ✓ ✗
Learning from EUnetHTA JA to
inform EUnetHTA JA2
Open ✗ ✗ ✓ ✗
Improvement of communication Open ✗ ✗ ✓ ✗
Work packages
WP4 Combined ✓ ✓ ✓ ✓
WP5 Combined ✓ ✓ ✓ ✗
WP7 Combined ✓ ✓ ✓ ✗
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37Formatting
It is important that questionnaires are designed to be visually attractive as this has been shown to
encourage high response rates.39 In this respect, the layout and ﬂow of the questionnaires was important
and the ordering of questions needed to be logical.Checking of recipient details
It was vital to have an accurate sampling frame for the questionnaires. This ensures that all relevant
recipients have been surveyed and ensures integrity of the response rate calculation. It is difﬁcult, but
necessary, to differentiate between genuine non-responders and those recipients for whom an incorrect
name or e-mail address has been used; therefore, the use of an accurate mailing is essential.42Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
It was feasible to survey the entire population and, therefore, no selected sampling was required. An Excel
database was obtained from the EUnetHTA JA secretariat which contained details of the EUnetHTA JA
project participants in the individual project work packages. This was restructured into a comprehensive
database of all the project participants using the following data ﬁelds:
l ﬁrst name
l surname
l e-mail address
l organisation
l membership of individual work packages.23
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METHODS
24The heads of each organisation were asked to conﬁrm the validity of the information of their staff working
for EUnetHTA JA. This feedback resulted in a fairly substantial reﬁnement of the contact database.
A pre-notiﬁcation e-mail was sent to all project participants in advance of sending them a questionnaire.
This enabled the correction of any incorrect information and querying of e-mails for which ‘bounce backs’
were obtained. Pre-notiﬁcation of survey recipients prior to the questionnaire send-out is a strategy that
has been shown to increase response rate by 50%.40 It emphasises the legitimacy of the questionnaire and
communicates the value of response.43 For the current study each recipient of a questionnaire was sent an
e-mail 1 week before the send-out notifying them when the questionnaire would be sent to them, the
importance of their completing it and the deadline for completion. This also served the purpose
of checking e-mail addresses and correcting any errors about work package membership (in the case of
project participants) or sending the survey to a nominated colleague instead (in the case of stakeholders).
Details of the representatives of the stakeholder organisations were also obtained from the EUnetHTA
JA secretariat.Evaluation of the plenary assembly meetings
All participants who attended a meeting were surveyed. Therefore, it was unnecessary to perform this
stage because the recipients were physically in the room.Piloting
One disadvantage of the use of self-completion questionnaires is that questions may remain
non-completed, without the possibility of explanation. Therefore, time and effort must be spent on
designing useful, unambiguous questions. It is important that both the reliability and validity of the
questionnaire instrument is assured:
l Reliability concerns how different people will interpret a question. For a question to be classiﬁed as
‘reliable’ respondents must interpret it in the same way and it must therefore be repeatable.36
l Validity concerns whether or not the questionnaire actually measures the data it intends to.27
Before sending out the questionnaire to the recipients it is essential to pilot it on a representative sample
ﬁrst. This is a ‘quality assurance’ method to ensure that the questionnaire contains the correct spelling, is
grammatically correct and has a good layout. It also aims to prevent any problems with comprehension
and to ensure that the format of the overall survey instrument and individual questions are appropriate.39
It was important to consider that this was a European project with participants communicating in the
common language of English. This was therefore not the native language of the vast majority of
participants. Special considerations must be given to the interpretation of question wording and answer
options by respondents who are not native English speakers, ensuring the concept is properly understood.
This meant that it was necessary to pilot the questionnaires with people who were non-native speakers of
English, including those whose primary language was French, German or Spanish.Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
Questionnaires were piloted with members of the lead partner organisation who were non-native English
speakers. Comments were also sought from members of the EUnetHTA JA executive committee and the
European Commission. A design workshop was held with members of WP6 in 2010 and the lead partners
of WP6 (French) and WP8 (Spanish) also piloted the questionnaires prior to the send-out.Evaluation of the plenary assembly meetings
The form was piloted by members of the lead partner organisation.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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When disseminating a questionnaire it is necessary to choose between the possible distribution methods
of postal, telephone or internet. Until the 2000s, the primary means of distribution of questionnaires
was by face-to-face interviews or postal questionnaires and the advantages and disadvantages of these
approaches have been discussed.36,40,41 However, the 2000s saw the advent of new distribution methods
such as e-mail and the internet. The earliest electronic questionnaires involved the distribution of a
document [designed in Microsoft Word® (Microsoft Corporation, Redmond, WA, USA) or similar] by
e-mail. The EUnetHTA 2006–8 project was also evaluated by questionnaire. However, these were sent by
e-mail and the respondent required to record their responses on a Microsoft Word document and e-mail
this back to the questionnaire administrator. The effort required in e-mailing the survey back may have
contributed to the low response rates received for that questionnaire (23–26% over the years 2006,
2007 and 2008).Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
The choice of mode of transmission of the questionnaires in the current research was between postal mail,
telephone, e-mail and web based. For this study the participants were geographically dispersed over
Europe and, therefore, postal distribution was not a practical possibility owing to ﬁnancial and logistical
limitations. Telephone questionnaires were also impractical. A web-based questionnaire that could be
completed at the convenience of the respondent was preferable and the recipients were familiar to e-mail
communications and using the internet.
Web-based surveys offered several advantages compared with post for the current research: there was a
signiﬁcant cost reduction when considering the international survey population and a quicker turnaround
time.44 In addition to electronic transmission of surveys by e-mail, web-based applications enable automatic
data collection. The design of web surveys may be more important than for print surveys. This is primarily
because a web-based survey can be displayed differently to a respondent as a result of computer-related
glitches and the coding system offers more design capabilities than print.44 However, the increased ability
for design capabilities must be used with some caution because too many design features may lead to
overcomplication and a decreased response rate.
Different possible online survey platforms were investigated for the distribution of the questionnaires and
SurveyMonkey.com® (Palo Alto, CA, USA) was selected for ease of use and function capability. A paid,
professional account was selected from SurveyMonkey.com.45 This enabled:
l an unlimited number of questions and responses
l a custom uniform resource locator (URL)
l a branded survey with a logo – use of the EUnetHTA logo and colours
l a survey completion progress bar
l a custom redirect on survey completion – to the eunethta.net project page
l a printable PDF version for sharing during design collaboration
l importing e-mails into the ‘survey manager’ send-out function
l easy tracking of non-respondents and distribution of follow-up e-mails.
Care was taken that the questionnaire invitations were not sent during the weekends and that the public
holidays in the different European countries were avoided. As far as possible these invitations were not
sent during the summer holiday season (particularly avoiding the month of August).Evaluation of the plenary assembly meetings
The analysis of the annual EUnetHTA JA plenary assembly meetings was performed by anonymous
self-completion paper questionnaires. These were included as part of the agenda pack given to the
meeting participants. They were reminded to complete the questionnaire and hand it in at the end of
the meeting.25
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26Follow-up of non-respondents
It is important that as many recipients as possible submit their replies because the non-respondents might
differ signiﬁcantly to the respondents, thereby introducing bias into the results.36 There seems to be no
generalisable recommendation for an acceptable survey response rate. However, this should aim for the
highest rate possible and above 50% has been deemed adequate.34,46
It should be noted that the questionnaire recipients were all associated with the EUnetHTA JA
project – either project participants or external stakeholders. Therefore, they had an implicit duty to
respond to the questionnaires. However, it was still necessary to employ appropriate strategies to obtain a
high response rate to limit bias. A review of methods to increase the response to postal and electronic
questionnaires revealed that the odds of response were increased by more than one-quarter when
non-respondents were adequately followed up.40Evaluation of the processes of the European network for Health Technology
Assessment Joint Action project
The recipients had been given a guarantee of conﬁdentiality but not anonymity. This meant that through
using the SurveyMonkey.com online platform it was possible to send targeted reminder e-mails to
non-respondents. These were personalised e-mails that contained a personal weblink to the questionnaire.
E-mails were designed to include two strategies that have been shown to be effective in increasing
response rate: each e-mail included a statement that indicated others had responded and provided a
deadline for response.40 Reminders were generally sent 1 week after the date requested for the
questionnaire completion and non-respondents were requested to complete the questionnaire within
3 weeks. Two follow-up reminders were sent at 3-weekly intervals.Evaluation of the plenary assembly meetings
Survey response was anonymous and there was no possibility of tracking non-respondents. Therefore,
it was not possible to follow up non-respondents.Analysis
The overall percentage response rate to questionnaires was calculated as:
ðNumber of questionnaires completed Number of questionnaires distributedÞ  100 ð1Þ
It is important that the response rate to individual questions was also deﬁned. The National Center for
Education Statistics has stated that key items should achieve a response rate of at least 90%.47
Accordingly, actual completion rates were shown for each individual question. Data from the two types of
question were analysed:
l The computer software program Statistical Product and Service Solutions (SPSS®, version 19; IBM, New
York, NY, USA) was used for the analysis of the quantitative questions. Descriptive statistics were
included for categorical data, showing frequency and percentages.
l Thematic analysis was performed on the qualitative data responses provided to the open questions.
Such inductive reasoning involves analysing the data to generate ideas.48 The grounded theory
methodology was used to compare pieces of data to develop conceptualisations to create descriptive
knowledge.48 Topics were identiﬁed and clustered into themes. This qualitative analysis was performed
by only one researcher owing to the resource limitation of the evaluation agreed with the EU. This has
a limitation because it might have biased the results as only one person’s opinion was used. The
software program NVivo® (Version 10; QSR International, Victoria, Australia) was used to help analyse
the qualitative comments. When analysing open-ended questions it is important to outline the main
themes and illustrate them as necessary with quotes36 and this was done in the individual survey
reports that were submitted to the secretariat annually.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Individual reports were written for each questionnaire. These individual questionnaire reports formed
appendices to the technical report submitted to the EUnetHTA JA secretariat each year.
l 2010:
¢ plenary assembly evaluation survey
¢ EUnetHTA JA participants’ 2010 baseline survey
¢ EUnetHTA JA stakeholder forum 2010 baseline survey
¢ EUnetHTA JA for those that applied to join the stakeholder forum but were not successful 2010
baseline survey.
l 2011:
¢ plenary assembly 2011 evaluation survey
¢ EUnetHTA JA participants’ 2011 interim survey
¢ EUnetHTA JA stakeholder forum 2011 interim survey.
l 2012:
¢ plenary assembly 2012 evaluation survey
¢ EUnetHTA JA participants’ 2012 ﬁnal survey
¢ EUnetHTA JA stakeholders’ 2012 ﬁnal survey.
These reports were uploaded to the EUnetHTA JA members only intranet website. Reports were written as
appropriate for work package leaders and tool developers. Articles were submitted to the EUnetHTA JA
project e-newsletters to encourage response rates and to report questionnaire results.Documentary analysis
Each of the eight individual work packages was responsible for writing a ﬁnal technical report about its
performance in the EUnetHTA JA and these were submitted to the secretariat in mid-January 2013. The
secretariat was requested to send a copy of each report for analysis in this evaluation. The documentary
analysis involved one of the researchers reading the report submitted by each work package and
identifying whether or not the work package stated it had produced its deliverable (in accordance with the
EUnetHTA JA Grant agreement).13 This analysis was limited because budgetary restraints of the evaluation
meant that it was performed by only one researcher. In addition, it consisted solely of whether or not a
work package had self-reported that it had produced the deliverable, rather than an actual observation of
the existence of a deliverable.studiesInforming clinical decision-makers about clinical research
under development: development of a data set to
inform a registry
The project was divided into three phases:
1. development of a data set on which to base a registry
2. assessment of the potential accuracy of that data set
3. building an electronic registry based on the developed data set.
These ﬁrst two phases are reported below; these are the stages of most relevance to the NIHR Health
Technology Assessment programme. The ﬁnal phase was performed by the French organisation, and
fellow member of EUnetHTA, Haute Autorité de Santé (HAS; French National Authority for Health).27
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28Developing the data set
The data set was developed through using the Delphi survey technique.49–52 This is a method designed to
facilitate a decision-making process by groups. It is a technique that aims to reach a consensus of a group
by distributing several rounds of anonymous structured questionnaires.50 The responses from each round
are fed back to participants and the responses obtained from a round are used to formulate the next
round.50 Opinions are collected and systematically analysed to obtain consensus.52Identifying participants
It was important that the data set should be of a minimum practical size, and limited to contact details and
a high-level project description. It appeared evident that for a registry to be both widely accepted and
useful the elements in it would need to be widely supported. Therefore, participants to our Delphi process
were recruited as widely as possible.
Recruited participants fell into four groups:
1. personal contacts
2. organisations identiﬁed through the International Network of Agencies for Health Technology
Assessment (INAHTA)53
3. organisations identiﬁed through EUnetHTA54
4. organisations identiﬁed through contacting groups 1–3.
We built our sampling frame by initially contacting organisations in groups 1–3. We asked each
organisation which responded if it was aware of other organisations which may be interested in
participating in this project. We then contacted all newly identiﬁed organisations (group 4), and repeated
this process until we had exhausted all suggestions.
We initially contacted organisations that were known to relevant individuals and organisations that
relevant individuals were aware had reputation as a funder or requester of pragmatic studies. A ‘funder of
pragmatic studies’ was deﬁned as an organisation which has a remit to allocate funds (either by grant or
through a contract) for the research costs associated with pragmatic primary research. The ‘study
requester’ is more interesting. Some organisations have a statutory power to request studies to be
delivered from certain private sector entities, for example HAS can request drug studies from the
pharmaceutical industry.
Organisations within two international membership organisations for HTA [INAHTA (global) and EUnetHTA
(European)] were also approached. They were asked for contact details of organisations within members’
countries which may fund clinical studies of this type. Each organisation that responded was also asked
about other groups that they were aware of which may have been interested in this project. These groups
were then contacted and, where they responded, the process was repeated (i.e. a snowball technique).
At the end of this process 17 organisations from eight countries on three continents had agreed to
participate. Some countries handled their responses centrally, pooling responses from several
organisations. In other countries organisations participated individually. This meant that 12 separate
entities responded to the Delphi rounds (Table 5).
Delphi rounds
All participants were asked to take part in up to three Delphi rounds: two were initially planned, with a
third held in reserve in case any issues were unresolved at the end of the second.
For each round, a background paper was prepared by the authors at NETSCC, outlining the issues to be
addressed in the round and the group’s thoughts so far. For the ﬁrst round the authors prepared an
initial draft of the data set in order to give the group something to start critiquing and changing. A
questionnaire was prepared using SurveyMonkey.com for participants to complete. The principles ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Respondents to the Delphi rounds
Country Organisation
UK Programme Grants for Applied Research
Research for Patient Beneﬁt
NETSCC
France Haute Autorite de Santé
Institut du Cancer
The Netherlands College voor Zorgverzekeringen
ZonMW
Norway Combined Norwegian response, co-ordinated by the Norwegian Knowledge Centre for the
Health Services
Israel The Israeli Centre for Technology Assessment in Health Care
Australia Australian Safety and Efﬁcacy Register of New Interventional Procedures – Surgical
USA Blue Cross Blue Shield Association Technology Evaluation Centre (also responding on behalf
of the Veterans’ Administration, Agency for Healthcare Research and Quality, and the
Veterans’ Administration)
Canada Institute of Health Economics
Canadian Institutes of Health Research
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(Identifying participants). Copies of the background documents and questionnaires are included in
Appendices 12–15.Validating the data set
After agreeing the elements of the data set, the next step was to validate the data set. This was done by
assessing the data set’s potential accuracy, its ability to match similar studies and identify dissimilar studies
as dissimilar. If the data set could not do this, then it would not be ﬁt for purpose. The number of trials we
had to consider was small – the aim of this phase was to look for a signal that the data set could be ﬁt for
purpose, not to deﬁnitively demonstrate so.
As a ﬁrst part of this phase we identiﬁed a set of three potential matching rules, based on matching one
or more of the elements of the PICO [population, intervention, comparison and outcome; deﬁnition of a
research question (e.g. did two elements in the database match on one, two or three elements of
population, intervention, and a union of the intervention and comparator conditions]. The intervention and
comparator ﬁelds were amalgamated for this matching process because a match should not depend on
which role a technology is fulﬁlling, just that it is present in the study.
For this phase Delphi participants were ﬁrstly asked to identify clinical and technological topics where they
thought that multiple agencies may have undertaken work. The four work areas that were most
commonly suggested were selected. For each clinical area we selected an exemplar study from the
NIHR HTA programme portfolio. Participants were then asked to submit descriptions of projects that they
had undertaken or considered which were similar to the exemplar studies, structured according to the
proposed data set. They were also asked to provide studies in similar areas which should not generate a
match with the index study when tested. Next, the previously identiﬁed matching rules were applied to
determine which had the best performance, as deﬁned by Delphi participants.29
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This chapter presents a summary of the results and accompanying discussion. For each section the resultsare presented followed by interpretation and recommendations.
Evaluation of the processes of the European network for Health
Technology Assessment Joint Action projectEvaluation of international projects
A project has been deﬁned as ‘directed work that is aimed at achieving speciﬁc goals within a deﬁned
budget and schedule’. An international project ‘involves multiple locations, entities, organizations and
business units’ across different countries.55 Therefore, the EUnetHTA JA was classiﬁed as an international
project. Such projects are complicated, owing to the large number of organisations, wide purpose and
scope and high cost.55 At its inception the EUnetHTA JA project had 35 government-appointed
organisations. Each of these organisations could have several employees working in a number of work
package projects. This meant that communication provided by the co-ordinating secretariat and the
speciﬁc work packages was important. The EUnetHTA JA had a wide purpose, which necessitated the
work to be divided into eight separate work packages. International projects operate in a unique context,
where different countries have different economic and political systems,46 all of which have an impact on
the management and success of the project.
The evaluation of a large project should include the traditional measures of whether or not the work was
completed according to time, cost and quality standards. This should also be expanded to include delivery
of new capabilities and business objectives, and assessment of the project’s long-term impact.56 Project
performance can be measured during the lifetime of a project. However, the success or failure of a project
can usually only be evaluated months or years after its ﬁnish, when the resultant impact can be
measured.57 Consideration of whether or not the deliverables were produced on time was within the
scope of the evaluation of the EUnetHTA JA. Unfortunately, the scope of the evaluation was limited by
the resources committed by the EU – this meant that evaluation of the project’s delivery according to cost
and quality standards and its long-term impact were outside the evaluation’s scope. Owing to limitations
mandated by the major funder (the EU), it was only possible to prepare the evaluation 6 months before
the end of the project. This is a major limitation of this evaluation process.
Different individuals can have varying measures of project success, depending on their relationship to
the project. Project team member’s perspective often includes whether or not they had a satisfactory
experience with the project and if it met their needs, while the sponsor considers if the project has
provided the desired performance improvement.56 Therefore, evaluation of participants’ perceptions of the
challenges and beneﬁts of the project was included in the evaluation. Project success can also be indicated
by high team satisfaction, good morale, increased skill, retention and growth of team members and
avoidance of burnout. Therefore, staff members were asked about their perceptions of the project. It was
interesting that there was a pattern of approximately one-third of project participants changing between
each year of the project. However, consideration about whether or not this might have been related to
poor experience on the project or natural movement of the employees was out of the scope of the
evaluation. Consideration of the views of external stakeholders were also included in the evaluation.
To achieve project success there must be a clear purpose, speciﬁc plans, commitment, open
communication, respect and trust, collaboration, political support, clear roles and responsibility and an
effective leadership style.5631
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SUMMARY RESULTS AND DISCUSSION
32Factors leading to the success of a complex project include:58
l clarity of the goals and commitment to them by the project team
l establishing smooth communications with supporting infrastructure
l recruiting project team members with sufﬁcient technical capabilities
l context of the project considered
l a supportive project culture.NIHRKey point 1
The EUnetHTA JA is an example of an international project composed of virtual work teams. Such projects
are complex and have speciﬁc implications. Project performance can be evaluated during a project. However,
evaluation can only be performed months or years after its completion. Therefore, the necessity of
performing the ﬁnal evaluation 6 months before the end of the project was a limitation.Response rate to questionnaires
It is important that high response rates are received to evaluation questionnaires. It is impossible to
conjecture about the opinions of non-respondents and how they might differ from those of respondents.
Therefore, it is essential to decrease the proportion of non-respondents to ensure the true validity of
the results.
The ﬁrst stage in achieving a high response rate is ensuring that the population survey list is complete and
valid. For the stakeholders’ surveys this was relatively straightforward because the secretariat maintains a
contact list for these organisations, which are few in number. However, this was more problematic for the
project participants’ surveys, perhaps because of the large number of project participants and the
complexity of the eight different work packages. This meant that a large degree of ‘data cleaning’ was
necessary, for example by contacting the leads of organisations and work packages to receive information
about their colleagues.Key point 2
There is a need for the secretariat to maintain complete and up-to-date details about the staff working on
this large international project.Disappointingly low proportions of questionnaires were completed during the internal evaluation of the
previous EUnetHTA 2006–8 project. The response rates for the three annual questionnaires were 23%
(2006), 23% (2007) and 26% (2008).12 Some possible factors that might have contributed towards this
low response rate could have included:
l The questionnaire needed to be completed as a Microsoft Word® document and then e-mailed back.
This required some effort from the respondents and there might have been concerns about the
conﬁdentiality of results.
l The questionnaire asked for insertion of the name of the respondent. This again might have caused
worries about the conﬁdentiality of data provided.
l The authors had intended individual participants to complete the questionnaires, but in some instances
organisational responses were provided.Journals Library www.journalslibrary.nihr.ac.uk
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resultant mitigating interventions taken for the evaluation of the EUnetHTA JA. Therefore, a structured
strategy was implemented to encourage a high response rate, which included targeted follow-up of
non-respondents as well as inclusion of both inducing and punitive factors (Box 2).
Project participants’ surveys
The following survey codes have been used throughout this report for ease of reporting:
l project participants’ 2010 survey; p2010
l project participants’ 2011 survey; p2011
l project participants’ 2012 survey; p2012.
The response rates to the project participants' questionnaires ranged from 86% to 88% (Table 6).
The number of project participants who answered the questionnaires is shown in Figure 3.
For the project participants’ surveys it was interesting to note that there was a small increase in response
rate by using a third send-out in 2010 and 2011 (a 5% and 2% increase respectively). Although the
increase was larger in 2012 (9%), a satisfactory response rate of 79% had already been achieved after the
second send-out.
If the same strategies are used to maximise response rate, consider in EUnetHTA JA2 that a third send-out
may not be required for participants.BOX 2 The strategy used to encourage a high response to project participant questionnaires
Structured strategy to encourage high response rates to project
participant questionnaires
Inducement factors
Certiﬁcates were awarded at the annual plenary assembly meeting.
A prize was awarded to the organisation with the highest response rates over the annual surveys.
Punitive factors
Non-respondents were reported to the secretariat and at the plenary assembly.
Non-respondents were reported to organisational leads.
TABLE 6 Response rates to the project participants’ questionnaires
Questionnaire
Number of
questionnaires distributed
First
mailing
Second
mailing
Third
mailing Total received (n)
P2010 175 67% 83% 88% 154
P2011 201 78% 84% 86% 172
P2012 204 72% 79% 88% 179
33
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Woodford Guegan et al. under the terms of a commissioning contract issued by the Secretary of
State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Responded
to P2010
only
(n = 42)
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only
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P2011
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FIGURE 3 Breakdown of responses to the project participants’ questionnaires.
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34Stakeholders’ questionnaires
For ease of reporting reference to the following survey codes have been used throughout this report:
l stakeholder forum 2010 survey; s2010
l stakeholder forum 2011 survey; s2011
l stakeholders’ 2012 survey (for members of the stakeholder forum); s2012a
l stakeholders’ 2012 survey (for those not successful in gaining a place on the forum); S2012b
l ‘other’ stakeholders’ survey 2010; O2010.
The response rates to the stakeholders’ questionnaire range from 60% to 83% (Table 7). The number of
project participants per year of the project is shown in Figure 4.TABLE 7 Response rates to the external stakeholders’ surveys
Questionnaire
Number of
questionnaires
distributed
First
mailing
Second
mailing
Third
mailing
Total
received
(n) Non-respondents
S2010 12 58% 58% 83% 10 ECPC, EGA
O2010 5 80% 100% – 5 –
S2011 12 25% 50% 67% 8 COCIR, EURODIS, EPF,
Eucomed
S2012a 12 42% 58% 75% 8 ECPC, EPF, EGA, Eucomed
S2012b 5 40% 40% 60% 3 EFNA, Europabio
NIHR Journals Library www.journalslibrary.nihr.ac.uk
New
recipients
Left
the project
(n = 41)
(23% of
P2010)
P2010
(n = 175)
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recipients
P2011
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P2012
(n = 204)
Left
the project
(n = 43)
(21% of
P2011)
(n = 67)
(33% of P2011)
(n = 46)
(23% of P2012)
FIGURE 4 Project participants in the different years of the project.
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The stakeholder organisations were appointed to the stakeholder forum, or were not appointed but were
kept informed by their representative, for the lifetime of the EUnetHTA JA project. This meant that,
although the individual contact person sometimes changed, the number and type of organisations did
not change.
However, it was interesting to observe that the number of project participants changed during the project.
The largest overall increase in members was seen from 2010 to 2011. Approximately one-quarter of
participants left the project after the initial year and one-third of the 2011 population was new. A similar
pattern was observed for the 2012 questionnaire when one-quarter of recipients were new and one-ﬁfth
had left after the 2011 questionnaire.
This has important implications for project management and induction of new members. This suggests
that organisational knowledge about the project might be lost and extra time required to initiate new
members. It should also be considered that the new members might differ in some facet compared with
the ones who have left, for example in outlook and knowledge and this might be reﬂected in the
differences in responses to the longitudinal questions.© Que
State f
journa
addres
Park, SKey point 3
It is recommended that concise induction material about the project is provided to facilitate the induction
progress of new project members.Project participant demographics
These results were mostly obtained from closed questions. A range of demographic questions were
included in all three annual questionnaires.35
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36As well as evaluating the EUnetHTA JA, the questionnaire also served a dual function of enabling data
capture of further information about the nature of member organisations and the project participants.
Knowledge of such information about network members could be important in fostering increasing
collaboration in the future.
There were a large number of medical doctors working in the HTA organisations, along with other
health-care professionals, economists, researchers and project managers. There was an apparent clustering
of participants having worked within HTA for between only 0 and 4 years. Approximately two-thirds of
agencies had organisational expertise available in health economics, clinical effectiveness research and
clinical expertise. These could be considered key expertise needed for preparation of HTA reports. Less
frequent, and possibly more specialist, skills that are not intrinsic to HTA were also available in some
agencies. This included skills in information technology (IT), communication, legal services, organisational
science and development of surveys. It could be important for members of the network to identify fellow
members who have a specialist skill and could help them with a particular task.
A list of ongoing HTA projects, and a ﬁnal published report, was produced by the majority of organisations:
88% and 81% respectively. An English summary was commonly produced. This would help collaboration
to a certain degree. However, a ﬁnal report completely available in English was always available in only
one-ﬁfth of organisations. This could hamper collaboration because the details of the ﬁndings and methods
sections would be inaccessible to persons not speaking the same native language. A list of planned HTA
projects was only publicly available in less than half of cases, but in addition approximately one-third of
organisations would share it within the EUnetHTA JA project. This demonstrates the importance of the
EUnetHTA JA project and would, hopefully, facilitate collaboration in future projects.NIHRKey point 4
This evaluation has contributed to awareness within the network of types of expertise available and the
nature of HTA information produced by individual organisations.Key performance indicators
Success criteria are measures by which the success or failure of a project can be judged. This extends
beyond the traditional measure of whether or not deliverables have been produced according to the
project plan.57
Key performance indicators were developed for the EUnetHTA JA project and these are shown in Box 3.
Project impact
The impact of the project was evaluated by assessing the deliverables of the project. These are the results,
or products, of the project. Some of these deliverables were tools and methods for conducting HTA. For
these cases the potential use in practice of these tools, and training requirements prior to use, were also
evaluated. Production of deliverables, according to the 3-year work plan and grant agreement,13 are
indicators of project management success. They allow assessment of the performance of the project
with respect to time (although considerations of quality and cost were beyond the scope of the
present evaluation).Production of deliverables
These results were obtained documentary analysis of work packages’ ﬁnal technical reports about whether
or not the deliverable actually had been produced.Journals Library www.journalslibrary.nihr.ac.uk
BOX 3 Key performance indicators for the EUnetHTA JA project
Project impact
l Production of deliverables according to the 3-year work plan and grant agreement.
l Objectives (as deﬁned in the Grant agreement) met.
l Additional added value generated.
Project effectiveness
l Effective communication within the project.
l Effective project administration by the secretariat.
l Optimal involvement of external stakeholders.
l Good management of the constituent work packages.
Lessons learned
l Progress from the predecessor EUnetHTA 2006–8 project.
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December 2012 (WP4 strand A)© Qu
State
journa
addre
Park,The HTA Core Model was developed as part of the EUnetHTA 2006–8 project. The development of an
online format of the tool aimed to make it easier to use and to enable easier access to information
(Ms Julia Chamova, EUnetHTA, Copenhagen, 2010, personal communication).i. The ﬁnal technical report submitted by WP4 in January 2013 indicated that this had been delivered.
1b. HTA Core Model on screening; March 2011 (WP4 strand A)
Applications of the HTA Core Model tool already existed for medical and surgical interventions and
diagnostic technologies, developed during the EUnetHTA 2006–8 project (Ms Julia Chamova,
EUnetHTA, Copenhagen, personal communication). An additional application of screening was
planned for the EUnetHTA JA project.i. The ﬁnal technical report submitted by WP4 in January 2013 indicated that this had been delivered.een
for
ls p
ssed
SouThe report speciﬁed that this had been validated during autumn 2012.2. A set of two core HTAs; December 2012 (WP4 strand B)
i. It was planned that two core HTAs would be produced by HTA agencies using the online tool.
This enabled application and ﬁeld-testing of the core model. The ﬁnal technical report submitted by
WP4 in January 2013 indicated that these had been delivered.
3. A methodological guidance that will be appropriate for the assessment of relative effectiveness of
pharmaceuticals; December 2012 (WP5)
This was a new activity of the EUnetHTA JA project, stemming from the wish of DG SANCO and
DG Enterprise to assimilate interest in joint assessments of relative effectiveness of pharmaceuticals
into existing networks, like EUnetHTA (Ms Julia Chamova, EUnetHTA, Copenhagen,
personal communication).37
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38i. The ﬁnal technical report from WP5 indicated that methodological guidelines would be ﬁnalisedNIHR Joand published at the end of February 2013 (therefore missing the December 2012 target).
There was a plan that this would be published in the planned special joint action edition of the
International Journal of Technology Assessment in Health Care in 2013. It was noted that this was a
model for rapid assessment. Owing to the high workload in WP5 it had been decided to not pursue
the model for full relative effectiveness of pharmaceuticals.4. Operational web-based toolkit including database-containing information on evidence generation on
new technologies; September 2012 (WP7a)
This activity continued from the previous project when the EIFFEL platform was developed to share
evidence on new technologies. This was reﬁned in the current project to create the EVIDENT database
(Ms Julia Chamova, personal communication).i. The ﬁnal technical report submitted by WP7 in January 2013 indicated that this had been
delivered. It was not possible to identify in what month this had been delivered and if this had met
the target of September 2012.5. Quarterly communication protocol for information ﬂow on ongoing/planned national assessments of
same technologies; December 2012 (WP7b)
This was a new activity – of developing a database for information on ongoing and planned
assessment, with the aim of providing alerts about topics with the potential for collaboration.i. The ﬁnal technical report submitted by WP7 in January 2013 indicated that this had
been delivered.6. Information management system (IMS) and the related documentation, processes and policies;
September 2012 (WP6)
Following on from the project, WP6 aimed to further develop the project intranet site to provide a
single point of access to resources that help with conducting HTA, with emphasis on automating
content update processes (Ms Julia Chamova, EUnetHTA, Copenhagen, personal communication).i. The ﬁnal technical report submitted by WP6 in January 2013 indicated that this had been
delivered. However, it was not possible to identify in which month this was produced.7. Communication and dissemination plan; June 2011 (WP2)
Building on the communication strategy developed during the previous project it was planned to write
and implement a further elaborated plan.i. According to the ﬁnal technical report of WP2 this was delivered according to the work plan in
month 18 (June 2011).8. Stakeholder policy; October 2010 (WP8)
Stakeholder involvement was considered during the 2006–8 project and formed part of the internal
evaluation during the ﬁnal year of the project. However, the EU Commission emphasised that
there must be greater involvement in the EUnetHTA JA project. This policy was required, for
implementation through a formal stakeholder forum (Ms Julia Chamova, EUnetHTA, Copenhagen,
personal communication).i. The ﬁnal technical report of WP8 indicated that this had been delivered (although it was not
possible to identify whether or not this had been in the target month).urnals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 379. Collaboratively developed business model for sustainability; December 2011 (WP8)
i. This detailed business model would address sustainable European collaboration on HTA. The ﬁnal
technical report of WP8 indicated that this had been delivered (although it was not possible to
identify whether or not this had been in the target month).
10. A relative effectiveness assessment of a (group of) pharmaceutical(s); March 2012© Que
State f
journa
addres
Park, Si. The ﬁnal technical report from WP5 indicated that the ‘pilot of rapid assessment of a
pharmaceutical’ had been published on the EUnetHTA website in January 2013.11. Interim and ﬁnal technical and ﬁnancial reports from the EUnetHTA JA project; various (WP1)i. This evaluation report is part of the ﬁnal technical report of the EUnetHTA JA compiled by the
secretariat. Therefore, it was not possible to evaluate whether or not this report would be submitted
to the EU Commission by the deadline.Anticipated use of deliverables
These results were obtained from a combination of closed and open questions.
It was important to consider whether or not project participants and stakeholders thought that these tools
would actually be helpful in day-to-day HTA work. In the ﬁnal year of the project, both participants and
stakeholders were asked how useful they thought they would ﬁnd deliverables, and activities, developed
as part of the project in their professional life. One of the limitations of performing the evaluation
6 months before the end of the project was that respondents were asked to make predictions – a
notoriously difﬁcult concept for questionnaire respondents and one that should be avoided as much
as possible.
The facet with the highest proportion rating as ‘very useful’ for both participants and stakeholders was
‘networking with contacts made from participating in the EUnetHTA JA’, with three-ﬁfths of participants
rating this very highly and over two-thirds of stakeholders reporting it to be very useful. The vast majority
of respondents found the networking they had experienced had been of at least some use.Key point 5
It is recommended that evaluation of the EUnetHTA JA2 includes consideration about the tangible beneﬁts of
networking. This could include a case-study approach to demonstrate the practical beneﬁts of networking.One-third of respondents did not think they would ﬁnd the HTA Core Model on screening useful or did
not know if they would or not. Over one-quarter of respondents did not think they would ﬁnd the
following tools useful, or did not know if they would or not; ‘A methodological guidance that will be
appropriate for the assessment of relative effectiveness of pharmaceuticals’, ‘Operational web based toolkit
including database-containing information on evidence generation on new technologies (EVIDENT)’ and
‘Accessing the EUnetHTA tools by a single sign on through the MO (members-only) site’.
Almost half of respondents thought that the HTA Core Model and the POP database would be ‘very
useful’. A slightly lower proportion of two-ﬁfths of respondents thought the EVIDENT database would be
‘very useful’.39
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40It should be considered that participant respondents have different types of professional activity, for
example in respect to whether or not they prepare HTA reports. Analysis of qualitative comments also
identiﬁed that the access to tools could vary for different organisations and be dependent on the access
policy for speciﬁc tools.NIHRKey point 6
It is still too early to assess the beneﬁt of the tools in practice, although prediction of use is encouraging. This
suggests that the EUnetHTA JA’s third objective of ‘application and ﬁeld-testing of tools’ has not been met.
However, results at this stage are positive and suggest that they will be of future beneﬁt. The EUnetHTA JA2
project will follow on with further real-life application and testing of the tools.Tools
The main deliverables of the EUnetHTA JA were a series of structures to help in the production process of
HTA reports – the tools. There were also tools to help communication within the project;
l tools for production of HTA reports: adaptation glossary, adaptation toolkit, core HTA model, EVIDENT
(formerly known as EIFFEL), POP workroom/database
l tools for communication: contact database, e-meetings, EUnetHTA toolbar, mailing list, MO website,
MO workrooms, news aggregator, workroom bulletin board.Use of tools
These results were obtained from a closed question included in all three of the questionnaires.
Unsurprisingly, the most often used tools were those for project communication – the MO intranet
website, workrooms and e-meetings. Not all members used the project intranet site (the MO website),
although the proportion of respondents using it increased from 2010 to 2012. However, the missing
proportion said they were aware of it and are likely to use it in the future.
Workrooms were areas assigned within the project intranet for the individual work packages. Although
approximately three-ﬁfths of respondents used them, they rated them poorly. It is, therefore, suggested
that their use is helpful, because they were used by a large proportion of participants. However, there is
obviously an important need for them to be improved in EUnetHTA JA2. Workroom bulletin boards were
less often used, with only approximately 15% of project participants reporting use. It seems that
respondents used the website, but not the subsplit workroom provisions. Further evaluation needs to be
performed in EUnetHTA JA2 to identify whether these workroom bulletin boards could be useful if they
were improved or if participants considered them superﬂuous and they communicate by other means,
such as e-mail.
There was increasing use of the following other communication tools from 2010 to 2012 (although
they were still only used by less than half of participants): contact database (a database of details of
all the project participants), EUnetHTA toolbar (used on the internet) and mailing list (a list of all
project participants).
Unsurprisingly, the results for use of the HTA tools were signiﬁcantly lower. This can be explained because
most of the tools were still in a development stage, even in summer 2012 (which again illustrates the
limitations of performing evaluation before the end of the project). The HTA Core Model was the tool that
the most participants had used, and the proportion that had used it doubled during the lifetime of the
project to three-ﬁfths. In each year, approximately 90% indicated they had used it or might use it in
the future. The adaptation glossary and adaptation toolkit were under development, and this is reﬂectedJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37in the results of limited use. Although being developed as part of the project, the EVIDENT database had
been used in the previous project (as EIFFEL) and, therefore, a number said they had used it. This database
was seen as being relatively less popular because approximately 60% saw a future use for it. The POP tool
was converted from a static datasheet to an interactive site during the project and this was reﬂected in the
results; the proportion of participants using it doubled to 50%. Roughly 80% had either used it or saw
future use for it.© Que
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The tools had not been delivered by the ﬁnal evaluation and, therefore, it was too early to assess their use
in practice. The majority of respondents saw future use for the tools, particularly in the HTA Core Model
and the POP database. The actual use of the developed tools is an important topic for evaluation in
EUnetHTA JA2.Priority for training
These results were obtained from a closed question included in all three of the questionnaires.
The HTA tools were consistently seen as being a higher priority for training throughout the lifetime of
the project than the project communication tools (which were mostly cited as low priority or of no
importance). Therefore, the ‘content’ tools were seen as of greater importance than the ‘process’ tools
of the project. Possible reasons for this include that there was greater need within the project for more
methodological tools, that such type of tools are more complex to use or that communication tools were
easy to navigate. In each year the tool most often cited as ‘top priority’ for training by project participants
was the core HTA model. The importance of training both partners and stakeholders in EUnetHTA tools
and methods was emphasised in the plans for the EUnetHTA JA2 project. One of the deliverables of the
JA2 project is ‘Report on yearly training courses on EUnetHTA tools and methodology’. It is planned that
three face-to-face training workshops will be held on EUnetHTA tools and methodology. It is also planned
that three additional training courses will be held for the core HTA model. These plans were proposed as a
result of evaluation questionnaire ﬁndings of EUnetHTA JA.Training method
These results were obtained from a closed question included in the 2010 and 2012 questionnaires.
In general, the most preferred training method for tools was self-directed with a manual. However, a
‘face-to-face workshop’ was the preferred training method for the HTA Core Model, with over half of
respondents preferring this option. As a consequence of the 2010 survey results, a face-to-face workshop
about the HTA Core Model was organised as part of the project. It was interesting that the proportion of
respondents requesting a face-to-face workshop about the EVIDENT and the POP databases noticeably
increased from 2010 to 2012. It is difﬁcult to conjecture the reason for this, but this could have been in
part due to satisfaction of respondents with the workshop they had attended about the HTA Core Model.
One advantage of using a manual is that learning is self-directed and can be undertaken at a time and
place to suit the convenience of the learner. Self-directed manual use is also a cheaper method and
negates the need to travel to attend a face-to-face workshop; however, it has the disadvantage that
queries and difﬁculties using a tool cannot be as easily resolved as they could be at a training workshop.41
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NIHRKey point 8
Self-directed manuals are considered a suitable training method for the project-focused tools. Face-to-face
workshops are preferred for the HTA methodology tools and this should be considered and developed in the
EUnetHTA JA2.Barriers to using the tools
These results were obtained from a closed question included in all three of the questionnaires.
Respondents were asked whether or not any barriers had prevented them using the tools from
‘organisational’, ‘training’, ‘the tool itself’ and ‘IT’. Encouragingly there was an overall general trend that
the frequencies of all barriers decreased during the lifetime of the project. This may have been because
problems were resolved during the project – informally or formally. There was a general trend that the
effect of training being a barrier to tool use decreased during the project throughout the lifetime of
the project from 2010 to 2012. It is possible that as the project progressed, participants picked up
knowledge about using the tools either informally or formally (i.e. by the training course for the HTA
Core Model). IT was seen as a signiﬁcant barrier to the performance of e-meetings and training was a
noticeable barrier to the HTA Core Model (and is reﬂected in the decision to hold face-to-face workshops
in EUnetHTA JA and EUnetHTA JA2). When asked in 2012 why they had stopped using a tool, few
responses were obtained. Reported problems included tools not yet being active, problems with passwords
and IT problems with e-meetings.Perceived ability of the European network for Health Technology Assessment
Joint Action project achieving its objectives
These results were obtained from a combined closed and open question included in the 2011 and
2012 questionnaires.
The difﬁculty of managing the diversity of project members, and formulating a goal that all members
remain committed to, over the long duration of an international project has been recognised.58 One factor
that can mitigate this is developing objectives at the start of the project. Achievement of deﬁned objectives
can also be used to measure the success of the project.57 Deﬁnition of the project objectives is also
important for managing the commitment of external stakeholders.
According to the grant agreement13 the overarching objective of the EUnetHTA JA was to ‘establish an
effective and sustainable HTA collaboration in Europe that brings added value at the regional, national and
European level’.
Project participants and stakeholders were asked in year 2 of the project what would indicate that this had
been achieved. They thought that this would have been achieved when a formal EU HTA agency/network
not dependent on project funding had been formed, collaboration was achieved, EUnetHTA tools were
adopted at a regional or national level, a library of HTA reports and topics was available, HTA was
included in decision-making and impact was evaluated. Stakeholders also cited reduction in duplication of
effort, evaluation of measurable objectives, consistent exchange of information and collaboration outputs
using national and regional levels. The majority of participants and stakeholders thought that such a
sustainable EU collaboration would bring added value to both the national and European level. However,
there was less conﬁdence about whether or not this would bring added value to the regional level, with
about one-third not knowing whether or not this would be achieved. Comments included that such added
value would be seen when there is a reduction in redundant work at the regional and national level and
better European leverage.Journals Library www.journalslibrary.nihr.ac.uk
FIGU
www
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37
© Que
State f
journa
addres
Park, SKey point 9
The fact that such a sustainable European collaboration (as deﬁned by the project participants and
stakeholders) had not been established following the EUnetHTA JA (necessitating a second joint action)
indicates that the project had not been successful at meeting its overarching objective.Almost three-quarters of the project participants and external stakeholders thought that the planned
EUnetHTA JA2 project was a useful follow-up to the EUnetHTA JA project. This suggests that there was an
apparent gap between the JA project and the permanent collaboration on HTA. Comments included that
the EUnetHTA JA2 was required to build on the EUnetHTA JA, the tools required further development,
there was a need to test the efﬁcacy/effectiveness of join report production, that the EUnetHTA JA2 would
act as a bridge to a permanent network for HTA, that it will have a different focus of operational work
which will identify feasible co-operation between HTA agencies and allow the testing of models of
iterative stakeholder involvement, it is a necessary follow-up to EUnetHTA JA and will provide the occasion
to examine in practice the methods developed.
The anticipated timeline of achieving a permanent European HTA network is shown in Figure 5.
The EUnetHTA JA had three deﬁned objectives, and participants and stakeholders were asked annually
whether or not they thought these would be achieved. These objectives were tangible, i.e. production of a
strategy business model document, delivery of tools and ﬁeld-testing of the tools. Documentary analysis
was also undertaken to assess whether or not these objectives had indeed been met.The timeline of reaching a sustainable and
permanent HTA network in Europe
2006–08
EUnetHTA
project
2006–08
EUnetHTA
Collaboration
2010–12
EUnetHTA
JA
2012–14
EUnetHTA
JA 2
2009
Call for
joint
action
2005
Call for
project
proposals
Health
Programme 2011
Call for
joint
action
2015+
European
network for
HTA
Legal basis:
Cross Border
Healthcare
Directive
Financial
support:
1) EU budget
2) Member
States
2008–11 2011 2011+
Draft Cross Border
Healthcare Directive
article on HTA network
CBHC
Directive
now
decided
CBHC Directive
Expert Group
for
HTA network
implementation
Legislation
net
net
16 EUnetHTA | European network for Health Technology Assessment | www.eunethta.eu Joint Action 2010−2012
RE 5 The anticipated timeline of achieving a permanent HTA network in Europe. (Reproduced from
.eunethta.eu with permission from EUnetHTA secretariat.)
43
en’s Printer and Controller of HMSO 2014. This work was produced by Woodford Guegan et al. under the terms of a commissioning contract issued by the Secretary of
or Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
ls provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
sed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
outhampton SO16 7NS, UK.
SUMMARY RESULTS AND DISCUSSION
44Development of a general strategy and business model for sustainable
European collaboration on health technology assessment
The majority of participants and stakeholders had conﬁdence that this objective would be achieved.
Indeed, this was the objective that participants and stakeholders had the highest conﬁdence would be
met. However, it was interesting that approximately one-tenth of stakeholder forum members in 2011 and
2012 did not think this would be achieved. According to the ﬁnal technical report, of WP8 this general
strategy and business model had been delivered by the end of the project.
This strand of activity is planned to continue in the EUnetHTA JA2 project, ‘Thus, an overarching objective
is to develop the background for a general strategy, the principles and the proposal for implementation of
a sustainable European Collaboration on HTA in the light of the Directive on CBHC . . .’.13NIHRKey point 10
The general strategy and business model were developed according to the work plan during the EUnetHTA
JA. However, further work is planned during the EUnetHTA JA2 project to further develop this towards a
sustainable European HTA Collaboration.Development of health technology assessment tools and methods
The majority of project participants thought this objective would be met. However, it is interesting to
note that participants’ conﬁdence in this being achieved apparently dropped from 2010 to 2012 by
approximately 10% and there was a corresponding rise in the number of respondents who indicated they
did not know if this would be achieved. There was a similar pattern of apparent doubt by stakeholders
because two-ﬁfths were unsure whether or not this would be achieved when asked in 2012.
The proposed HTA tools and methods were all developed according to the grant agreement and the work
plan (see Chapter 1, Project deliverables for further details): HTA Core Model, EVIDENT and POP database.
The methodological guidelines for relative effectiveness assessment of pharmaceuticals were predicted to
be delivered by the end of February 2013. It is notable that further work is planned in the EUnetHTA JA2
project to develop the HTA Core Model. Deliverable 10 will be an ‘Upgraded and updated package of HTA
Core Model’. This is to include ‘updated applications on medical/surgical interventions, diagnostic and
screening technologies and pharmaceuticals’.13Key point 11
All HTA tools and methods were delivered according to the work plan and hence it appears that this
objective was achieved. However, further work is planned in EUnetHTA JA2 to further develop the HTA
Core Model.Application and field-testing of developed tools and methods
The majority of participants and stakeholders again showed some apparent conﬁdence that this objective
would be achieved. However, a large number of respondents indicated ‘don’t know’. This might have
been because they thought that an objective would not be met but were reluctant to choose the negative
option choice, but it is difﬁcult to conjecture in the absence of probing respondents to explain their
response in greater depth. The apparent conﬁdence of the participants decreased over the years and the
proportion who did not know increased. In contrast the number of stakeholders who thought this wouldJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37be achieved increased over time whilst the number who did not know decreased. However, the number of
stakeholders in the forum who did not know whether or not tools would be applied and ﬁeld-tested was
large: three–ﬁfths in 2010 and a half in 2012.
The general objective of the EUnetHTA JA2 is stated in the grant agreement as being ‘to strengthen the
practical application of tools and approaches to cross-border HTA collaboration . . .’ (page 35). The ﬁrst
part of this aim indicates that application and ﬁeld-testing of tools had not been fully completed in the
EUnetHTA JA as a follow-up project was necessary. This was speciﬁed in the grant agreement as ‘The JA2
will complement the current JA1 by testing the implementation of structures and tools developed
previously by way of conducting a set of pilot assessments on technologies to be selected according to
common information needs’.13© Que
State f
journa
addres
Park, SKey point 12
It appears that this objective of application and ﬁeld-testing of tools had not been completely fulﬁlled by the
EUnetHTA JA project and a follow-up EUnetHTA JA2 project was necessary.Perceived achievements of European network for Health Technology
Assessment Joint Action
These results were obtained from a combined closed and open question in the 2012 questionnaire.
Consideration of beneﬁts provided to team members by participation in a project has often been
overlooked, or combined into consideration of meeting the project’s objectives.48 However, it is an
important measure of the success of a project. It was a positive ﬁnding that the majority of participants
thought that the project had achieved what their organisation had hoped for. However, it was concerning
that less than half of project participants said that the EUnetHTA JA had achieved what they personally
had hoped it would. There was also a large proportion of participants who did not know whether or
not it had achieved what they wanted. This, therefore, poses the suggestion that they went into the
project not knowing what they wanted it to achieve.
Those who felt achievements had been made cited collaborations and connections developed, successful
project progress, network development, the tools and methods developed by the project, information
exchange between project members and the effect of greater awareness of policy-makers about HTA in
general. In addition to delivering according to the project objectives, this indicates added value of the
project. Those who felt that achievements had not been made cited slow progress, lack of change at their
local agency, lack of collaborative HTAs produced, difﬁculties inherent in an international project, lack of
cohesion and participation, tools not ﬁt for purpose and that a self-sustaining collaboration had not yet
been established. A noticeably larger proportion of participants indicated that they had personally got
what they hoped from the project. Reasons included networking, HTA knowledge, information sharing,
collaboration, involvement in HTA report production, usefulness of the POP database, ability to act as an
ambassador for EUnetHTA and support for establishment of HTA in their own country. One-tenth had not
personally got what they hoped from the EUnetHTA JA and reasons included unclear localisation of work,
lack of interaction with academia, they had been instructed to take part, tools not being used and
difﬁculties in collaboration.45
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NIHRKey point 13
The main success criteria of a project are meeting its objectives and producing its deliverables according to
plan. However, added-value gains are also important. These included networking and information exchange.
Such tangible beneﬁts should be measured by the evaluation of the EUnetHTA JA2.Benefits
These results were obtained from an open question asked in all three of the questionnaires.
Beneﬁts of the EUnetHTA JA from participants’ perspectives included information sharing, collaboration,
forming a network, development of methods and tools for doing HTA, networking and greater awareness
of recent developments. After analysis of the emergent themes from the P2010 questionnaire results the
prevalent project beneﬁts were categorised into a quantitative question using a three-point Likert scale.
‘Networking with colleagues’ and ‘sharing information’ were the two most common project beneﬁts
classiﬁed as ‘very useful’. When combined into frequencies for all beneﬁts of some use, the vast majority
(nine-tenths) of participants found networking, information sharing and awareness of HTA developments
of greatest beneﬁt.
The ultimate aim of the European HTA projects is to lead to the formation of a sustainable network. It is
encouraging that participants found beneﬁt from networking with others. This might mean that they have
built connections with counterparts in different organisations and are able to learn from them and share
their own experiences, and it would be useful to investigate this further in EUnetHTA JA2. As well as sharing
local information, participants were also able to increase their knowledge about speciﬁc HTA-related
developments. Other beneﬁts were cited as capacity building, training and face-to-face meetings.Key point 14
Networking was an added beneﬁt of the project process of the EUnetHTA JA project. It is important that this
is further evaluated in the EUnetHTA JA2 project to identify what tangible beneﬁts this has led to, e.g. in
terms of topic identiﬁcation, collaboration on HTA reports, etc.Project effectiveness
The effectiveness was evaluated by the processes of the project. These are the inputs into the project that
may lead directly or indirectly to the success of the project.57 These project processes can be used to
subjectively evaluate the performance of a project.Set-up of the project
Project start-up
These results were obtained from a combined closed and open question included in the 2010 questionnaire.
Approximately three-ﬁfths of participants were satisﬁed with the set-up of the project, but one-ﬁfth
thought it could have been better. Suggestions included better transparency, decreased bureaucracy,
better communication from the JA secretariat and the EU Commission, greater preparation time and
maintenance of constant personnel dealing with the project.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37The initiation stage of a project is crucial. The most important factor is gaining consensus from project
participants about what is to be achieved, and how this should be done, at the outset.55 A well-planned
project will avoid scope creep further down the line by deﬁning the purpose, scope, roles, costs
and schedule.© Que
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More time should be factored in for this crucial design stage for complex projects than was allowed for the
EUnetHTA JA. It is important that individual participants feel included in this formative stage and
communication is clear at the outset. This stage is important in ensuring all participants are clear at the outset
and it should not be rushed.Organisation into work packages
These results were obtained from a combined closed and open question included in the
2010 questionnaire.
In common with other such international projects, the EUnetHTA JA project was structured by division into
eight distinct work packages. The majority of participants and stakeholders who expressed an opinion
thought this structuring was positive, but approximately one-quarter of participants thought there would
also be negative aspects associated with this division of work. Concerns centred around possible overlap
between the aims and work of individual work packages and the importance of effective communication
between them. Most projects funded by the EU are formed in this structure of individual work packages
that can be viewed as discrete projects. As one participant responded, ‘it is difﬁcult to see how else the
project could have been arranged’. However, this structure means that communication was required
between the individual work packages to avoid duplication of work and, wherever possible, enable
collaboration. This was done by bimonthly meetings of the executive committee, which included the
leaders of all work packages along with the secretariat and the representative of the European
Commission. Such a steering committee is recommended for complex, international projects. These
committees prevent tension between the individual projects and allow for greater ﬂexibility at the
operational level.58 In their consideration of international project management Lientz and Rea
considered having two committees: an overseeing committee and one composed of more senior work
package leaders.55Key point 16
Consideration could be given to establish a second committee in the EUnetHTA JA2. This could be made up
of an individual worker of each work package and could meet virtually by e-meetings to strengthen links
between the subproject teams.Sufficient resources
These results were obtained from a combined closed and open question included in all of the
three questionnaires.
Participants provided broadly similar results between 2010 and 2012, with only about a half indicating that
their organisation had sufﬁcient funding and three-ﬁfths indicating that there was sufﬁcient staff. The
proportion that thought they did not have enough resources was fairly constant at approximately one-ﬁfth47
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48over the 3 years. A large number of participants indicated that they did not know whether or not their
organisation had sufﬁcient funding or staff to fulﬁl their obligations to the EUnetHTA JA project. This may
be because not all respondents were senior enough to know details about ﬁnancing, but a lack of staff
might be more apparent to them. In hindsight, it might have been better to have asked this question to
the organisational lead to obtain views from only senior staff (although this might be biased).
It is obviously important that organisations had sufﬁcient staff and resources to be able to fulﬁl their
commitment to the EUnetHTA JA. From the data collected it is unclear whether it was actually the case
that organisations did not have sufﬁcient resources or this was the perception of their staff. Implications of
insufﬁcient funding cited by project participants were that the work required extra time for completion
than had been estimated or organisations were subsidising the work themselves by working at weekends,
devoting more staff to EUnetHTA than were paid by project funding. Lack of staff meant increased
workload within the team, and this could have a negative effect on staff morale. For an international
project it is important to realise the importance of the self-interest and resources of each of the individual
organisations at the start.55 It is important that the individual participant organisations feel that they will
beneﬁt from the project. It cannot be assumed that organisations will contribute their best resources or
effort to the project, to make up any shortfall. This can mean that the work was conducted to a basic
standard, with the project work being viewed as a non-priority task. Conﬂict with normal work of a project
participant is also an important factor. Most international team members are not solely dedicated to the
project, but must fulﬁl requirements of their regular job in addition.55 This could also lead to decreased
enthusiasm within an organisation for participation in future international projects. This seemed to be
particularly important in this project because the funding was obtained in a 50 : 50 ratio from the EU and
the member state.
Cultural factors and different styles of work in an international project should also not be overlooked.
Business needs are diverse in each country involved in the project. The project should address such local
issues otherwise it will be seen as negative – requiring resources but not delivering beneﬁts.55 Also, in the
EUnetHTA JA the individual work packages can be seen as inter-related individual projects. It is important
to realise that these projects can share the same resources and together can exact too high a stress level
from workers.55NIHRKey point 17
There should be greater use of project management and budgeting techniques in the EUnetHTA JA2 to
ensure sufﬁcient resources are allocated to organisations and speciﬁc tasks.Difficulty joining the project
These results were obtained from a combined closed and open question included in the 2010 questionnaire.
Hearteningly, less than one-tenth of respondents reported a problem with their organisation joining the
project. Problems reported included lack of a plan, lack of transparency and lack of distinction in work
between performed in the preceding collaboration year and the start of the EUnetHTA JA project. It is
important that the process for organisations joining a project is straightforward and easily manageable.
Almost one-quarter of project participants in 2010 had a suboptimal or mixed understanding about the
information that was required from the secretariat before the project started. The proportion who
understood requirements increased from before the project began (two-ﬁfths) to after the project started
(three-ﬁfths). Concerns included that the information was not always clear and recognition about the
complexity of the project. The relative scarcity of problems can be seen as a good indicator of success.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37It should also be borne in mind that the number and types of organisations within the EUnetHTA was a
ﬂuid situation, with organisations able to leave and join during the project. It would be useful to have a
type of induction process for organisations that joined part-way through the project. It could also be useful
to produce a map of the characteristics and expertise of the different organisations joining the project, to
enhance collaboration opportunities within the network.© Que
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Organisations had mostly had a good experience of joining the project, although communication from the
secretariat during this period could have been improved somewhat. However, other organisations
subsequently joined the EUnetHTA JA project when it was already established. It would be useful to produce
an induction pack for such organisations for the EUnetHTA JA2.Succession planning
These results were obtained from a combined closed and open question included in the 2010 questionnaire.
Almost two-ﬁfths of organisations had no succession plan in place in case a member of staff became ill or
left the organisation, with a further one-ﬁfth not knowing whether or not they had one. It is vital that
there is a plan in place in case members of staff leave, to ensure that this does not affect the work of the
project. Loss of team members can mean that experience and knowledge is lost and activity in an
organisation can grind to a halt.55 In combination with the ﬂuid nature of high turnover of project staff,
there was an apparent lack of succession planning. This again reinforces the need for communication and
induction of new staff. Examples of this included the secretariat administrator going on maternity leave
and the individual leading the contribution of the lead partner of WP2 leaving mid-way through the
project. For an international project, there needs to be a local commitment that the project team is stable
and committed, and members are not pulled off the project by local management to perform other
work.55 However, in practice little can be done to mitigate the effect of individuals leaving to take up other
jobs, going on maternity or sick leave or dying.Key point 19
In future international HTA projects all participant organisations should be responsible for outlining who will
be locally responsible for an organisation’s commitment to the project if key staff become unavailable.Challenges
These results were obtained from an open question included in all of the three questionnaires.
Qualitative comments from participants about the challenges inherent in the project included the large
scope of the project, its international nature, high workload, limited time and resources, the work itself,
communication, administration, national/organisational conﬂict, requirements of individual work packages,
imbalance between contributions of participants and problems with collaborative working. A speciﬁc
problem in 2010 and 2011 was orientation within the project.
After analysis of the emergent themes from the P2010 results, the prevalent project challenges were
categorised into a quantitative question using a three-point Likert scale. A large effect was assigned to
conﬂict with other work activities and insufﬁcient organisational funding and staff. Combining the49
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50frequencies for the effects showed that approximately three-quarters were affected to some degree by
conﬂict with other work and insufﬁcient staff and funding. The effects of insufﬁcient organisational
funding and staff, and conﬂict with other work have been discussed in earlier sections.
The effects of the large project scale and demands of the individual work packages were small.
Interestingly, the demands of individual work packages seemed to increase between 2011 and 2012. The
large project scale is one of the inherent problems of international projects and this leads to a complex
nature of subprojects. A large proportion of project participants were members of more than one work
package, which meant they had to juggle various work demands.
Hearteningly, more than half of respondents experienced no effect from difﬁculty in communicating
in English and difﬁculties in communicating generally. Communication is affected by various types of
culture and it can be difﬁcult to manage different styles in an international project.58 In addition, project
participants had various natural and functional languages. In the EUnetHTA JA project it was necessary to
use a common language, which was English. However, it must be considered that the use of a language
by non-native speakers can result in insufﬁcient project feasibility, loss of speed, loss of creativity, poor
decisions, underuse of resources and unexpected misunderstandings. It is possible that such problems
were experienced by participants, but were not deemed sufﬁciently important to affect the project
work signiﬁcantly.NIHRKey point 20
Broadly speaking, communication within the EUnetHTA JA project was successful. However, coping with the
large project scale and conﬂicts from work of the subprojects was more of a challenge. The greatest
challenge was from conﬂict from other work and insufﬁcient staff and funding. This could be helped by
greater use of project planning techniques.Support from the secretariat
Secretariat leadership
These results were obtained from a combined closed and open question included in all of the
three questionnaires.
Approximately three-ﬁfths of respondents thought the secretariat had offered effective leadership. The
number of respondents who thought the leadership was OK (but could be better) increased from less than
one-tenth in 2010 to one-ﬁfth in 2012 suggesting an apparent slight decrease in conﬁdence as the
project progressed. The qualitative data revealed that concerns included negative aspects relating to
communication from the secretariat, implications of changes in the secretariat staff, recognition of the
difﬁculty of the task, a distant style used, and a lack of direction provided by the secretariat and that this
needs to evolve in the future.
Important attributes for leaders of international projects have been deﬁned.55 These include
problem-solving ability, ability to cope in multiple cultures with diverse political problems, tenacity and the
capability of pursuing issues, ability to communicate, a sense of humour, familiarity and knowledge of
the business and prior experience in projects. It is also important that the project leader is aware of the
intra- and inter-organisational links in the project and is aware of the hidden agenda of
individual organisations.
Owing to the speciﬁc nature of the EUnetHTA JA project, it was also important that the leader had a
strong steer for HTA in Europe. It has been recommended that there are two leaders for internationalJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37projects.58 In the EUnetHTA JA project, as in the EUnetHTA 2006–8 project, the leadership was provided
by Finn Borlum Kristensen. The secretariat manager was Julia Chamova. From the comments above, it
would seem that the leadership was sometimes perceived as somewhat distant and this could be helped
by more regular communication about ‘leadership issues’ with participants throughout the project. There
was some concern expressed about the over-reliance on Finn Borlum Kristensen and what would happen if
he became ill.© Que
State f
journa
addres
Park, SKey point 21
Consideration could be given in future projects to have a deputy leader, possibly based in another country.Secretariat administration
These results were obtained from a combined closed and open question included in all of the
three questionnaires.
Effective project administration is essential for any international project. Such a co-ordination role can
organise the project ﬁles and project history, oversee the lessons learned and issues log, and support and
mentor the project leaders. As such, the secretariat functioned as the project management ofﬁce and it
had an important role in both the internal project processes (e.g. monitoring the performance of individual
work package projects) and connection to the external world (e.g. by interacting with external
stakeholders). For the EUnetHTA JA project, as for the EUnetHTA 2006–8 project, this function was
performed by the secretariat, based at the National Board of Health, Denmark.
Approximately three-ﬁfths of respondents thought the administration had been effective. The proportion
who thought secretariat leadership was OK (but could be better) rose from one-tenth in 2010 to one-ﬁfth
in 2012. This indicates that there was a slight increase in dissatisfaction with the administration as the
project progressed. The qualitative data showed that concerns included, problems with e-mail, general
communication problems, too short timelines, quicker feedback required, problems with work packages
and the belief that more staff were needed in the secretariat.
The main method by which the project secretariat communicated with work package leaders and
individual project participants was by e-mail. Therefore, participants were asked about their opinions about
the nature of this communication. Approximately three-quarters of respondents thought the e-mails
from the secretariat were acceptable, in terms of frequency and content. Comments related to clarity,
frequency and length, that e-mails had improved from the previous EUnetHTA project, the importance of
ensuring relevant addressee and suggestions for improvement (e.g. to use a standard template and include
the work package number and deadline in the subject line). Although e-mail is a practical mode of
communication, it is low down the hierarchy of communication methods because of its inherent problems.
Suggestions have been made to improve e-mail communications in international projects. These include
using speciﬁc titles, making the important point(s) in the ﬁrst six to eight lines and avoiding overloading
participants with e-mails.55Additional support from the secretariat
These results were obtained from a combined closed and open question included in the 2010 and
2011 questionnaires.
Approximately one-ﬁfth of respondents in 2011 thought there were other activities that the secretariat
could do to support the project, and this proportion had risen from 2010. Suggestions included facilitating
relationships, providing greater feedback, providing advice about monthly budgeting, being more51
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52customer orientated, facilitating development of effective tools, facilitating information exchange,
providing project management and enabling effective communication.NIHRKey point 22
Overall, participants were positive about the assistance offered by the secretariat. Various additional activities
were suggested, and it is hoped that in EUnetHTA JA2 with greater funding the activities can be expanded,
for example to include support with project budgeting and project management.Communication
Communicating in English
These results were obtained from a combined closed and open question included in all of the
three questionnaires.
In any international project, communication is likely to be difﬁcult because all members do not share a
common language. It is important that there is a common language for communication.58 Encouraging,
approximately three-quarters of respondents had not experienced any signiﬁcant problems when
communicating in English during the project. The qualitative data showed that concerns included
recognition of the inherent nature of communication problems, difﬁculty with English text, difﬁculty with
audio, difﬁculty with speech, the need for greater time when communicating in English, recognition that
language barriers exist, differences between nationalities, causes problems during meetings, difﬁculty in
ﬁnding staff with good English-language skills and the suggestion of checking of documents by native
English speakers. It should also be considered that there can be cultural aspects of communication. For
example, Scandinavians and north Europeans tend to use a low-context style, where communication is
explicit and unambiguous. In comparison in high-context styles (typical of southern Europeans), meanings
of words can be hidden.58Key point 23
Attention must be given to the difﬁculty of communicating in a common language. This should include
consideration of strategies to overcome this, such as factoring in more time for dialogue and considering the
possibility of getting documents checked by native English speakers.Communication methods
These results were obtained from a combined closed and open question included in the 2011 and
2012 questionnaires.
Owing to the large and complex structure of the project, it was essential that communication was optimal.
Participants working on tasks in the individual work packages were examples of virtual teams, ‘. . . teams
of workers who are dispersed across geographical, temporal, and organizational boundaries, yet
collaborate using information and telecommunications technology’.55 To help facilitate this, a large number
of different types of communication methods were used. Of these, the apparent most useful mechanism
was face-to-face meetings. This method was most frequently described as very useful in all years (although
this decreased from three-quarters in 2011 to two-thirds in 2012). In the hierarchy of communicationJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37methods, in person communication has been ranked as the gold standard method because it is possible to
see a person’s body language and catch the tone of voice and any speciﬁc nuances.55 This method is also
the best mode for establishing trust59 and discussing any controversial issues.58 The observed inclination for
face-to-face meetings might indicate that the EUnetHTA JA is a ‘relationship-orientated culture’ as such
cultures prefer face-to-face meetings because of the beneﬁts of physical, social and situation context.58 A
preference for face-to-face meetings goes hand-in-hand with the importance of networking and reinforces
the importance of participants meeting in person as opposed to working solely in virtual teams. However,
the beneﬁts of this communication method need to be balanced with the inherent implications in terms of
ﬁnancial and logistical costs. Therefore, it is important that face-to-face meetings are conducted in an
optimal manner and this demonstrates the importance of evaluating the policy-setting annual plenary
assembly meetings.
Other popular methods for communication were by using the project intranet (the MO website) and by
secretariat e-mails. These e-mails were a synchronous mode of communication, in that all (relevant)
participants received the information at the same time. This is a communication better suited to
task-orientated communications.58 The MO website acted as the project intranet and was a central
repository of project information. A large proportion of members did not know about the effectiveness of
the plenary assembly. This was to be expected, because only one representative per organisation was
permitted to attend this meeting.
Participants considered that communication could be improved in the EUnetHTA JA2 by having a formal
communications plan, devoting more resources to it, improving the current systems (e-meetings,
secretariat, website), using social networks, online tools, expanding networking opportunities, using
project management techniques and improving communication with stakeholders. Stakeholders mostly
considered this from the perspective of their receiving more information themselves rather than
communication between workers on the project. Social interactions and networking is especially
important for geographically dispersed teams.59 In this respect, use of social networks such as Facebook
(San Francisco, USA), Twitter (San Francisco, USA), LinkedIn (San Francisco, USA). may be useful. This point
will be further investigated in the EUnetHTA JA2.© Que
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The most popular form of interaction was from face-to-face meetings and these should be used wherever
appropriate in the EUnetHTA JA2. It is important that lessons are learned about how such meetings should
be conducted and evaluation of the plenary assembly meetings is important in this respect. The project
intranet site was very important and should be improved in the EUnetHTA JA2, particularly with respect to
the workroom areas.External promotion
These results came from an open question included in the 2012 questionnaire.
For projects generally little attention has been given to project marketing, which is concerned with
communicating the long-term consequences of a project. The relationships between internal and external
stakeholders are important. Suggestions for improvement included the need for a greater presence at
conferences, need for more published information, improvement of the public website, national relevance
should be communicated to countries, a need to target relevant stakeholders, social networks should be
employed, missing an individual approach, more training needed and that promotion will be demonstrated
best by collaborative HTA reports. There should be a distinction between whether the project has been
insufﬁciently promoted externally or if that is a perception. This workstrand was the subject of the53
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54dissemination work package, WP2. Detailed comments about the functioning of this work package are
described below.NIHRKey point 25
External promotion of the project should be improved for the EUnetHTA JA2 project. Strategies that have
been suggested include better public website, advertisement of timelines and achievements, use of social
media, etc.Operation of work packages
Participants were asked questions in each questionnaire about the work packages they were involved with.All work packages
All project participants, both members and non-members, were asked general questions about
the individual work packages. External stakeholders were also asked for their opinions about the
work packages.
Notably concern was expressed from the participants about the tool-generating work packages: WP4 (by
almost one-quarter), WP5 (by almost one-ﬁfth) and WP7 (by almost one-ﬁfth). One-ﬁfth of respondents
had concerns about WP8. Almost half of respondents did not know if they had concerns about WP2 or
WP3, and it is speculated that the fact these respondents did not know if they had concerns or not
indicated a general lack of knowledge about these work packages. In contrast, external stakeholders
had a higher rate of concerns about work packages which were not associated with developing HTA tools,
i.e. WP1, WP2, WP3, WP6 and WP8.
This apparent concern about HTA tool-generating work packages by participants was apparently not
reﬂected in whether or not participants thought their objectives would be met. However, for most work
packages over half of the respondents did not know whether or not the objectives would be met. It is
possible that respondents who were not part of a speciﬁc work package did not know whether or not the
objectives of other work packages would be met or it could be that they thought the objectives would
not be met but were unwilling to provide a negative response. The proportion of respondents who did not
know was also very high for the stakeholders, again over 50%. This could suggest a lack of conﬁdence in
work packages being able to meet their objectives. Stakeholders showed lack of knowledge about
objective meeting by work packages not associated with developing HTA-tools.
Approximately one-ﬁfth of participants thought they had not received appropriate communications from
the majority of work packages. However, a higher proportion thought they had not been adequately
informed about WP2 and WP8. Two-ﬁfths of stakeholders thought they had received insufﬁcient
communication from WP1. One-quarter of stakeholders thought they had received insufﬁcient
communication from WP2, WP6 and WP8.
There were minimal proportion of participants who expressed an opinion that work packages were not
worth having. However, approximately half of respondents did not know if WP2 and WP8 were worth
having in the project.
There was an indication from stakeholders that they had received insufﬁcient communications from work
packages in which they were not members of. They requested greater involvement of stakeholders in
other work packages (e.g. by stakeholder advisory groups being set up) and involvement of professionals
with specialist expertise in dissemination and business development.Journals Library www.journalslibrary.nihr.ac.uk
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For the following section, project participants who were members of the individual work packages were
asked detailed questions about them.
The individual work packages of the EUnetHTA JA can be viewed as individual projects in a portfolio. A
virtual organisation is formed of virtual groups of workers.59 A virtual work place forms a barrier to the
richness of face-to-face interactions and for this reason the usefulness of face-to-face meetings have been
used to jump-start an effective team.59 Three factors are important for the performance of successful
virtual teams: shared understanding, integration (working together in a way that creates value) and mutual
trust.59 A list of attributes of team members of international projects has been developed, which includes
experience in similar projects, previous experience in international projects, ability to work with other
people on tasks, ability to solve problems and work within the organisation, sensitivity to issues and
potential problems, availability from their other work to perform tasks on the project, communication skills,
ambition and energy, ability to cope with different cultures, ability and willingness to travel, and the ability
to work hard at understanding and getting ideas across.55 All project members have a responsibility for
building trust, communicating, using and adhering to common ground rules and managing conﬂicts.58
Duties of a project manager of an international project include deﬁning the project by dealing with
ambiguity and politics, organising the project, dealing with the routine work, addressing issues and crises,
leading by example, co-ordinating administration (e.g. logistical arrangements of face-to-face meetings.55
Trust between project members is of vital importance in international projects, alongside the belief that
fellow team members are putting their best efforts into the work and everyone is working towards the
project goal.58 Such trust is one of the prerequisites of managing global teams. This is difﬁcult to establish
in an international project because of knowledge of collaborating partners being low and reliance on
virtual working practices.58 It is also helpful to have informal interaction opportunities for each team.
Some of the main sources of conﬂict in international projects include ambiguity of project objective,
insufﬁcient authority of the project manager, manpower resources, costs, equipment and facilities,
priorities and responsibilities.58 One factor that can be important in the on-time delivery of a project is
‘adequacy of documentation of organisational responsibilities on the project’.57Work package 1: co-ordinationl There appeared to be a slight depreciation over time as the proportion who agreed increased and
proportion who strongly disagreed decreased for leadership and communication being effective within
the work package and deliverables being clear.
l The proportion who disagreed increased over time about the objectives of the work package being
clear and the amount of work being manageable, which was one-tenth in 2012.
l Approximately one-ﬁfth disagreed that the work package had beneﬁted from the inclusion
of stakeholders and one-quarter that all partners had contributed to the work adequately
(2012 questionnaire).
l Almost one-third did not know how this work package had progressed in 2011, but this decreased in
2012 where approximately half thought it had been OK and half that it had progressed well.
l The proportion of respondents having concerns about the work package increased over time to
one-ﬁfth in 2011. The qualitative data showed that concerns included continuity, high dependency
on the lead, too many face-to-face meetings, increased workload, overlap with EUnetHTA JA2 and
about the business model.
Overall, this work package appeared to perform well over time with respect to effective leadership, clear
objectives and manageable workload. However, concerns included the beneﬁt of stakeholder inclusion
and equal contribution of partners. There appeared to be a strong dependency on the lead partner.
Concerns about the delivery of the business model and overlap with the EUnetHTA JA2 project have been
addressed previously.55
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56Work package 2: disseminationl The proportion of respondents who disagreed about leadership and communication being effective
within the work package increased over time to one-quarter and two-ﬁfths respectively.
l The proportion of respondents who did not know was two-ﬁfths or more for the planning timeline
being clear, objectives being clear (P2011), progression of the work package over the past year
(P2011), frequency of e-meetings, frequency of face-to-face meetings and whether or not the work
package had communicated adequately with other work packages.
l Four-ﬁfths did not know about the beneﬁt of involving stakeholders in the work package.
l One-ﬁfth of respondents thought the progression of the work package was poor. The qualitative data
showed that concerns included the need for more communication, internally and externally, and more
support from the co-lead partner.
Overall, this work package appeared to have performed somewhat poorly, with respect to effective
leadership and communication. Particular concern was about the leadership, communication and beneﬁt
from the involvement of stakeholders. It was relevant that the representative from the colead organisation
had died and the representative from the lead partner organisation had left part way through the project.
This emphasises the importance of continuity of a project and the need for induction processes so that the
project can continue seamlessly.Work package 3: evaluation
This work package only contained one organisation (NETSCC) and two members of staff and, therefore,
the evaluation questions were not asked for this work package.Work package 4: core health technology assessment model
This was one of the core work packages of the EUnetHTA JA, with the aim of producing a tool for
performing HTA. Therefore, stakeholders were also asked about how they thought it had performed.
l The proportion of respondents who agreed increased, but the proportion who strongly agreed
decreased for leadership being effective, objectives being clear, and deliverables being clear.
l The proportion of respondents who disagreed about communication between members being effective
increased over time to one-ﬁfth in 2012.
l Approximately one-ﬁfth of respondents disagreed about the amount of work being manageable,
collaboration between members to produce core HTAs and beneﬁt from the involvement of
stakeholders. About two-ﬁfths disagreed about whether or not all members had contributed to the
work adequately.
l The proportion with general concerns about this work package decreased over time from one-quarter
to one-ﬁfth. The qualitative data showed that concerns included the applicability of the model,
co-ordination issues, communication issues, workload and that stakeholders had been of little use
l By the ﬁnal year approximately half of respondents thought it had progressed OK and half that it had
progressed well. The qualitative data showed that concerns included slow progress, lack of
participation in pilots and would form the basis for EUnetHTA JA2.
l Stakeholder concerns included limited applicability of the model in practice.
Overall, this work package appeared to perform well, with respect to effective leadership, and clear
objectives and deliverables. However, some concerns were expressed about the amount of work,
collaboration on the work, contribution of members and involvement of stakeholders. This was one of the
work package that contained a larger amount of participants, which could have magniﬁed intrinsic
difﬁculties in communicating, dividing the work evenly and working together.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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This was one of the core work packages of the EUnetHTA JA, with the aim of producing a tool for
performing HTA. Therefore, stakeholders were also asked about how they thought it had performed.
l There appeared to be some degree of improvement in the leadership being effective and
communication between members being effective because one-tenth disagreed in 2010, but this
decreased to zero in 2011 (when one-tenth did not know).
l The proportion of respondents who disagreed about the amount of work being manageable increased
to approximately one-third and a similar proportion disagreed about the contribution of staff.
l Almost one-ﬁfth disagreed about the division of work and one-ﬁfth disagreed about the number of
face-to-face meetings being appropriate.
l Approximately half did not know about the beneﬁts of stakeholder involvement, but half agreed
involvement of stakeholders had beneﬁted the work package.
l Concerns about the work package’s progress decreased from two-ﬁfths in 2010 to one-ﬁfth in 2011.
The qualitative data showed that concerns included that there had been a change in focus from
developing a full and rapid model for assessment to only a rapid model, high workload beyond the
schedule, applicability concerns, insufﬁcient number of face-to-face meetings, and difﬁculty in
managing stakeholder and political interest.
l The qualitative data showed that stakeholder concerns included lack of involvement, lack of
information exchange and inappropriate inﬂuence of industry.
Overall, this work package appeared to perform well, with respect to effective leadership and
communication. However, there were concerns about the amount of work, division of work, contributions
of members and the number of face-to-face meetings (in 2010). This was again one of the work packages
with a large number of members, which could cause intrinsic difﬁculties and the need for face-to-face
meetings is highlighted. There was an apparent perception of high workload. It is difﬁcult to conjecture
whether there was too much work that had grown from the work plan or if this was members’
perceptions. It is important that workers contribute as equally as possible so that the burden can
be shared.Work package 6: information management systeml There appeared to be improvement over the lifetime of the project, with the proportion of
respondents who agreed decreasing and the proportion of those who strongly agreed increasing for
communication between members being effective, objectives being clear, the planning timeline
is clear and number of meetings was appropriate.
l Approximately one-tenth of respondents thought the technical issues were unclear in 2011.
l Three-ﬁfths of respondents did not know about the beneﬁts of involving stakeholders in the
work package.
l Approximately one-ﬁfth of members had concerns about the work package, which included
that the work was dependent on the other work packages, the inherited IT system from the
previous project and they would appreciate e-meetings to discuss the work between the planned
face-to-face meetings.
l The proportion of respondents who thought the project had progressed well increased from
approximately one-half to two-thirds in 2012.
Overall, this work package appeared to perform very well, with respect to effective communication
between partners, clear objectives, clear planning timeline and an appropriate number of e-meetings.
Some concern was shown about the equal involvement of members and of stakeholders. The information
technology infrastructure is important for a geographically dispersed project and the other work packages
were dependent on it.57
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58Work package 7: new technologies
This was one of the core work packages of the EUnetHTA JA, with the aim of producing a tool for
performing HTA. Therefore, stakeholders were also asked how they thought it had been performed.
l There was a noticeable level of disagreement in 2010, which improved slightly over the project;
communication between members being effective (one-quarter in 2010), objectives being clear
(one-ﬁfth in 2010), leadership being effective, deliverables being clear and planning timeline
being clear.
l The proportion of respondents who strongly agreed about the leadership being effective increased,
while the proportion who disagreed also increased between 2010 and 2012.
l Three-ﬁfths of participants were unsure about the beneﬁt of involving stakeholders.
l Only about one-third of respondents agreed or strongly agreed that all members had contributed to
the work adequately.
l The proportion who thought progress had been good increased in 2011 to three-ﬁfths. The qualitative
data showed that concerns included that the two strands had developed quite differently: lack of
partners populating the POP database and obscure development of EVIDENT.
l The qualitative data showed that stakeholder concerns included delay in deliverables and lack of
involvement of stakeholder advisory groups (SAGs) in the process.
One of the objectives of the process evaluation was to ‘prospectively be vigilant of emerging issues and
support the achievement of objectives’. It was identiﬁed in the ﬁrst survey in 2010 that there were
concerns about the leadership of WP7. This matter was raised with the lead organisation of WP7 and the
executive committee. The WP7 lead partner explained that they had experienced lack of staff to fulﬁl some
of their leadership activities as a result of a staff member going on maternity leave and they had plans to
resolve this matter. This was not an apparent problem in the next annual survey of 2011 and so it seemed
that the matter had been effectively resolved.
Overall, this work package seemed to progress quite well. After a somewhat disappointing start, it seemed
to improve over the life of the project. However, there were some apparent concerns over unequal
contribution of partners to the work.Work package 8: strategy and business model developmentl There was still signiﬁcant disagreement in 2012 of at least one-ﬁfth for communication being effective
and the deliverables and objectives being clear.
l Two-ﬁfths did not know if all members had contributed to the work adequately.
l Almost half did not know about communication with other work packages and the beneﬁt of
involvement of stakeholders in the work package work.
l This work package was split into three subsections and by the end of the project about one-tenth of
respondents for each section thought it had progressed poorly.
l Approximately one-third of respondents had concerns in 2010 about the work package, but this
decreased to one-ﬁfth in 2011. The qualitative data showed that concerns included confusion about
constitution and structure of the work package into three different work streams.
This was a complex work package and was subdivided into three separate work streams. This was
reﬂected in the concerns expressed about the work package’s structure and may have impacted on
concerns about the communication, deliverables and objectives.Plenary assembly meetings
Paper questionnaires were distributed to participants of the annual plenary assembly meetings and the
response rates are shown in Table 8.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 8 Response rates to the plenary assembly questionnaires
Questionnaire
Number of
questionnaires distributed Response rate Total n received
Plenary assembly evaluation 2010 39 74% 29
Plenary assembly evaluation 2011 47 77% 36
Plenary assembly evaluation 2012 50 78% 39
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37The plenary assembly was an annual meeting to which a representative of all project participant
organisations was invited, alongside members of the stakeholder forum. It had an elected chairperson and
was a policy-setting forum. These meetings were costly, in respect of ﬁnancial cost of members travelling
to a foreign city and person-hours involved. Therefore, it was essential that these meetings were as
productive as possible. The academic literature shows that it is important that meetings are reviewed at
their outset and learning used to improve future events.60 Therefore, the meetings were evaluated and
the results fed back to the secretariat in a detailed report to lead to quality improvement initiatives.
The ﬁndings will be of use in planning the plenary assembly meetings of the EUnetHTA JA2.
A meeting can be considered a project tool.61 Meetings can fulﬁl various functions; information sharing,
brainstorming, problem solving, and decision-making and socialising.61 Characteristics of meetings have
been studied and classiﬁed as temporal (relating to the use of time in a meeting, e.g. use of a break),
physical (relating to the meeting environment, e.g. meeting space), procedural (relating to how the
meeting is conducted, e.g. following a formal agenda) and attendee (relating to members, e.g. the role of
the meeting facilitator).61Objectives
Participants were asked a closed question in each questionnaire about whether or not they thought the
meetings’ objectives had been achieved.
Overall, approximately one-tenth of meeting participants did not know whether or not the meetings’
objectives had been met in 2010 and 2012. About one-ﬁfth were not sure for the 2011 meeting. It is
recommended that the meeting objectives are made explicit from the outset. It was concerning that
one-tenth of participants thought the meeting’s objectives had not been met in 2011. Causes for concern
included questions not being answered, lack of useful information and lack of time for debate. When
indicating that the meeting objectives had been met, it appeared that participants cited factors that had
been important for them personally, such as information gain and endorsement of decisions.© Que
State f
journa
addres
Park, SKey point 26
The objectives of the meeting should be made explicit on the agenda before the meeting.Most preferred aspect
Participants were asked an open question in each questionnaire about what the best aspect of the
meeting had been.
Overall, meeting participants seemed to appreciate meeting people face-to-face, discussions, information
sharing, social activity and good meeting logistics.59
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60The academic literature has shown that the agenda is crucial in meetings and it has been recommended
that meetings begin with a few easy items to settle participants in.60 Difﬁcult items should be placed
around breaks. Frequent breaks should be factored into meetings because concentration typically wanes
after about 45 minutes. This also enables participants more opportunities for informal networking. Larger
meetings have been correlated with a lower quality and demonstrated the need for a facilitator. Other
attributes that have a positive effect include having a break, sufﬁcient lighting and temperature of the
room, room space and refreshments.61Least preferred aspect
Participants were asked an open question in each questionnaire about what the worst aspect of the
meeting had been.
In 2010 problems seemed to centre around technical problems with microphones during the meeting and
difﬁculties getting to the venue. Good meeting logistics are important for a successful interaction and
functioning microphones are an important facet of this. In 2011 there were apparent difﬁculties posed
because of the meeting venue (such as seeing the slides) and chairing of the meeting (such as lack of
summing up and apparently treating comments at different levels). It is crucial that tables and chairs are
positioned so that the chairperson and all the members may participate appropriately. The academic
literature has shown that seating the chairperson separately might help them exert their authority over
proceedings60 and it is important that participants are able to express their opinions and everyone is heard,
and that discussions are respectful.61 How the participants viewed the meeting can have important attitude
and behavioural implications and can impact negatively on the ability of a meeting to reach its goal and
support of future meetings. Perception of meetings can also have an effect on employee morale. In 2012
there was an apparent lack of people participating in discussions in the plenary assembly meetings. A
common theme throughout the three meetings was lack of time for discussions and participants wishing
the opportunity to prepare themselves in greater detail before the meeting. Statistically signiﬁcant beneﬁts
have been found in the academic literature with prior access to an agenda and it is believed that this helps
in setting expectations in advance of the meeting and allows for pre-meeting preparation.61 The working
environment of meetings is very important and emphasises the ﬁnding that this affects mood and
inﬂuences behaviour.61 To make meetings more interesting the format of presentations in the plenary
assembly meetings can be changed, for example using group breakout sessions and different visual
presentations (e.g. ﬂip charts, video clips, etc.). Other important facets of a meeting include a productive,
morale-boosting nature and presentations of adequate content and length.61Meeting attributes
In 2011 and 2012 participants were asked to rate attributes of the meeting in a combined closed and
open question.
The factor that was rated very good most often was the social event. The second best was meeting or
networking with colleagues, with 97% of participants in 2011 and 99% in 2012 rating this as good
or very good. An important facet of building trust within an international team is providing informal
interaction opportunities.58 Establishing trust is integral for a successful international project, but is difﬁcult
to establish. It cannot be achieved by a one-off meeting but takes time and is a reiterative process in
order to cement relationships.58 The importance of combining a team meeting with a team-building
activity, such as having a meal in a restaurant, has been emphasised.58 Reviews of research have
highlighted the importance of initial face-to-face meetings in ‘jump starting’ effective virtual teams.59
It was noticeable that the meeting venue in 2011 was poor – only 8% rated this as very good compared
with 64% in 2012. Leadership of the meeting was also better in 2012 than 2011 with 95% rating this as
good or very good in 2012. In decision-making meetings the chairperson should use a participatory style
rather than an autocratic one. At the end of a meeting the discussions should be summarised and actions
denoted.62NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The concept of a project’s value can also be reﬂected in its worth to different stakeholders.63 Stakeholders
can be deﬁned as ‘actors who have an interest in the issue under consideration, who are affect by
the issue, or who – because of their position – have or could have an active or passive inﬂuence on the
decision-making and implementation process’.64 Alongside the individual project participants this also
included external stakeholders. Such stakeholders for a project can be from heterogeneous organisations,
from different cultures and hold different values.63 Knowledge about relevant external stakeholders is vital
for international projects. It is important that their inﬂuence level is assessed and their objectives in relation
to project strategies and deliverables identiﬁed. Stakeholder position in a project can be deﬁned as ally
(agree with the need for the project, support the strategies and can inﬂuence other stakeholders), oppose
(disagree with the strategies and dissent from the project) and neutral (do not have a special interest, but
will not suffer from the project’s completion).65 It is important that an analysis of stakeholders is performed
at the start of a project. This allows mapping of an individual stakeholder’s relation to the project, as well
as the relationship between stakeholders.64Views of project participants about the involvement of stakeholders
Participants were asked open questions in 2011 and 2012 about concerns associated with involvement of
stakeholders in the project. They were asked what the beneﬁts of stakeholder involvement had been by an
open question included in the 2011 questionnaire.
When participants were asked in 2012, only two-ﬁfths had no concerns about the actual involvement of
stakeholders in the EUnetHTA JA. A further two-ﬁfths did not know if they had concerns and one-ﬁfth had
concerns. Only one-third of participants had no concerns about the level of commitment of stakeholders,
one-ﬁfth had concerns and half did not know. The qualitative data showed that concerns centred around
lack of participation and commitment of stakeholders and the heterogeneous nature of stakeholders.
Therefore, there was a large proportion of concern or apparent lack of knowledge, which might have
indicated a lack of added value.Response rates to stakeholder questionnaires
For the S2011 survey, only half of the four industry representatives and half of the four patients/consumers
responded. The situation was repeated in S2012 (although the individual non-responding organisations
were different). It may be that lack of response is itself of value (e.g. leading to the speculated conclusion
that the stakeholder organisation does not consider EUnetHTA of sufﬁcient importance to engage with),
but it would be preferred to have this opinion explicitly stated. Unfortunately, it was beyond the scope of
the evaluation (agreed with the EU Commission) to include follow-up of non-respondents.© Que
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Stakeholders must commit to answer evaluation questionnaires in the EUnetHTA JA2, so that their opinions
can be considered.Formation of the stakeholder forum
A combination of closed and open questions were included in the questionnaires about the formation of
the forum, its purpose, why stakeholders had applied to join it, what they could contribute and whether or
not appropriate organisations had been included.
A prerequisite of the EUnetHTA JA project was an acknowledgement of the importance of communicating
with stakeholders.13 With this aim a formal stakeholder forum was established in 2010. This contained
four seats for stakeholder categories of industry, patients/consumers, providers and payers. Stakeholders
became aware of this forum from various avenues, including from the EU Commission, the EUnetHTA61
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62secretariat and key project personnel and other stakeholders. Stakeholders had applied to be an external
stakeholder for various reasons, including contributing to the JA project, to enable reciprocal working
patterns and ensuring a balance of stakeholder expertise. Stakeholders believed they could contribute to
the project by providing specialist HTA knowledge, providing access to experts, providing a governance
role and disseminating the project results. They saw the purpose of the forum as facilitating the
stakeholder involvement process by providing an intermediary link between the stakeholders and the JA
project, overseeing work package and SAG activities, developing consensus for decision-making and being
‘transparent, responsive, accountable and participative’.
In practice, only two organisations applied for the four seats in both the provider and payer categories.
This only represents half-capacity take-up and it is suggested that possibly these were inappropriate types
of stakeholder expertise to include in the project or that the call for stakeholders was too limited. There
were more participants than spaces for the industry and patients/consumer groups, and this meant that
some applicants were excluded. The perceived risk from non-inclusion of these organisations were
suggested as missing expertise, decreased scope of JA activities, decreased conﬁdence in the project and
inclusion of less experienced representatives. It was notable that only one-ﬁfth thought that the way of
setting up the forum was straightforward. The qualitative data showed that concerns included the process
itself, that it was organised to fulﬁl a certain type of stakeholder involvement, restricting stakeholder
members prevented equal contributions, lack of clarity about why applicants were rejected and complexity
in assigning a representative. However, about three-quarters of stakeholders questioned near the end
of the project thought the formation of the forum had been an effective mechanism for involving
stakeholders. Over two-thirds of respondents surveyed in 2012 thought the appropriate organisations had
been included. Those members who had applied to join the forum but had been excluded from the forum
were represented by a representative for their speciﬁc group. At the start of the project the majority of
these organisations were concerned that they would not be represented adequately. However, these
concerns appeared unfounded because by the end of the project all agreed that they had been kept
adequately updated by either their forum representative or by the secretariat.
The qualitative data showed that there were apparent initial concerns about the formation of the forum
because it was seen as a complicated business and there were concerns about restriction of expertise.
However, by the end of the project this was seen as having been an effective mechanism and mostly
included the correct stakeholders. Those who had not been successful in gaining a place had been kept
informed by their representative.NIHRKey point 28
Overall, the stakeholder forum seemed to be an effective means of involving external stakeholders in the
EUnetHTA JA. Non-members appeared to have been adequately informed by their designated representative.Operation of the stakeholder forum
A combination of closed and open questions were included in the questionnaires to identify stakeholders’
views about the operation of the forum, whether or not it was fulﬁlling its purpose and comments on the
meetings held.
In 2011, all respondents agreed that the forum was fulﬁlling its purpose, recognising an initial start-up
period. It was seen as being inclusive, evolving and that there was increasing trust. Its purpose was cited
as being a special advisory group to the executive committee, commentating on work package tasks,
overseeing SAGs, gaining consensus for decisions. The majority thought membership was involving what
they had envisaged and it seemed to be improving over time. However, in 2012 about one-third thought it
was not fulﬁlling its purpose and about one-third did not know if it was or not. Of the third who thoughtJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37it was not fulﬁlling its purpose, half were patient organisations and half were industry. It could be worth
probing stakeholders in greater depth to analyse why the functioning of the forum appeared to depreciate
between 2011 and 2012 (but unfortunately this was beyond the scope of the evaluation agreed with the
EU Commission).
Regular stakeholder meetings were held (both electronically and face-to-face) and almost three-quarters
thought these had been useful. In general, these seemed to be appreciated, were well organised and of a
suitable frequency. Suggestions for improvement included having pre-preparation materials sent in
advance, a stakeholder chairperson, facilitating more contribution from stakeholders and more suitable
agenda items following greater dialogue about setting the agenda.© Que
State f
journa
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Park, SKey point 29
Stakeholder forum meetings were appreciated and should continue in the EUnetHTA JA2. Improvements
could be made, for example by having a more participatory nature, greater dialogue about setting the
agenda and considering having a stakeholder chairperson.Half of respondents had concerns about the principles of stakeholder involvement in the EUnetHTA JA
(stakeholder policy and standard operating procedures). Of these ﬁve organisations all types of stakeholder
were included.Key point 30
There is a need to review the documents and processes for stakeholder involvement in EUnetHTA JA2.Nature of being a stakeholder of the European Network for Health
Technology Assessment Joint Action
A combination of closed and open questions were included in the questionnaires about what it meant to
be a stakeholder in the project: how they had been involved, how their opinions and expertise had been
used, if adequate feedback had been received and how involvement of stakeholders could be improved in
EUnetHTA JA2.
At the start of the project stakeholders thought their involvement and contributions would include general
input and speciﬁc HTA knowledge/expertise, attending meetings, being involved in work packages,
facilitating experts, sharing information, providing a governance role and disseminating project results. In
the interim year, almost three-quarters of stakeholders indicated that involvement in the stakeholder forum
had involved what they thought it would, although some concerns centred around balance of the forum’s
representativeness. During the project and at the end, they commented how they had been involved. This
broadly included the activities they had anticipated, along with being a member of SAGs, participation in
the plenary assembly, organising a joint industry response, regular contact with work package leaders,
participating in the EUnetHTA JA conference and in discussions about the future of EUnetHTA JA2.
However, it was of concern that almost three-quarters had worries about the actual involvement of
stakeholders in the EUnetHTA JA1. Half did not think that their organisation’s expertise had been
appropriately used. Of these ﬁve organisations, two were from industry, two were patient organisations
and one was a payer organisation.63
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64Half had concerns about the ‘principles of stakeholder involvement in the EUnetHTA JA’. The majority of
stakeholders either had concerns about the commitment of stakeholders in the JA or did not know if they
had concerns or not. Of the four who had concerns, two were from patient organisations, one was from
industry and one was from providers.
About one-third of stakeholders thought that stakeholders’ views were not adequately considered and the
proportion of those who thought that were considered increased from one-third to one-half by the ﬁnal
year. The two organisations which disagreed were industry and patient organisations. Suggestions for
improvement included involving stakeholders at an earlier stage in iterative planning, producing summaries
of contributions and making the forum more participatory in nature.NIHRKey point 31
There was a sense that stakeholders thought they had much to offer the work of the EUnetHTA JA project
but that they could have been involved to a greater degree.In the interim year, the majority thought that being a member of the stakeholder forum had been a good
use of their organisation’s time, but this decreased to two-thirds in 2012. The organisations which thought
it had not been a good use of time were both patient organisations. In contrast all organisations who
were not participants of the forum had ‘got what it hoped by being a Stakeholder of the JA’ and that it
had been a useful use of their time. Participation was seen to confer beneﬁts to stakeholders; increasing
general HTA knowledge, recognition for the umbrella stakeholder organisation and ability to comment on
documents before publication.
Stakeholder advisory groups were formed for WP4, WP5 and WP7 with the purpose of organising
stakeholder input into the work of the EUnetHTA JA. This way of working was apparently well received,
with about two-thirds of respondents appreciating this style of involvement. However, the qualitative data
showed that concerns included short timelines for responding to consultations and the diverse nature of
the stakeholder forum made it difﬁcult to balance points of view.Key point 32
Developed during the project, stakeholder advisory groups appeared to function well. Concerns, such as
short timelines for responding to consultation and the difﬁculties of obtaining a balance view should be
addressed in EUnetHTA JA2.The stakeholders did not know at baseline whether or not they would be provided with adequate
feedback about the project and they suggested that a stakeholder chairperson be appointed to better link
them to the project. However, these fears seemed to be unfounded because the majority thought they
had received adequate feedback in the interim and ﬁnal years. There were still some suggestions for
improvement, such as that having earlier information about work packages would enable better
participation. The one organisation that disagreed was a patient organisation.Journals Library www.journalslibrary.nihr.ac.uk
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The provision of information to stakeholders had generally been adequate. Improvements could be made,
for example by providing information earlier, etc.There was some apparent concern by some members that the forum was a homogeneous group of
experts who could be biased (particularly towards the pharmaceutical industry). In the future, efforts must
be made to ensure greater participation and representation of all groups’ views.Key point 34
The different natures, interests and level of inﬂuence must be recognised in EUnetHTA JA2. Processes and
documents must ensure a participatory nature and inclusion of the views of all relative stakeholders.Improvement in European network for Health Technology Assessment
Joint Action 2
Stakeholders considered that positive involvement had been seen through SAGs, that the diversity of
different stakeholder groups on the forum needs to be managed and that earlier involvement of
stakeholders, such as in formulating the project objectives and evaluation criteria, would be appreciated.
Participants also thought that stakeholders should be involved earlier in the process, that the involvement
of stakeholders should prevent bias towards industry, that the forum had been a good mechanism and
that communication between project participants and stakeholders should be improved.Key point 35
There was a sense that stakeholders appreciated involvement in the EUnetHTA JA. However, they felt they
had more expertise to offer and this could be facilitated by earlier and more inclusive involvement in work
package tasks with longer deadlines for review. Participation could also be helped by an inclusive stakeholder
forum that appreciated the heterogeneous nature of stakeholders and valued contributions from all
groups equally.European network for Health Technology Assessment Joint Action 2
The EUnetHTA JA2 project has been formed by a grant agreement with the European Commission. Its
general objective is to ‘strengthen the practical application of tools and approaches to cross-border
HTA collaboration’.66 It is notable that the main outcome of the EUnetHTA JA2 will be similar to the
overarching objective of the EUnetHTA JA, ‘the implementation of the permanent network for HTA in
Europe’.66 This project will operate from 2012 to 2015 and it will be composed of the following
work packages:
l WP1 – co-ordination
l WP2 – dissemination
l WP3 – evaluation
l WP4 – testing collaborative production of HTA information for national adaptation and reporting
l WP5 – applying the HTA Core Model for rapid assessment for national adaptation and reporting65
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66l WP6 – information management infrastructure and services
l WP7 – methodology development and evidence generation: guidelines and pilots production
l WP8 – maintenance of HTA Core Model infrastructure to support shared production and sharing of
HTA information.Purpose
The majority of stakeholders, and almost three-quarters of participants, thought the EUnetHTA JA2 would
serve as a useful follow-up to the EUnetHTA JA project, with the rest not knowing whether or not it would
be. Comments revolved around the fact that EUnetHTA JA2 would beneﬁt from the experiences of the
EUnetHTA JA, that it is a necessary follow-up project, that it has a different focus, that further
development of tools for HTA is required, there is a need to test the effectiveness of joint report
production, this would identify co-operation between agencies and enable examination of the methods
developed in actual practice. It was seen as a bridge between the EUnetHTA JA and the permanent
network. This seemed to be an indication that the EUnetHTA JA had not completely fulﬁlled its objectives
and that it needed a further joint action project to be able to actually apply the tools in practice.Concerns
The proportion of project participants who had concerns about the EUnetHTA JA2 project decreased from
2011, when over half had concerns, to 2012, when approximately one-ﬁfth had concerns. Different
concerns were noted in the 2 years. The qualitative data showed that concerns in 2010 included worries
about an overlap with the current JA, HTA reports, poor deﬁnition of the project and political aspects. The
qualitative data showed that concerns in 2011 included integration of deliverables, scope of the project
and involvement of the correct expertise. Lack of resources was noted in both years. Almost one-third of
stakeholders had concerns, which included stakeholders not being sufﬁciently involved or representation
of different stakeholders. These also included commitment of governments to implement outputs and the
need to have clear obligations and a timetable. About one-third of project participants had concerns about
the actual planning process, which included lack of time in submitting the plans, and problems with the
overlap between the two projects. About three-ﬁfths thought it was having an impact on the time
available for work on the EUnetHTA JA project. Suggestions for how it could have been better included
having more time for preparatory work, a bigger focus on capacity building, greater stakeholder input and
incorporating recognised project management techniques.Lessons learned from the European network for Health Technology
Assessment Joint Action
Project participants and stakeholders had different perspectives on what could be learnt from the
EUnetHTA JA to inform the next project. Participants recognised the importance of collaboration and
communication and contribution of participants, better project planning and budgeting, more accurate
scoping of work at the start, information sharing, development of tools and appropriate involvement of
stakeholders and experts. Stakeholders felt less complexity and greater transparency was needed, a
formalised lessons learned document was required from the EUnetHTA JA to build on and stakeholder
involvement should be strengthened.Involvement of stakeholders
Suggestions for improving the involvement of stakeholders included earlier involvement, need for more
balanced representation to avoid industry bias, recognition that they have an important role in validating
the tools, sharing deliverables with them, the positive effect of SAGs and to share timelines earlier. This
indicates the impression that stakeholder involvement was a developing process; it was recognised as
needed from the EUnetHTA 2006–8 project, developed through the EUnetHTA JA project with the
establishment of the stakeholder forum and SAGs and needs further evolvement in the EUnetHTA JA2
project. In this respect, it is hoped that the lessons learned from the evaluation of the JA project will
be helpful.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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It was not possible to progress from the EUnetHTA JA to the permanent network, but a bridging project
seemed necessary: the EUnetHTA JA2 project. It is important that lessons are learned from the EUnetHTA JA.
These included utilising better project planning and budgeting and stakeholder involvement. Stakeholder
involvement is seen as an evolving process; recognised as needed by the EUnetHTA 2006–8 project,
developed during the EUnetHTA JA project and requiring further development in the EUnetHTA JA2 project.Lessons learned from the European network for Health Technology
Assessment 2006–8 project
The objective of the EUnetHTA 2006–8 project was:. . . to establish an effective and sustainable European network of Health Technology Assessment to
inform policy decisions. The overall strategic objective is to connect public national health technology
assessment (HTA) agencies, research institutions and health ministries, enabling an effective exchange
of information and support to policy decisions by member states.A key part of effective project management is learning from previous experiences, in a quality
improvement process. This should ensure that learning is embedded into continuous improvement of
project processes.57 Therefore, it was important to identify the recommendations made in the evaluation
report of the EUnetHTA 2006–8 project and to assess whether or not these had been acted on for the
EUnetHTA JA. Similarly to the EUnetHTA JA project, one work package was responsible for the internal
evaluation of the EUnetHTA 2006–8 projects and delivering a ﬁnal report. This included the following
recommendations ‘for a future sustainable network’67 shown in Box 4 below.
It is important to note that the recommendations that were made from the evaluation of the EUnetHTA
2006–8 project were for ‘the future sustainable network’ which, at the time of writing the report, was
thought to be established in 2009. However, this was not achieved as anticipated directly following the4 Recommendations from the EUnetHTA 2006–8 project [Haheim LL, Iglesia II, Laubli M, Gasparetto T,
zalez-Enriquez J, Trofimovs I, et al. EUnetHTA Internal Evaluation Report (2006–2008). 2008.
: www.eunethta.eu/outputs/eunethta-internal-evaluation-report-2006-2008 (accessed March 2014)]67
1. Secure funding and maintain a dedicated co-ordinating secretariat.
2. Ensure efﬁciency through an organisational structure made up of work packages managed by a core of
dedicated partners, with less committed partners taking part as a wider review group.;
3. Continue developing and evaluating the tools as necessary and in real settings.
4. Involve people in the work to ensure commitment, a high level of knowledge, and a broad basis for
decision-making processes.
5. Encourage collaboration and communication among all parties to ensure coherence within groups and
within the EUnetHTA collaboration.
6. Continue developing the communication platform and clearinghouse functionality to make the EUnetHTA
collaboration the central reference point for HTA in Europe.
7. Arrange face-to-face meetings at the outset of group or committee work to strengthen social coherence
and reach a common understanding of the work.
8. Evaluate the technical communication platform.
9. English has been the main language and should continue to be so.
67
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682006–8 project. Instead, it was necessary to have the EUnetHTA JA project and the EUnetHTA JA2 project
to bridge the gap between the initial EUnetHTA 2006–8 project and the sustainable network which is
currently expected to be established by 2015.Secure funding and maintain a dedicated co-ordinating secretariat
The EUnetHTA 2006–8 project was cofunded by an EU grant and the individual participating organisations in
a ratio of 1 : 1. For the EUnetHTA JA this was also part funded, in a 1 : 1 ratio from the EU and from Associate
partner organisations.13 As for the EUnetHTA 2006–8 project, the main partner was the Danish Health and
Medicines Authority (formerly the National Board of Health). It acted as a dedicated co-ordinating secretariat
and led the co-ordination work package (WP1). One aim of this work package was to ensure the submission
of technical reports to the EU Commission on time and meeting deadlines of deliverables.
In the EUnetHTA JA project, the co-ordinating secretariat was maintained. Evaluation results showed that
approximately three-ﬁfths of project participants thought they had provided effective administration and
three-quarters thought their communication by e-mails was adequate. Other activities that could be
performed by the secretariat included a greater role in facilitating relationships, providing project
management guidance and providing greater feedback about the project. It is suggested that this be
considered for EUnetHTA JA2.
Conclusion: Funding was secured for the JA project. The secretariat was maintained as a dedicated
co-ordinating support.Assure efficiency through an organisational structure made up of work
packages managed by a core of dedicated partners, with less committed
partners taking part as a wider review group
The evaluation of the 2006–8 project concluded that ‘work packages have proven to be a good working
model’, while recognising that clariﬁcation was needed about how each partner could contribute. The
structure of work packages had been shown to be effective by the previous project and is a common
method of organising the structure of international projects.58 Therefore, this structure was chosen again
for organisation of the EUnetHTA JA project.
The majority of participants and stakeholders who expressed an opinion in the evaluation of the EUnetHTA
JA thought this method of organising the work was positive. However, approximately one-quarter of
participants thought there would also be negative aspects associated with this division. Concerns centred
around possible overlap between the aims and work of individual work packages and the importance of
effective communication between them.
Each work package was led by a designated lead partner organisation and the executive committee
brought these organisations together, along with the plenary assembly chairperson and EU representative,
every 2 months.
In the EUnetHTA JA project there were some apparent suggested cases of unequal contributions
from partners. Going forward to the EUnetHTA JA2 project there are plans to manage contributions
by classifying organisations as either ‘active’ or ‘less active’ and managing ﬁnancial
reimbursement accordingly.
Conclusion: The same work package format (common to DG SANCO-funded projects) was used for the
EUnetHTA JA. Some concerns about apparent unequal contributions means that organisations will be
graded for the level of their activity in the EUnetHTA JA2.Continue developing and evaluating the tools as necessary
Evaluation of the previous project identiﬁed that tools had been produced within the project lifecycle
according to the scheduled timeframe. However, it identiﬁed that adjustments and further development ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37ideas was needed and, therefore, tools had not been piloted in a real-life setting (although two pilots had
been performed for the HTA Core Model; ‘core HTA on drug-eluting stents’ and ‘core HTA on multislice
computerised tomography angiography’). One of the three speciﬁc objectives of the EUnetHTA JA project
was ‘application and ﬁeld-testing of developed tools and methods’.
The documentary analysis revealed that most of the 11 project deliverables had been produced by the
end of the EUnetHTA JA project. These included the following tools; HTA Core Model on screening, an
‘operational web-based toolkit including database-containing information on evidence generation on new
technologies’ and a ‘quarterly communication protocol for information ﬂow on ongoing/planned national
assessments of same technologies’. It was predicted that the ‘methodological guidance that will be
appropriate for the assessment of relative effectiveness of pharmaceuticals’ would be delivered after the
project end, in February 2013.
Although the HTA tools had been further tested in the EUnetHTA JA project there seemed little
opportunity to evaluate their use in practice. Therefore, one of the main tasks of EUnetHTA JA2 must be
to pilot the tools in actual practice of preparing HTAs.
Conclusion: The HTA tools and methods had been further developed in the EUnetHTA JA project.
However, there had been little opportunity to evaluate their use in practice and this appears to be the task
of the EUnetHTA JA2 project.Involve people in the work to ensure commitment, a high level of knowledge
and a broad basis for decision-making processes
One of the apparent added values of the EUnetHTA JA project was the opportunity for project participants
to network and share information with each other. This contributed to achieving a high level of
knowledge within the project.
Some considerable turnover in project participants was seen during the lifecycle of the project and it is
important to develop a suite of induction materials to involve new staff in the work quickly and efﬁciently.
In view of this turnover it was of concern that only two-ﬁfths of respondents were aware that their
organisation had a sufﬁcient plan to mitigate this in succession planning. Commitment to the work might
be affected by lack of staff or resources and careful budgeting and project planning would help this in
the EUnetHTA JA2.
Conclusion: One of the added values of participation in the project included information sharing.
Commitment to the work was demonstrated by the fact that all deliverables were produced according
to the work plan. Potential turnover of staff must be managed and processes implemented to
manage resources.Encourage collaboration and communication among all parties to ensure
coherence within groups and within European network for
Health Technology Assessment
It is slightly ambiguous what the evaluation considered as ‘all parties’ and ‘groups’. Members seemed to
collaborate on the work effectively within the separate constituent work packages. It was notable that one
of the main beneﬁts of the EUnetHTA JA project was seen by participants as networking. There seemed to
be little evidence of tangible collaboration on HTA during the EUnetHTA JA, although some was
performed using the HTA Core Model. More collaboration is planned during the EUnetHTA JA2.
Communication within the EUnetHTA JA appeared to be effective and the mechanism most preferred by
project participants was face-to-face meetings.
Conclusion: Members appeared to collaborate on the tasks within work packages. There was less
evidence on collaboration on HTA reports, but this will be progressed in the EUnetHTA JA2 project.
Communication seemed to be effective and face-to-face meetings were the preferred mechanism.69
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70Continue developing the communication platform and clearinghouse
functionality to make European Network for Health Technology
Assessment the central reference point for HTA in Europe
This was not continued during the JA project.
Conclusion This was not continued in the JA project.
Arrange face-to-face meetings at the start of group or committee work
to strengthen social coherence and reach a common understanding
of the work
Networking was highly valued by project participants and face-to-face meetings were the preferred means
of communication. It has been suggested that such meetings are important in fostering trust between
virtual teams of an international project.
Conclusion: Face-to-face meetings seemed highly valued by project participants and should be arranged
for the start of group work in the EUnetHTA JA2.
Evaluate the tools in real work settings and the technical
communication platform
As discussed previously, the focus of the EUnetHTA JA seemed to be on the development of the tools.
The focus of the EUnetHTA JA2 will be on evaluating the tools in real work settings. The technical
communication platform of the information management system performed well. The intranet site was
used by most members. However, some improvements in the workrooms and for the e-meeting system
were required.
Conclusion: There appeared little chance to evaluate the tools in real-life work settings, and this will be
the focus of EUnetHTA JA2. The information management system supported the communications of the
project well.English has been the main language and should continue to be so
In an international project it is practical if a common language is used. It was encouraging that the
majority of participants had not experienced a serious difﬁculty with either written or spoken English.
Conclusion: Communicating within the project in English has worked well and this should continue for
the EUnetHTA JA2 project.Conclusions
Nature of the project and the evaluationl The EUnetHTA JA was a complex international project with a 3-year lifecycle.
l This evaluation has contributed to the awareness within the network about types of expertise available
in, and HTA information produced by, member organisations.
l There was a high degree of project participant turnover within the lifecycle of the project. This
necessitates the provision of high-quality induction materials.
l The evaluation methodology of repeat cross-sectional population surveying by online questionnaires
worked well. The strategy for optimising response rates was effective.
l One of the requirements of the EUnetHTA JA project was to have this internal evaluation. However
the ﬁnal evaluation results had to be collated 6 months before the end of the project, which limits the
evaluation. To be most effective, ﬁnal evaluation of a project should be done following its end, to
enable assessment of impact.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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the project had been met.
l The majority of deliverables were produced by the end of the project, according to the ﬁnal technical
reports submitted. The methodological guidance for the assessment of relative effectiveness of
pharmaceuticals was predicted to be delivered in the month following the project close (by the end of
February 2013).
l The project’s overarching objective was to ‘establish an effective and sustainable HTA collaboration in
Europe that brings added value at the regional, national and European level’. Using the deﬁnitions
provided by project participants and stakeholders it appeared the JA had not been successful in
meeting this objective. The foundations laid by the EUnetHTA 2006–8 and the EUnetHTA JA project
will be followed by the EUnetHTA JA2 project before evolving into the permanent network in 2015.
l The business model and strategy was delivered as planned. This strand of activity is being continued in
the EUnetHTA JA2.
l The HTA tools and methods were produced as planned. It is notable that further development of the
HTA Core Model is planned during EUnetHTA JA2.
l The objective of application and ﬁeld-testing of HTA tools and methods was apparently not met and
this will be further explored in EUnetHTA JA2.
l Only half of respondents thought the EUnetHTA JA had achieved what they wanted, but a larger
proportion had personally beneﬁted from the project. Such added value included networking,
information sharing and improved awareness of HTA developments.
l The tools had not been delivered by the time that the ﬁnal evaluation was conducted and, therefore,
it was too early to assess their quality and use in practice. Project participants had used the tools for
communication, including the project intranet. Future beneﬁt was anticipated from use in practice of
the HTA Core Model, the POP database and, to a slightly lesser extent, the EVIDENT database. The
highest priority for training was the HTA Core Model. Face-to-face workshops seemed to be the
training method of choice for these ‘content’ tools. Self-directed training with a manual was preferred
for the ‘process’ tools – the project communication tools. There is a need to evaluate the effectiveness
of the HTA methodology tools in EUnetHTA JA2.Project effectivenessl Effectiveness was measured by evaluating the processes of the project.
l The set-up of the project, including structure into eight work packages, seemed to be effective. The
need for communication between the work packages was emphasised to prevent duplication of effort
and harmonisation of processes.
l Only about half of respondents thought funding was sufﬁcient and budgeting and project planning
processes should be used in EUnetHTA JA2 to help with this. Succession planning within organisations
is also essential.
l The main challenges of being involved in the project were insufﬁcient funding or stafﬁng and
conﬂicts with other work. Other problems included the large project scale and demands of individual
work packages.
l Overall the leadership and administration from the secretariat had been effective. There was some
apparent concern about the over-reliance on the project’s leader.
l The majority of participants had not experienced a signiﬁcant problem in communicating in English,
the ofﬁcial language of the project. The most effective method of communicating was by meeting face
to face.
l There seemed to be a lack of knowledge from participants about the work packages that they were
not involved in and this could be improved for the EUnetHTA JA2.
l The plenary assembly meetings had generally worked well. There seemed to be some problems due to
the room lay out in 2011 and lack of involvement of participants in 2012.71
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72l Involvement of stakeholders seemed to be an evolving process that began in the EUnetHTA 2006–8
project, progressed during the EUnetHTA JA project and requires improvement in the EUnetHTA JA2
project. Analysis of stakeholders’ views was hampered by the fact that not all organisations had
completed their questionnaire. All organisations must commit to answer evaluation questionnaires in
the EUnetHTA JA2, so that their opinions can be considered.
l Overall, the stakeholder forum seemed to be an effective means of involving external stakeholders in
the EUnetHTA JA. Non-members appeared to have been adequately informed by their designated
representative. Stakeholder forum meetings were appreciated and should continue in the EUnetHTA
JA2. Improvements could be made, such as by having a more participatory nature, greater dialogue
about setting the agenda and considering having a stakeholder chairperson. Participation could also be
helped by an inclusive stakeholder forum that appreciated the heterogeneous nature of stakeholders
and valued contributions from all types of members equally. There is a need to review the documents
and processes for stakeholder involvement in EUnetHTA JA2.
l Developed during the project, SAGs appeared to function well. Concerns, such as short timelines for
responding to consultation and the difﬁculties of obtaining a balanced view should be addressed in
EUnetHTA JA2. The different natures, interests and level of inﬂuence of different stakeholder
categories must be recognised in EUnetHTA JA2. Processes and documents must ensure a participatory
nature of inclusion of the views of all relative stakeholders. There was a sense that stakeholders
appreciated involvement in the EUnetHTA JA. However, they felt they had more expertise to offer and
this could be facilitated by earlier and more inclusive involvement in work package work with longer
deadlines for work review.
l EUnetHTA JA2 is the follow-up project to the EUnetHTA JA and there was an overlap between the
two. It was not possible to progress from the EUnetHTA JA to the permanent network, but a ‘bridging’
project seemed necessary – the EUnetHTA JA2 project. It is important that lessons are learned
from the EUnetHTA JA. These included utilising better project planning and budgeting and
stakeholder involvement.Lessons learned from European network for Health Technology Assessment
2006–8 project
Overall the EUnetHTA JA project seems to have used the recommendations made by the internal
evaluation of the EUnetHTA 2006–8 project with the following being maintained: a co-ordinating
secretariat, structure made up of work packages, development of tools, involvement of participants,
development of the communication platform, holding face-to-face meetings and using English as a
common language. In addition, there seemed to have been some improvement in involving stakeholders in
the EUnetHTA JA compared with the EUnetHTA 2006–8 project, aided by the formation of a stakeholder
forum. However, there seemed to be limited progress on collaboration between partners and evaluating
the tools in real-work settings. The clearinghouse functionality developed during the EUnetHTA 2006–8
project had been apparently abandoned.Key project success criteria
Success criteria were developed for the project and have been previously deﬁned. These were individually
assessed and comments have been provided in Table 9.
Recommendations
l The ﬁnal part of the internal evaluation had to be performed 6 months before the end of the
EUnetHTA JA project. For future projects the ﬁnal evaluation should be performed after the end of the
project, thereby allowing assessment of the project’s impact.
l Owing to the large turnover of participants in the project, it is recommended that an induction pack be
produced to orientate new staff.
l It is important that a valid database of all project participants is maintained by the secretariat and kept
up to date. It is also the responsibility of leads or organisations, and work package leads, to provide
details of any changes of staff in a timely manner.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 9 Comments about achievement of project success criteria
Project success criteria Comments
Production of deliverables according to
the 3-year work plan and grant agreement
Most deliverables were produced by the end of the project. One was
anticipated to be delivered in the month following the project close
(February 2013) and was delivered March 2013
Objectives (as deﬁned in the grant
agreement) met
More work in EUnetHTA JA2 will enable meeting the overarching
agreement of establishing a permanent network. The three subobjectives
were met
Additional added value generated Additional value included networking, information sharing and increased
knowledge of HTA developments
Effective communication within
the project
No serious communication problems were reported. Face–to-face meetings
were the preferred communication method
Effective project administration by
the secretariat
Leadership and administration by the secretariat was effective. Possible
additional functions were cited by respondents and these could be
considered for EUnetHTA JA2
Optimal involvement of
external stakeholders
Stakeholder involvement had evolved from the EUnetHTA 2006–8 project
with respect to the formation of the stakeholder forum. This can be
continued in the EUnetHTA JA2 project, particularly in managing the
interests of the heterogeneous stakeholders
Good management of the constituent
work packages
Overall, work packages seemed to perform well. There were some concerns
about WP2 and WP8. There were some intrinsic difﬁculties in managing of
the large number of participants in WP4 and WP5
Progress from the predecessor
EUnetHTA 2006–8 project
Recommendations from the EUnetHTA 2006–8 project seemed to have
been acted on
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37l The evaluation strategy was effective for project participants. If the same inductive and punitive factors
are used, it might not be necessary to deliver a third send-out to participants.
l Half of patient groups and half of industry did not complete their evaluation questionnaires. All
stakeholders must commit to answering their evaluation questionnaires in the EUnetHTA JA2 so that
their views may be considered.
l During the evaluation it was possible to identify whether or not deliverables had been produced
according to the 3-year work plan. However, it was beyond scope to assess the quality of
these deliverables.
l There is a need to investigate the quality and usability of the HTA methodology tools in real-world HTA
practice. There should be an assessment of the quality, usability and cost-effectiveness of the HTA Core
Model compared with other methods of HTA report production within the EU. Similarly, the
effectiveness and cost-effectiveness of the POP database should be assessed. In regard to the POP
database, it is recommended that it be assessed how many collaborations have been undertaken as a
result of its use.
l In future HTA collaborations, the involvement of stakeholders needs to evolve. This process had begun
in the EUnetHTA 2006–8 project and developed during the EUnetHTA JA with the establishment of the
stakeholder forum. Involvement of stakeholders in the EUnetHTA JA2 needs to expand, particularly in
regard to managing heterogeneous stakeholder groups.
l Some progress seems to have been made since the EUnetHTA 2006–8 project in areas such as reﬁning
the HTA tools. However, there has been some suggestion that other aspects (including the
communication plan and the business model and application of the tools) need further development.
This is planned during the EUnetHTA JA2.
l The HTA tools had not been delivered by the ﬁnal evaluation and, therefore, it was too early to assess
their use in practice. The majority of respondents saw future use in the HTA Core Model and the POP
database. These tools should be evaluated in real-life practice in the EUnetHTA JA2.73
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74l It is recommended that evaluation of the EUnetHTA JA2 includes consideration about the tangible
beneﬁts of networking and information exchange. This could include a case-study approach to
demonstrate the practical beneﬁts of networking, such as collaborations initiated and topics identiﬁed.
Any beneﬁts should be compared with the costs that face-to-face meetings entail.
l Efforts should be made during the EUnetHTA JA2 to improve the project intranet (the MO website),
especially with regard to the workrooms and bulletin boards.
l Face-to-face training workshops about the HTA methodological tools (HTA Core Model), POP and
EVIDENT should be performed in the EUnetHTA JA2. Self-directed training with a manual is more
appropriate for the project-focused tools.
l More time should be factored in for the crucial design stage of large, complicated HTA projects. This
enables learning from previous similar projects. It is important that individual participants feel included
in this formative stage and communication is clear at the outset. This stage is important in ensuring all
participants are clear at the outset and should not be rushed.
l Consideration could be given to establish a second ‘operational’ committee in the EUnetHTA JA2. This
could be made up of an individual worker of each work package and could meet virtually to
strengthen links between the subprojects.
l The greater use of project management and budgeting techniques could be used in the EUnetHTA JA2
to ensure sufﬁcient resources are allocated to organisations and speciﬁc tasks.
l In future international HTA projects all participant organisations should be responsible for outlining
who will be locally responsible for an organisation’s commitment to the project if key staff
become unavailable.
l Consideration should be given in future projects to have a deputy leader, possibly based in
another country.
l Various additional activities that could be performed, and it is hoped that in EUnetHTA JA2 with
greater funding the activities can be expanded, such as to include support with project budgeting and
project management.
l The most popular form of interaction was face-to-face meetings, and this should be considered in the
EUnetHTA JA2. It is important that lessons are learned about how such meetings should be conducted
and evaluation of the plenary assembly meetings is important in this respect.
l External promotion of the project should be improved for the EUnetHTA JA2 project. Strategies that
have been suggested include a better public website, advertisement of timelines and achievements and
greater use of social media.
l Overall, the stakeholder forum seemed to be an effective means of involving external stakeholders in
the EUnetHTA JA.
l The objectives of plenary assembly meetings should be made explicit on the agenda before
the meeting.Informing clinical decision-makers about clinical research
studies under development: development of a data set
to inform a registryDelphi round 1
Response rate
Thirteen organisations had agreed to participate in the Delphi round. The ﬁrst-round questionnaire was
distributed in October 2010. Following a targeted follow-up strategy, 12 of the organisations responded:
a 92% response rate.Language
All organisations from countries where English is not the common language of everyday use supported
English being the main language of the data set.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37One-quarter of respondents suggested some kind of native (i.e. non-English) language involvement would
be useful. Therefore, this issue was carried forward to the second Delphi Round.Coding systems
Half of respondents recommended using a coding system/controlled vocabulary in addition to English.
All those who recommended using a coding system supported medical subject headings (MeSH).
Overwhelmingly the use of terms was supported over codes. The use of ATC (Anatomical Therapeutic
Chemical Classiﬁcation System) was suggested by one respondent and this issue was carried forward to
the second Delphi Round.Population Intervention Comparison and Outcome
The majority of respondents recommended keeping the intervention and control as separate headings,
rather than combining the two. This was seen to confer the advantages of:
l clarity in the designs of trials, and the use of technologies in different countries
l searching within the database for technologies which are being compared
l the absence of comparator indicating that a study may not be comparative.Contact
All respondents indicated that e-mail is an appropriate default contact method.Study title and research question
There was a mixed result about whether or not a study’s title should be recorded in a country’s native
language as well as English. This issue was carried forward to the second Delphi round.Unit of registration
Having a unique identiﬁer for each record was essential. This would be further explored in the second
Delphi round.Source of research idea
Giving a fully referenced source for a research idea was recommended by the majority of respondents.Outcomes
It was recommended that a menu of outcomes was developed (including a subsequent trial or
registry number).Types of other information
Types of other information were recommended and this will be explored in the second Delphi.Delphi Round 2
Response Rate
The second Delphi Round was sent to the 12 organisations that had responded to the ﬁrst Delphi round. The
questionnaire was sent in November 2010 and a targeted follow-up strategy resulted in 10 organisations
responding, giving an 83% response rate.Language
There had been indication from the ﬁrst Delphi round that consideration should be given to including
native language.
The majority agreed that adding optional non-English-language ﬁelds for the study title and research
question was appropriate.75
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76Coding system
A respondent had suggested including ATC codes.
Only a minority of respondents were able to provide ATC codes for their projects. Therefore, it was
decided not to add a speciﬁc ﬁeld for this. However, it may be appropriate for the database programmer
to consider encouraging inclusion of these codes in a descriptive free-text ﬁeld.Unique identifier
It had been identiﬁed from the ﬁrst Delphi Round that not all organisations maintain unique identiﬁers for
their projects.
Respondents indicated that it would be suitable for either an organisation to allocate a unique identiﬁer
for a project, or the registry would generate one.Outcomes
A list of outcome possibilities was derived from the responses to the second Delphi round questions.
Study went ahead:
1. type of study (required)
i. funded as a trial (include trial reference number from registry, or similar information)
ii. funded as another type of study (include reference number and registry, if any)
iii. results likely to be available on <date>
iv. study going ahead (if no other outcome appropriate)
2. funding arrangements (optional)
i. cofunded with speciﬁed public sector funder(s)
ii. cofunded with speciﬁed private sector funder(s)
iii. not cofunded
iv. cofunding arrangements not available.Study did not go ahead:
1. lack of clinical need for knowledge
2. lack of researcher capacity
3. competing studies already under way leading to a lack of clinical capacity to deliver the research
4. lack of research funding.Unit of registration
We suggested the unit of registration should be the project, which may contain one or more substudies in
parallel or series. The majority of respondents agreed with this suggestion. Therefore, the unit of
registration will be the overarching project, with details of substudies recorded in the summary ﬁeld.Other informationl Based on the results received from the respondents it was decided that an optional summary ﬁeld
would be included in the data set. A country ﬁeld would also be included, with the possibility of
recording multiple countries against this ﬁeld.
l All respondents supported the inclusion of the planned country, where a planned study would be
undertaken. A country ﬁeld will be included, with the ability of recording multiple countries against
the ﬁeld.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Respondents were asked what clinical areas should be used to test the data set. Suggestions received from
more than one organisation were:
(a) trastuzumab for breast cancer
(b) transcatheter aortic valve implantation (TAVI) compared with other surgery for aortic stenosis
(c) vertebroplasty and kyphoplasty compared with conservative therapy (e.g. physiotherapy, occupational
therapy) for compression fractures in osteoporosis
(d) bevacizumab for macular degeneration compared with bevacizumab for other indications.
Therefore, these indication and intervention combinations were used for efﬁcacy testing of the data set.Potential accuracy testing
The Delphi participant organisations were asked to complete the data set for studies they were aware of
from their own organisations which may be similar to the exemplar studies listed above.
Both authors reviewed the submitted data and made decisions on whether or not the elements for any
pair of studies were sufﬁciently similar that a funder would consider them a close match. Disagreements
were resolved by discussion. Had discussion not resolved disagreements we would have referred the
disagreement to an identiﬁed third person within our organisation, but this did not arise.
The results of the comparisons are shown in Tables 10–13 below.
We then derived the sensitivity, speciﬁcity, positive and negative predictive values for each matching rule
by constructing a 2 × 2 table of whether or not a project was intended to match the exemplar study on
one axis, and whether or not the reviewers considered that it matched the other and then applying a
standard technique using the statistical computing package R® (version 2.15.3).82TABLE 10 Consideration of the data set for studies relating to trastuzumab in breast cancer
Study
Intended
match Population
Intervention/
control Outcomes
Reference Study: UK
(PERSEPHONE)68
Women with
HER-2+ breast
cancer
Trastuzumab
(different
durations)
Quality of life
Disease-free
survival
Netherlands (real-world efﬁciency of trastuzumab in
early breast cancer) (Benien Vingerhoed Van Aken,
ZonMW, 2011, personal communication)
Y ✓ ✓ ✗
France (protocol of herceptin adjuvant with reduced
exposure)69
Y ✓ ✓ ?
UK and others (Synergistic Or Long Duration; SOLD)70 Y ✓ ✓ ?
UK [an international RCT to compare TARGeted
Intra-operative radioTherapy (TARGIT) with
conventional post-operative radiotherapy for women
with early breast cancer]71
N ✗ ✗ ✓
N, no; Y, yes.
A tick symbol (✓) indicates that the reviewers thought that this element of the study was sufﬁciently similar that a funder
would consider it a close match.
A cross symbol (✗) indicates that the reviewers thought that the element was sufﬁciently dissimilar that a funder would not
be interested.
A question mark (?) indicates that the reviewers considered there was some non-important overlap.
Many of these projects are internal to the individual agencies and details are not publicly available. Therefore, references
have not been included for some studies.
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TABLE 11 Consideration of the data set for studies relating to bevacizumab and ranibizumab in wet age-related
macular degeneration
Study
Intended
match Population
Intervention/
control Outcomes
Reference Study: UK (IVAN)72 Patients with wet
AMD
Bevacizumab
Ranibizumab
Visual acuity
Quality
of life
Netherlands [comparing the effectiveness and
costs of bevacizumab to ranibizumab in patients
with exudative age-related macular degeneration
(COSD)] (Benien Vingerhoed Van Aken, ZonMW,
2011, personal communication)
Y ✓ ✓ ?
Netherlands (cost-effectiveness and outcome of
current treatment strategies in exudative
age-related macular degeneration)73
Y ✓ ✓ ✓
UK (a multi-centre RCT comparing the efﬁcacy,
safety and cost-effectiveness of intraocular
telescopic devices compared with standard
intraocular lens implants in visual impairment in
age-related macular degeneration) (Internal
NETSCC data)
N ✓ ✗ ✓
UK (assessment of the effectiveness of the Acrysof
natural intraocular lens in retarding the
progression of age-related macular degeneration)
(Internal NETSCC data)
N ? ✗ ?
UK (verteproﬁn photodynamic therapy for
neovascular age-related macular degeneration:
cohort study for the UK)74
N ✓ ✗ ✓
UK [Macular EpiRetinal brachytherapy versus
Lucentis Only Treatment (MERLOT). A randomised
controlled trial of epiretinal brachytherapy for
previously treated neovascular age-related macular
degeneration]75
Y ✓ ✓ ✓
UK (regenerative laser therapy in the treatment of
early age-related macular degeneration) (Internal
NETSCC data)
N ? ✗ ✗
N, no; Y, yes.
A tick symbol (✓) indicates that the reviewers thought that this element of the study was sufﬁciently similar that a funder
would consider it a close match.
A cross symbol (✗) indicates that the reviewers thought that the element was sufﬁciently dissimilar that a funder would not
be interested.
A question mark (?) indicates that the reviewers considered there was some non-important overlap.
Many of these projects are internal to the individual agencies and details are not publicly available. Therefore, references
have not been included for some studies.
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TABLE 12 Consideration of the data set for studies relating to transcatheter aortic valve replacement for
aortic stenosis
Study
Intended
match Population
Intervention/
control Outcomes
Reference Study: UK (UK-TAVI)76 Patients with
moderate and severe
aortic stenosis
Transcatheter
aortic valve
replacement
Open aortic
valve
replacement
Quality of
life
Survival
Norway [a randomised clinical trials of
transcatheter aortic valve implementation
compared with surgery in patients with high
risk aortic valve stenosis (tentative title)]
(Inger Natvig Noderhaug, Kunnskapssenteret,
2011, personal communication)
Y ✓ ✓ ✓
France (medical and economic assessment
of aortic valves)77
Y ✓ ✓ ✓
USA (the PARTNER trial: Placement of AoRTic
TraNscatheter Valve Trial)78
Y ✓ ✓ ✓
N, no; Y, yes.
A tick symbol (✓) indicates that the reviewers thought that this element of the study was sufﬁciently similar that a funder
would consider it a close match.
Many of these projects are internal to the individual agencies and details are not publicly available. Therefore, references
have not been included for some studies.
TABLE 13 Consideration of the data set for studies relating to vertebroplasty in osteoporosis
Study
Intended
match Population
Intervention/
control Outcomes
Reference study: UK (vertebroplasty versus
physiotherapy for osteoporotic vertebral collapse)
(Internal NETSCC data)
Patients with
symptomatic
osteoporotic
vertebral collapse
Vertebroplasty
Kyphoplasty
Physiotherapy
Usual care
Quality
of life
Pain
Netherlands (percutaneous vertebroplasty in the
treatment of osteoporotic vertebral fractures)79
Y ✓ ✓ ✓
UK [SPinal Osteoporotic Fracture Exercise Trial
(SPOFET)] (Internal NETSCC data)
N ✓ ✓ ✓
UK [Local Anaesthetic with BupivacaineE and
Lidocaine for vertebral fracture trial (LABEL)]80
Y ✓ ✓ ✗
UK [a pragmatic randomised controlled trial
of screening for osteoporosis in older
women (SCOOP)]81
N ✗ ✗ ✗
N, no; Y, yes.
A tick symbol (✓) indicates that the reviewers thought that this element of the study was sufﬁciently similar that a funder
would consider it a close match.
A cross symbol (✗) indicates that the reviewers thought that the element was sufﬁciently dissimilar that a funder would not
be interested.
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80Sensitivity and specificity calculations
All ﬁgures followed by 95% conﬁdence interval, calculated using the statistical computer package R.82
Sensitivity and speciﬁcity calculations were computed and these are shown in Table 14. The data set is
provided in Table 15.TABLE 14 Sensitivity and speciﬁcity calculations for the data set
Rule
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
Positive predictive
value (95% CI)
Negative predictive
value (95% CI)
Match at least one
element in P(IC)O
1.0 (0.62 to 1.0) 0.43 (0.10 to 0.82) 0.73 (0.54 to 0.92) 1.0 (0.19 to 1.0)
Match at least two
elements in P(IC)O
1.0 (0.62 to 1.0) 0.57 (0.18 to 0.9) 0.79 (0.49 to 0.95) 0.79 (0.49 to 0.95)
Match at least three
elements in P(IC)O
0.5 (0.19 to 0.81) 0.86 (0.42 to 1.0) 0.83 (0.36 to 1.0) 0.55 (0.23 to 0.83)
CI, conﬁdence interval.
TABLE 15 The data set (version 5)
Number Item Deﬁnition Mandatory Example
1 Funder The name of the funder
considering the study
Y NIHR Health Technology
Assessment programme
2 Contact
e-mail of
funder
A contact e-mail for
the funder
Y hta@hta.ac.uk
3 Title The English title for the study Y Multi-centre randomised controlled
trial of the cost-effectiveness of
intra-inguinal percutaneous
transluminal angioplasty (PTA) vs.
reconstructive surgery for severe
limb ischaemia (BASIL)
4 Native
language
title
The native language title for the
study, expressed in the preferred
language of the funder
Y Multi-centre randomised controlled
trial of the cost-effectiveness of
intra-inguinal percutaneous
transluminal angioplasty (PTA)
compared with reconstructive
surgery for severe limb
ischaemia (BASIL)
5 Unique ID A unique ID for the study. This
will be a unique code for the
study either provided by
the funder or generated by the
database. In combination with
item 1 it will uniquely identify a
study within the database
Y 96/05/01
6 Country One or more countries where the
study is planned to take place
Y UK
7 Source of
question
Where the question came from,
e.g. was it speciﬁed by a national
policy-making or research
co-ordinating body
N URL of NICE guidance specifying
the question
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 15 The data set (version 5) (continued )
Number Item Deﬁnition Mandatory Example
8 Research
question
(English
language)
The primary research question of
the project, expressed in English
language
Y What is the clinical effectiveness
and cost-effectiveness of angioplasty
compared with surgery in the
management of severe limb ischaemia?
9 Native
language
research
question
The primary research question
of the project, expressed in the
preferred language of the funder
N What is the clinical effectiveness and
cost-effectiveness of angioplasty
compared with surgery in the
management of severe limb ischaemia?
10 P English-language description of
the population eligible for study
inclusion
N Patients with limb ischaemia
11 P-MESH MeSH codes or terms for the
populations eligible for study
inclusion (may need to refer to
anatomy and disease process)
Y Femoral artery (A07.231.114.351)
12 I English-language description of
the new intervention(s)
considered in the study
N Angioplasty
13 I-MeSH MeSH codes or terms for the new
intervention(s) considered in
the study
Y Angioplasty (E02.148.050)
14 C English-language description of
the control intervention(s)
considered in the study
N Surgery
15 C-MeSH MeSH codes or terms for the
control intervention(s) considered
in the study
Y Blood vessel prosthesis implantation
(E04.100.814.868.500)
16 O English-language description of
the key outcome of interest
N Mortality, amputation, quality of life,
cost-effectiveness
17 O-MeSH MeSH codes or terms for the key
outcomes of interest
Y Fatal outcome
(E05.318.308.985.550.325)
Amputation (E04.555.080)
Quality-adjusted life-years
(E05.318.740.100.500.700)
Cost–beneﬁt analysis
(N03.219.151.125)
N, no; Y, yes.
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82It was demonstrated that a registry for matching pragmatic clinical studies under consideration by funding
agencies could be built on a very small data set. This would include 10 unique items, of which only ﬁve are
required to describe a study and the rest are metadata.
By the end of the ﬁrst Delphi round the participants had agreed on the overall shape of the data set,
honing down to the most important information to be contained.
l demographics/epidemiology – funder, contact details
l trial speciﬁc – title, PICO, outcome.
Discussions had been initiated about the most appropriate use of language; whether entering data in
English alone was acceptable or if users who usually worked in other languages should have the option to
include data in that language too.
The trade-offs between human-readable language and coding systems for the elements of the data set
that would describe the key elements of a study were also discussed. A small selection of coding systems
were considered.
In round 2, several smaller issues which had arisen in round one were addressed. This included the way
organisations group and refer to their studies internally. By the end of the round the coding system,
the role of non-English entries and a menu of possible outcomes to record had been agreed. Another
important element of round 2 was establishing clinical and technology areas within which to validate the
data set. Responders were asked to suggest areas where they might have appropriate studies to carry out
some efﬁcacy testing.
By the end of the second round it was clear that participants agreed about the elements of the data set,
so the efﬁcacy-testing phase was initiated. Participants were asked what the characteristics of a good
matching algorithm would be. There was general agreement that the best algorithm would minimise false
negatives, and that false-positive matches were more acceptable than false-negative ones.
The characteristics of the matching rules assessed vary as might have been expected. The more elements a
test tries to match before declaring two studies are similar, the higher the speciﬁcity and positive predictive
value, and the lower the sensitivity and negative predictive value.
It is likely that the most important characteristic of a future database to a funder is the negative predictive
value. The funder wants to ensure that they know about all potentially similar studies, and a high negative
predictive value (ideally 100%) would provide this reassurance. They also do not want be ﬂooded with
false matches – although we know from the Delphi survey that the groups who responded would prefer
false-positive matches to missing potential similar studies – although their attitude may change if any data
set implemented is unable to minimise false positives. Unfortunately, as the predictive values of a
diagnostic test are dependent on population-level frequencies, it is not possible to calculate these without
implementing an actual registry. Useful estimates of positive and negative predictive values can only be
obtained from a live database containing real-life examples of studies, so this should be done for any
subsequent database which may be developed from this data set.
It was envisaged that such a registry could be built progressively as subscribers query the database. Studies
entered to search for possible matches would be entered into the database as well as used for searching.
Should a match be identiﬁed, then the registry would alert both the organisations who entered the
matched studies. Those organisations would then discuss between themselves whether the match was
true or false, and what (if anything) to do about it. Using this approach would result in minimal extra work
for funders searching for similar studies. It would be useful if they could return when a ﬁnal decision isNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18370 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 37made on their proposed study. This would enable entry of information on when the study is no longer
under consideration to record what its fate was, and more importantly, so the study is no longer ﬂagged
up as a possible match for other organisations. However, there could be a default time to retire a study
from matches after a particular time should a data owner not return to update their records. There were
insufﬁcient data to decide on efﬁcacy regarding diagnostic studies. Depending on the future use of this
data set, it would probably be worth investigating in future in a live database registry.
Overall, it seems that a database based on this data set is plausible. Success will depend on the willingness
of the research community to engage with it. It will be necessary to develop matching rules within a live
database, but we have suggested some starting points.83
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We describe in detail the activities that the authors led on in the EUnetHTA JA, and that werepart-funded by both the NIHR Health Technology Assessment programme and the
European Commission.
The impact and effectiveness of the project was evaluated by self-completion questionnaires of project
participants and external stakeholders, and documentary analysis. One of the best things was the
opportunity for networking with HTA experts from other countries. Many learning points were identiﬁed
which will be helpful to the follow-up EUnetHTA JA2 project.
A data set was developed to inform the creation of a registry for prospective clinical studies. It is
hoped that it will help identiﬁcation of similar studies that are being planned and enable alignment of
outcome measures.85
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